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ABSTRACT
Resveratrol, a natural polyphenol compound found in red wine, the skins of
grapes, and other plant products, has been used as a traditional medicine for thousands of
years throughout human history, but current research has revealed this natural component
is capable of modulating a variety of immunological, microbial, and epigenetic
mechanisms to improve overall health and well-being of hosts that consume it. Colitis, an
inflammatory bowel disease characterized by chronic inflammation in the colon and
rectum, which has been associated with colon cancer. This cancer incidence is rising in
younger adults in the US. Thus, newer approaches to prevent colitis and colon cancer are
critical. In this dissertation, data and evidence is presented which demonstrate that
resveratrol, natural polyphenol can attenuate murine models of colitis and prevent colitisassociated colon cancer. In addition, in-depth mechanistic studies will provide evidence
that resveratrol suppresses inflammation in the colon by regulating the host-gut
microbiome, as well as inducing epigenetic changes via modulation of small noncoding
RNA molecules that target key gene transcripts involved in key immunologic processes.
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CHAPTER 1
INTRODUCTION
1.1 COLITIS AND COLITIS-ASSOCIATED COLON CANCER
Inflammatory bowel diseases (IBDs), such as ulcerative colitis (UC) and Crohn’s
disease (CD), are chronic digestive diseases defined by often uncontrollable
inflammation along the gastrointestinal tract and colon (Singh et al., 2014b). The
incidence and prevalence of these diseases has risen since 1980 in many parts of the
world, particularly in the United States (Molodecky et al., 2012), and there is an alarming
trend of these diseases increasing in the pediatric population (Ong et al., 2018; Sykora et
al., 2018). Even more concerning is the link between colitis and an increased
susceptibility to developing colorectal cancer (CRC) in animal models and the human
patient population (Al Bakir et al., 2018; Foersch et al., 2012; Yang et al., 2018a). Colitis,
as a form of IBD, has a complex etiology often attributed to many interrelated genetic,
dietary, and other environmental factors (Hart, 2019; Mikhailov and Furner, 2009).
Current conventional treatment options (e.g. steroids and immunosuppressive drugs)
often have adverse side-effects, or in some cases, colitis patients are non-responsive to
these conventional therapies (Antonelli et al., 2018). With increasing incidence, a link to
development of CRC, and lack of effective treatment options, more studies are focusing
on preventative measures to decrease colitis incidence.
Recent advances in next-generation sequencing technology have shown that IBD
may also result from alterations in the composition and function of gut microbiota,
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referred to as dysbiosis. The gut microbiota also interact closely with dietary components
to maintain normal immune system homeostasis in the gut. Whether dietary supplements
that are effective against colonic inflammation mediate their effects through modulation
of gut microbiota is an area of investigation that is novel and highly significant.
Colorectal cancer (CRC), which is characterized by tumor development in the
large intestine, ranks as third among cancer incidences and fourth in cancer-related
mortalities worldwide (Global Burden of Disease Cancer et al., 2015). Despite an overall
decrease in CRC incidence in the United States among all race and ethnic groups due to
standardized screening guidelines (Edwards et al., 2014), there has been a rise in
prevalence of this disease among young adult patients which prompted the American
Cancer Society to suggest the recommended age for CRC screening be lowered from 50
to 45 (Pittman, 2018). Even with conventional chemotherapy options, which have major
negative side-effects, patients often show chemo-resistance (Bose et al., 2011). It is for
this reason, the emphasis has been on prevention of CRC development and regular
screening to detect and cure at an early stage. CRC development, is also associated with
chronic inflammation and high levels of circulating inflammatory biomakers (Lopez et
al., 2018; Song et al., 2018). Recent reports have shown that inflammation induced by
certain types of diet and alterations in the microbiome is associated with increased risk of
CRC development in men and women (Liu et al., 2018; Tabung et al., 2018). By the
same token, diet and life styles that promote chronic inflammation in the gut is associated
with dysregulation in the microbiome and development of colon tumorigenesis (Chen et
al., 2017; Song et al., 2015). Together, such studies suggest that use of preventative
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agents against colonic inflammation, or colitis, could be beneficial in reducing the
incidence of CRC.
1.2 RESVERATROL
Resveratrol (3,4,5-trihydroxy-trans-stilbene) is a natural polyphenol produced by
several plants in response to injury or when the plant is under attack by pathogens such as
bacteria or fungi (Singh et al., 2007). Resveratrol has been extensively studied for its
therapeutic benefits against a wide array of diseases including cancer, cardiovascular,
neurological and inflammatory diseases (Altamemi et al., 2014; Cui et al., 2010; de la
Lastra and Villegas, 2005; Guan et al., 2012; Rieder et al., 2012; Singh et al., 2007; Singh
et al., 2010; Wu et al., 2005). Resveratrol mediates these anti-inflammatory effects
through multiple pathways (Rieder et al., 2012). For example, resveratrol has been shown
to attenuate colitis by upregulating of silent mating type information regulation-1
(SIRT1) in immune cells which is associated with the T regulatory cells (Treg) induction
and activation of hypoxia-inducible Factor 1α (HIF-1α)/MTor signaling pathway (Singh
et al., 2010; Yao et al., 2015). Resveratrol has also been shown to induce unique
microRNA that trigger anti-inflammatory pathways as well as induce myeloid-derived
suppressor cells (MDSCs) (Altamemi et al., 2014; Cui et al., 2010; Singh et al., 2010;
Singh et al., 2012). While resveratrol has been shown to alter the gut microbiome in
various disease models (Diaz-Gerevini et al., 2016; Etxeberria et al., 2015; Jung et al.,
2016; Tung et al., 2016), these studies have captured only an association between
resveratrol-induced modulations in gut microbiota and the disease outcome. Thus,
conclusive evidence, such as through fecal transfer, is lacking to connect resveratrol-
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induced modulation in gut microbiota and its beneficial effects against disease
pathogenesis.
In addition, resveratrol has been shown to be a promising preventive measure to
suppress chronic inflammation leading to tumor development (Busbee et al., 2013).
Resveratrol has already been shown by our lab, as well as others, to possess a myriad of
anti-cancer effects, including those related to CRC. This natural compound has been
shown to be effective at preventing the proliferation and survival of human CRC cells as
well decrease CRC disease severity and tumor development in relevant animal CRC
models (Busbee et al., 2013; Elshaer et al., 2018; Hofseth et al., 2010). Some of the
mechanisms by which resveratrol has been shown to prevent colon cancer cell
proliferation and invasion metastasis include regulation of key cellular signaling
pathways such as NF-Κb-dependent cellular processes (Buhrmann et al., 2017),
PI3K/Akt signaling (Zeng et al., 2017), modulation of histones and sirtuins (San
Hipolito-Luengo et al., 2017), inhibition of cyclooxygenase-2 (Cox-2) expression (Gong
et al., 2017), and alterations in gene-regulating microRNAs (miR) (Yang et al., 2015).
Previous reports from our lab have shown that resveratrol is able to alter expression of
certain miRs (miR-101b and miR-455) that target inflammatory mediators such as
interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-α), and COX-2 in the dextran
sodium sulfate (DSS)-induced colitis-associated tumorigenesis Apc(Min/+) mouse model
(Altamemi et al., 2014). In addition, in the AOM/DSS CRC model, we have shown that
resveratrol downregulates inflammatory stress markers such as p53 to modulate the T cell
response (Cui et al., 2010). However, while the regulation of these host-derived cellular
mechanisms play an important role in resveratrol-mediated CRC treatment, recent
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research has shown the gut microbiome is also a key player in both CRC disease
development and progression (Chen, 2018). Nonetheless, whether the ability of
resveratrol to suppress CRC is related to its action on gut microbiota remains a possibility
that needs to be explored.
1.3 THE GUT MICROBIOME
The gut microbiome, a diverse ecosystem consisting of gut commensals including
bacteria and fungi, has been shown to have a great impact on human health and disease,
particularly in CRC (Jobin, 2017; Rezasoltani et al., 2017; Zou et al., 2018). For example,
patients diagnosed with CRC were found to have distinct microbiome profiles compared
to healthy controls, and this microbial signature was found to be altered after treatment
with probiotics (Hibberd et al., 2017). Interestingly, after oral administration of
antibiotics to deplete the gut microbiome, tumor burden was decreased in a CRC murine
model, but this effect was negated in Rag-deficient mice that lacked mature T cells and B
cells (Sethi et al., 2018). This study highlights the importance of the interplay between
the host immune defense the microbiome. While resveratrol has been shown to modulate
the host immune response to promote anti-inflammation as previously discussed and has
been shown to alter the microbiome in other disease models (Chen et al., 2016; Kim et
al., 2018; Qiao et al., 2014; Zhao et al., 2017), there currently are no reports determining
if resveratrol-mediated alterations in the gut microbiome can influence the immune
response to protect against CRC development caused by chronic colitis.
1.4 MICRORNA
microRNA (miRNA or miR) are small 18-25 nucleotide non-coding RNAs that
regulate the expression of several protein-encoding genes post-transcriptionally by either

5

inhibiting translation of targeted-miR or leading to the degradation of certain targetedmRNA transcripts, and even though they make up only 3% of the human genome, it has
been estimated that these non-coding RNAs regulate around 90% of genes (Guo et al.,
2018). Canonical miR biogenesis begins in the nucleus when miR genes are transcribed
by either RNA polymerase II or III to produce primary miRNA transcripts (pri-miRNAs).
While still in the nucleus, pri-miRNA is cleaved by a class 2 RNAase III enzyme, called
Drosha, to create a 60-70 nucleotide hairpin structured precursor (pre-miRNA). The preRNA is then shuttled from the nucleus to the cytoplasm by Exportin 5 (Exp5), where it is
released by Exp5 when GTP on the Exp5-associated Ran cofactor is converted to GDP.
While in the cytoplasm, another RNase called dicer cleaves pre-miRNA into a duplex
intermediate. The duplex intermediate is bound to an Argonaute (AGO) protein to form a
AGO:mature miRNA strand complex, where one strand of the intermediate is discarded
(Catalanotto et al., 2016).
miRs were found to be important in both the development and progression of
colitis, particularly in terms of regulating inflammation, serving as disease biomarkers,
and responding to therapies (Feng et al., 2018; Lopetuso et al., 2018; Minacapelli et al.,
2019; Morilla et al., 2018; Schonauen et al., 2018; Singh et al., 2014a). The importance
of miRs in regulating colitis was highlighted in our previous report showing that
deficiency in only one miR (miR-155) was able to protect mice from developing severe
colitis symptoms by a reduction in the inflammatory T helper (Th) type responses (Singh
et al., 2014a).
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1.5 PROBLEM AND HYPOTHESIS
IBD patients represent a high risk group for developing colitis-associated CRC,
and these diseases, which currently has no cure, result in an overall decrease in quality of
life and an increase in health care costs. There is need to seek out new and novel
treatments to combat the inflammatory response initiated by colitis and colitis-associated
colorectal cancer. Therefore, we examined how the use of natural product, resveratrol,
could prevent colitis-induced T cell activation and inflammation which could lead to
colorectal cancer. Based on recent findings that resveratrol has anti-inflammatory and
anti-microbial properties, we hypothesized that resveratrol would be a novel treatment for
colitis and colitis-associated CRC in relevant mouse models through alterations in gut
microbiota and regulating certain miRs during inflammation.
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CHAPTER 2
RESVERATROL MODULATES THE GUT MICROBIOTA TO PREVENT MURINE
COLITIS DEVELOPMENT THROUGH INDUCTION OF TREGS AND SUPPRESSION OF
TH17 CELLS
2.1 ABSTRACT
Inflammatory diseases of the gastrointestinal tract are often associated with
microbial dysbiosis. Thus, dietary interactions with intestinal microbiota, to maintain
homeostasis, play a crucial role in regulation of clinical disorders such as colitis. In the
current study, we investigated if resveratrol, a polyphenol found in a variety of foods and
beverages, would reverse microbial dysbiosis induced during colitis. Administration of
resveratrol attenuated colonic inflammation and clinical symptoms in the murine model
of TNBS-induced colitis. Resveratrol treatment in mice with colitis led to an increase in
CD4+FOXP3+ and CD4+IL-10+ T cells, and a decrease in CD4+IFN-γ+ and CD4+IL17+ T cells. 16S rRNA gene sequencing to investigate alterations in the gut microbiota
revealed that TNBS caused significant dybiosis, which was reversed following
resveratrol treatment. Analysis of cecal flush revealed that TNBS administration led to an
increase in species such as Bacteroides acidifaciens, but decrease in species such as
Ruminococcus gnavus and Akkermansia mucinphilia, as well as a decrease in SCFA ibutyric acid. However, resveratrol treatment restored the gut bacteria back to homeostatic
levels, and increased production of i-butyric acid. Fecal transfer experiments confirmed
the protective role of resveratrol-induced microbiota against colitis inasmuch as such
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recipient mice were more resistant to TNBS-colitis and exhibited polarization towards
CD4+FOXP3+ T cells and decreases in CD4+IFN-γ+ and CD4+IL-17+ T cells.
Collectively, these data demonstrate that resveratrol-mediated attenuation of colitis
results from reversal of microbial dysbiosis induced during colitis and such microbiota
protect the host from colonic inflammation by inducing Tregs while suppressing
inflammatory Th1/Th17 cells.
2.2 INTRODUCTION
Here, we demonstrate that during colitis, microbial dysbiosis takes place in the
host, which leads to the activation and differentiation of inflammatory effector T cells
and inhibition of Tregs. However, upon treatment with resveratrol, these changes are
reversed, leading to the development of an anti-inflammatory Treg response. More
importantly, we conclusively prove that this mechanism is driven by resveratrol-mediated
alterations in the gut microbiome by performing fecal transplant experiments, thereby not
only reinforcing the notion that resveratrol is a potential therapeutic against colitis, but
also providing a key mechanism through which resveratrol mediates its effects.
2.3 MATERIALS AND METHODS
Animals. Female BALB/c mice (aged 6-8 weeks) were purchased from the
Jackson Laboratories (Bar Harbor, ME). All mice were housed at the AAALACaccredited animal facility at the University of South Carolina, School of Medicine
(Columbia, SC). All procedures were performed according to NIH guidelines under
protocols approved by the Institutional Animal Care and Use Committee.
Effects of resveratrol on colitis in mice. To test the efficacy of treatment with
resveratrol in an in vivo TNBS-induced colitis mouse model, we used TNBS, purchased
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from Sigma-Aldrich (St. Louis, MO). After lightly anesthetizing the mice with controlled
isoflurane vaporizer chamber (5% isoflurane with 75% CO2/25% O2), TNBS was
administered intrarectally one time into female BALB/c mice at a dose of 1 mg
dissolved 0.1 ml of 50% ethanol using a 38 mm catheter, as previously reported (Elson et
al., 1996). For treatment groups resveratrol, purchased from Sigma-Aldrich (St. Louis,
MO), was administered orally using a 30 mm oral gavage needle at 100 mg/kg, a dose
established in our previous studies (Singh et al., 2010), in a total volume of 100µl in
appropriate vehicle of 1% carboxymethyl cellulose (CMC). Resveratrol was given 24
hours prior to TNBS injection and given daily this way until completion of the
experiment (5 days). Two control groups were used for this study. One control group
only received appropriate vehicle (CMC), while the other control group received 100
mg/kg resveratrol dissolved in CMC vehicle. Neither of these control groups received
injection of TNBS. The evaluation of colitis clinical signs was done by measuring the
weight of mice in all groups daily and performing colonoscopy every other day after
TNBS-colitis induction. Colonoscopy scores were determined using a scoring system
previously published (Kodani et al., 2013). In addition, blood was collected prior to
experimental endpoint and serum samples were separated and stored at -20°C for colitisassociated biomarker detection. All experimental mice studied were also given intrarectal
injections of 50% ethanol to ensure changes in the gut were due to either TNBS or
treatment and not attributed to alterations by ethanol. Resveratrol efficacy was also tested
in the dextran sodium sulfate (DSS) model of colitis. DSS (3%) was used to induce
disease as previously reported (Cui et al., 2010), and treatment groups (DSS+Resveratrol)
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were given oral administration of 100 mg/kg of the compound daily throughout the 14day experiment.
Histology analysis. Animals were euthanized 5 days after injection of TNBS
using the drop jar method containing 5% isoflurane (260 mL in 1 L drop jar) for overdose
inhalation, and the proximal portion of colons were excised and cleaned by saline
flushing. The length of colon was measured before fixing the excised tissue with 4%
paraformaldehyde. Colon pieces were embedded in paraffin, cut into 5µm sections,
deparaffinized in xylene, serially diluted in decreasing concentrations of ethanol, and
stained with hematoxylin-eosin (H&E) for histopathological examination and Periodic
Acid Schiff (PAS) staining to assess mucosal mucin production and presence of goblet
cells. Histological scoring of colon sections was determined using previously published
criteria (Akgun et al., 2005).
Serum evaluation by enzyme-linked immunoabsorbant assay (ELISA). Acute
phase serum amyloid A (SAA), Lipocalin-2 (Lcn2), myeloid peroxidase (MPO), and
interleukin-10 (IL-10) levels in the serum were measured by using enzyme-linked
immunosorbent assay (ELISA) kits. SAA ELISA kit was purchased from Abcam
(Cambridge, United Kingdom), Lcn-2 ELISA kit was purchased from Thermo-Scientific
(Waltham, Massachusetts, USA), MPO ELISA kit was acquired from LifeSpan
BioSciences (Seattle, WA) and the IL-10 Luminex ELISA kit was purchased from
Biolegend (San Diego, CA). All kits were used in accordance with the respective
manufacturer’s protocol.
Flow cytometry staining and analysis. Cells from mesenteric lymph nodes were
isolated and the red blood cells were lysed using lysis buffer (Sigma, St Louis, MO). Cell
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suspensions were filtered using sterile 70 micron filters (Sigma, St Louis, MO). Fourcolor flow cytometric analysis was performed following blocking with Fc receptor. All
cells were washed with FACS staining buffer (PBS with 1% fetal bovine serum), then
stained with FITC-labeled anti-CD3, PE-labeled anti-CD8 and PE-CY7-labeled anti-CD4
at manufacturer suggested concentrations (Biolegend, San Diego, CA). For intracellular
staining, cells previously stained for membrane proteins were fixed and permeabilized
using a Fix/Perm kit (Biolegend, San Diego, CA). Cells were stained with PE-Cy7labeled CD4, PE-labeled Foxp3, FITC-labeled IL10, PE-labeled IFN-γ, and FITC-labeled
IL-17 (Biolegend, San Diego, CA). Flow cytometry data was analyzed using a CXP
FC500 flow cytometer (Beckman Coulter, Brea, CA) and the gating strategy for shown
represented plots is shown in Figure 2.1.
Genomic DNA extraction and 16S rRNA gene sequencing. Colonic flushes
were used for pyrosequencing analysis to characterize the gut microbiome composition.
The extraction of genomic DNA from colonic flushes was carried out using the QIAamp
DNA Stool Mini Kit (Qiagen, Hilden, Germany) according to the manufacture's
instruction. The DNA concentration were determined using a NanoDrop ND-1000
spectrophotometer and stored at −20°C until further processing. Amplification of the 16S
rRNA V3-V4 hypervariable gene region was carried out using the 16S V3 314F forward
(5′TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCCTACGGGNGGCWGCAG
3′) and V4 805R reverse primers
(5′GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGACTACHVGGGTATCT
AATCC3′) with added Illumina adapter overhang nucleotide sequences. The PCR
conditions used were as follows: 3 minutes (min) at 95°C, follow by 25 cycles of 30
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seconds (s) at 95°C, 30 s at 55°C and 30 s at 72°C, and a final extension at 72°C for 5
min. Each reaction mixture (25 μl) contained 50 ng of genomic DNA, 0.5 μl of amplicon
PCR forward primer (0.2 μM), 0.5 μl of amplicon PCR reverse primer (0.2 μM) and 12.5
μl of 2× KAPA Hifi Hot Start Ready Mix. Each reaction was cleaned up with Agencourt
AMPure XP beads (Beckman Coulter, Indianapolis, IN). Attachment of dual indices and
Illumina sequencing adapters was performed using 5 μl of amplicon PCR DNA product,
5 μl of Illumina Nextera XT Index Primer 1 (N7xx), 5 μl of Nextera XT Index Primer 2
(S5xx), 25 μl of 2× KAPA HiFi Hot Start Ready Mix, and 10 μl of PCR-grade water in
this case. Amplification was carried out under the following conditions: 3 min at 95°C,
followed by 8 cycles of 30 s at 95°C, 30 s at 55°C, and 30 s at 72°C, and a final extension
at 75°C for 5 min. Constructed 16S rRNA gene libraries were purified with Agencourt
AMPure XP beads and quantified with Quant-iT PicoGreen dsDNA Assay kit (Thermo
Fisher Scientific, Waltham, MA). Library quality control and average size distribution
were determined with the Agilent Technologies 2100 Bioanalyzer (Agilent, Santa Clara,
CA). Libraries were normalized and pooled to 40 nM based on quantified values. Pooled
samples were denatured and diluted to a final concentration of 6 pM with a 30% PhiX
(Illumina, San Diego, CA) control. Amplicons were subject to pyrosequencing using the
MiSeq Reagent Kit V3 in the Illumina MiSeq System.
Microbial 16S rRNA gene analysis of sequencing data. The online 16S analysis
software from National Institute of Health (NIH, Baltimore, MD), known as Nephele
(https://nephele.niaid.nih.gov/), was used to analyze sequencing data collection from the
Illumina MiSeq platform. FASTQ sequences were uploaded to Nephele and the 16S
metagenomics application was performed. Groups of related DNA sequences were
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assigned to operational taxonomic units (OTUs), and Nephele-generated output files were
analyzed to determine gut microbial composition. Linear Discrimination Analysis Effect
Size (LEfSe) was performed on Nephele-generated OTU output data in order to
determine microbial biomarkers among experimental groups as previously described
(Segata et al., 2011).
Quantitative Real-Time PCR. For validation of bacteria identified by 16S rRNA
gene analysis, qRT-PCR was used. DNA was extracted from cecal samples using the
QIAamp DNA Stool Mini Kit (Qiagen, Hilden, Germany). Samples were analyzed by
PCR using primers designed to amplify bacterial 16S rRNA genes. For quantification of
Ruminococcus gnavus (5′AGAGGGATGTCAAGACCAGGTA,
3′TACTAGGTGTCGGGTGGAAAAG), Akkermansia muciniphila
(5′GTATCTAATCCCTTTCGCTCCC, 3′GACTAGAGTAATGGAGGGGGAA), and
Bacteroides acidifaciens (5′GTATGGGATGGGGATGCGTT,
3′CTGCCTCCCGTAGAGTTTGG) the StepOnePlus Real-Time PCR system was used.
Fold changes from PCR analysis were obtained by using the delta-delta CT method with
comparison to the control group (Vehicle).
SCFAs identification and quantification. Colonic flushes were collected
immediately after euthanasia by excising colon tissues and flushing them with PBS.
Samples were collected into in 2 ml Eppendorf tubes under anaerobic conditions.
Samples collected were immediately frozen at −80 °C for future analysis. Samples were
analyzed for SCFA concentrations using 2-Ethylbutyric acid as internal standard as
previously described (Chitrala et al., 2017). Briefly, the cecal samples (100 mg) were
suspended and homogenized in water. After centrifugation for 10 min at 12,000 rpm, the
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supernatant was acidified by addition 25% metaphosphoric acid. The internal standard
was added into the supernatant. SCFAs were identified and quantified using a HP 5890
gas chromatograph configured with flame-ionization detectors (GC-FID) and SCFAs
were identified using control standard compounds purchased from Sigma-Aldrich.
Fecal transfer experiment. Fecal material from TNBS+Vehicle or
TNBS+Resveratrol mice was collected 48 hours after the last day of oral gavage
treatment in the experimental model (day 5) from colonic flushes under anaerobic
conditions (using anerobic glove box chamber) prior to inoculation into recipient mice in
200 μl of PBS. Fecal material was collected 48 hours after the last treatment to ensure
that resveratrol had been absorbed in the tissues and eliminated from the feces prior to
collection, as studies have shown this natural compound is rapidly absorbed and
eliminated after consumption (Busbee et al., 2013). Before the fecal transfer, recipient
mice (6 weeks old) were treated with streptomycin and penicillin to deplete endogenous
gut microbiota. Penicillin (1g/L) and streptomycin (1g/L) were dissolved in sterile water
and 100 µl were fed into mice by oral gavage once a day for four consecutive weeks, as
previously described (Khosravi et al., 2014). Depletion of microbiota was validated by
PCR analysis using 16S rRNA gene Eubacteria primer (5′ATTACCGCGGCTGCTGGC,
3′ACTCCTACGGGAGGCAGCAGT). Colitis induction was performed as previously
described. Briefly, on the last day of antibiotic treatment, prior to disease induction,
recipient mice were given feces (5g/L stocks from disease and treated groups) by oral
gavage (100 µl) for 5 days. Body weights were measured daily and colonoscopy was
performed every other day. At the end of experiment, the mice were sacrificed and colon
tissues were taken for histopathology analysis by staining with H&E and PAS as
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described already. Mesenteric lymph nodes were taken and T cell phenotyping was
performed using flow cytometry as described above.
Statistical Analysis. GraphPad Prism software (San Diego, CA) was used for all
statistical analysis. For the in vivo mouse experiments, groups of 5-10 mice were used
per experimental group. For in vitro assays, all experiments were performed in triplicate.
For statistical differences, one-way ANOVA was used for each experiment, and Tukey’s
post-hoc test was performed to analyze differences between groups, unless otherwise
indicated. A p value of at least ≤ 0.05 was used to determine statistical significance.
2.4 RESULTS
Resveratrol attenuates TNBS-induced colitis
In the current study, we tested the ability of resveratrol to attenuate a wellcharacterized TNBS-mediated murine model of colitis (Kim and Berstad, 1992). We used
4 groups of mice: Vehicle alone, resveratrol alone, TNBS+Vehicle, and
TNBS+Resveratrol. TNBS administration caused colitis with significant decrease in
body weight (~20%) when compared to Vehicle- or resveratrol-treated only groups, as
depicted in Figure 2.2A. However, in the TNBS+Resveratrol group, the weight loss was
significantly reversed (~8%). Additionally, the TNBS+Vehicle group showed ~60%
survival, while TNBS+Resveratrol group showed 100% survival (Figure 2.2B). Colitisinduction caused an overall decrease in the colon length in TNBS+Vehicle groups
compared to those treated with either Vehicle or Resveratrol alone, as shown in Figure
2.2C-D. However, TNBS+Resveratrol groups showed a significant increase in colon
length when compared with the disease group (TNBS+Vehicle). Colitis is also
characterized by large productions of inflammatory biomarkers such as SAA, Lcn2, and
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increased MPO activity, which are often used in the diagnosis of the severity of colitis
(Martinez-Moya et al., 2012; Singh et al., 2012). The level of these biomarkers were
significantly elevated in the TNBS+Vehicle group (Figure 2.2E-G), but
TNBS+Resveratrol showed significant decreases in the levels of all those inflammatory
biomarkers, collectively showing that resveratrol was able to ameliorate the colonic
inflammatory response induced by TNBS. Similar results were obtained in DSS-induced
colitis model with the current resveratrol treatment regimen. Oral administration of
resveratrol prevented DSS colitis-induced weight loss (Figure 2.3A) and colon shortening
(Figure 2.3B-C).
Colonoscopic examination at 3 different time points (days 0, 3, and 5) during the
experiment gave a clear picture of the development of colitis-associated lesions and tissue
sloughing after TNBS injection (TNBS+Vehicle), but TNBS+Resveratrol mice showed
marked decrease in tissue disruption (Figure 2.2H-I). Histological examination of
formalin-fixed colon tissues stained with H&E was also performed (Figure 2.4A), which
showed a significant amount of cellular infiltration and loss of mucosal architecture in the
TNBS+Vehicle group compared to naive mice treated with either just Vehicle or
resveratrol alone. In contrast, TNBS+Resveratrol mice showed marked reduction in
cellular infiltration, resembling the control groups. We also performed PAS staining on
fixed colon tissue to determine normal arrangement and distribution of mucin and goblet
cells within the colon mucosa. Mice challenged with TNBS showed high reduction in the
number of goblet cells and mucin thickness, which was greatly returned to normal levels
and size of mucin thickness in colons excised from TNBS+Resveratrol mice, similarly to
naïve mice treated with Vehicle or resveratrol only (Figure 2.4B). Histological scores of
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colons from TNBS mice treated with resveratrol (TNBS+Resveratrol) showed a
significant decrease in disease parameters compared to TNBS+Vehicle mice, which had
much higher scores than the controls groups (Figure 2.4C). These data suggested that
resveratrol prevents the colonic tissue damage induced by TNBS, which includes loss of
the naturally-occurring protective mucous layer.
Resveratrol treatment reduces inflammatory T cell subsets and increases
anti-inflammatory Tregs
In order to examine the T cell subsets during disease and treatment states,
we isolated cells from the mesenteric lymph node of all groups and phenotyped these
cells using flow cytometry. First, we looked at expression of the general T cell marker
(CD3) which showed a significant increase in the percentage in TNBS+RES mice, while
TNBS+Resveratrol treatment led to a marked decrease (Figure 2.5A). We next looked at
both T helper (CD4+) and cytotoxic (CD8+) T cell subset populations and showed
significant increases in both CD4+ and CD8+ T cells in TNBS+Vehicle mice compared
with those that were treated with Vehicle or resveratrol alone (Figure 2.5B), but this was
effectively reduced in TNBS+Resveratrol groups. We then performed
intracellular/intranuclear staining to identify the effect of resveratrol on specific CD4+ T
cells subsets which include inflammatory IFNγ- and IL17-producing CD4+ T cells, in
addition to anti-inflammatory CD4+FOXP3+ and CD4+IL10+ populations. The data
showed a significant increase in percentages of both anti-inflammatory CD4+FOXP3+
and CD4+IL10+ cells population in the TNBS+Resveratrol group when compared
TNBS+Vehicle, and this increase in CD4+FOXP3+ populations were also observed in
naïve mice treated with resveratrol (Figure 2.5C-D). In contrast, intracellular staining for
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CD4+IFNγ+ and CD4+IL17+ showed significant increases in both percentage and absolute
cell number in TNBS+Vehicle mice, while those in the TNBS+Resveratrol had a reversal
in this effect (Figure 2.5E-F). Absolute cell numbers of T cells and T cell subsets in the
MLN confirmed these findings (Figure 2.5G). Collectively, these data showed that
resveratrol treatment reduces the inflammatory T cell response during TNBS-induced
colitis, while promoting the production of anti-inflammatory T cell subsets, mainly Tregs
and IL-10-producing CD4+ cells. This increase in Tregs was also observed in naïve mice
that were treated only with resveratrol alone.
Alterations in gut microbiota and SCFA composition in colitis-induced mice
treated with resveratrol
Next, we analyzed the gut microbiota from the all experimental groups to
determine whether or not resveratrol altered the gut microbial composition during colitis.
From colonic flushes, we isolated genomic DNA and performed 16S rRNA gene
sequencing, analyzing the sequenced reads with the NIH-based Nephele online analysis
tool. Nephele analysis output showed that the alpha diversity, represented as chao1, in
naïve mice treated with resveratrol had the most diverse gut microbial compositions when
to the other groups (Figure 2.6A). In terms of beta diversity, depicted as a PCA plot,
samples clustered within their respective groups, with TNBS+Vehicle samples showing
more dissimilarity compared to Vehicle-treated, or those groups treated with resveratrol
(Resveratrol or TNBS+Resveratrol) (Figure 2.6B). 16s rRNA gene sequencing analysis
from Nephele allowed sample reads to be classified into OTUs from phylum to the
species level, and output data up to the genus level is summarized in Figures 2.7-2.9. In
order to determine the most divergent and potential microbial biomarkers within
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experimental groups, LeFSe analysis was performed with comparisons of TNBS+Vehicle
vs TNBS+Resveratrol (Figure 2.6C-D). The results showed that TNBS+Vehicle mice had
increased abundance of Bacteroides acidifaciens compared to the other groups (Figure
2.6E), while naïve or TNBS-induced colitis mice treated with resveratrol had enrichment
of bacteria belonging to the genus Ruminococcus (Figure 2.6C). At the species level,
Ruminococcus gnavus and Akkermansia muciniphila showed a significant increase in
TNBS+Resveratrol groups when compared to TNBS+Vehicle groups (Figure 2.6F-G). It
is interesting to note that mice treated with resveratrol alone also showed increases in
Ruminococcus gnavus (Figure 2.6F). In order to validate our sequencing results at the
species level, we performed PCR using bacterial species-specific primers. As shown in
Figure 2.6H-J, Bacteroides acidifaciens was increased in the TNBS+Vehicle group
compared to naïve mice treated with Vehicle or resveratrol only, but this species was
reduced in the TNBS+Resveratrol group (Figure 2.6H). In addition, Ruminococcus
gnavus and Akkermansia muciphila species showed significant increases in abundance in
groups treated with resveratrol (Resveratrol or TNBS+Resveratrol) when compared to
those treated with only vehicle (Vehicle or TNBS+Vehicle) (Figure 2.6I-J).
Lastly, we measured the SCFA production in response to these changes in
the gut microbiome composition (Figure 2.10). The data showed that acetic acid and ibutyric acid concentrations were significantly reduced in the TNBS+Vehicle groups
when compared to Vehicle, while naïve mice treated with resveratrol and TNBS+RES
groups showed significant increases in these SCFAs (Figure 2.10A, 2.10C). However,
propionic acid, n-butyric acid, i-valeric acid, n-valeric acid, and n-copric acid showed no
significant changes among the various groups (Figure 2.10B, 2.10D-F). Together, these
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data suggested that treatment with resveratrol, particularly in colitis induced conditions,
significantly altered both the gut microbiome composition and SCFA production.
Fecal transfer from resveratrol-treated groups attenuates TNBS-induced
colitis and alters the immune response
In order to determine whether or not resveratrol-induced alterations in the
gut microbiome contributes to the altered immune response in colitis, we performed fecal
transfer experiments following treatment of mice with antibiotics to deplete the existing
gut microbiota. While there were no significant differences observed in body weight of
mice in the wild-type and antibiotic-treated mice (Figure 2.11A), PCR for the universal
Eubacteria 16S rRNA gene confirmed that the microbiome was depleted in antibiotictreated mice prior to inoculation with fecal material (Figure 2.11B-C). TNBS-exposed
mice were inoculated with either feces from TNBS-treated mice ((FT) TNBS+Vehicle),
or inoculated with feces from TNBS+Resveratrol-treated mice ((FT) TNBS+Resveratrol).
(FT) TNBS+Vehicle mice showed a gradual decrease in body weight until the
termination of the experiment (Figure 2.11D). However, (FT) TNBS+Resveratrol mice
showed resistance to loss of body weight. TNBS-induced colitis mice transferred with
feces from TNBS+Vehicle also had shorter colons when compared those receiving fecal
transfers from TNBS+Resveratrol-treated mice (Figure 2.11E-F). Looking at colitisassociated inflammatory biomarkers such as SAA, Lcn2, and MPO, we found that the
(FT) TNBS+Resveratrol group had significantly lower levels of these inflammatory
biomarkers compared to the (FT) TNBS+Vehicle group (Figure 2.11G-I). In addition,
colonoscopy examination showed increased ulceration and sloughing in portions of the
colon in (FT) TNBS+Vehicle mice, while (FT) TNBS+Resveratrol groups showed
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reduced presence of colon tissue destruction (Figure 2.11J, top panel). Colonoscopy and
histological examination of formalin-fixed colon tissues stained with H&E also showed
that (FT) TNBS+Resveratrol mice showed no signs of cellular infiltration and tissue
destruction, while (FT) TNBS+Vehicle mice had these colitis-associated observations
(Figure 2.11J-K).
Lastly, we performed T cell CD4+ phenotyping of the mesenteric lymph
nodes in these fecal transfer experiments. The data showed that there was significant
increases in CD4+FOXP3+ Tregs (Figure 2.11L), though not in CD4+IL10+ (Figure
2.11M), populations in the (FT) TNBS+Resveratrol group compared to (FT)
TNBS+Vehicle, and the inflammatory Th1 (CD4+IFNγ+) and Th17 (CD4+IL17+)
numbers were significantly reduced in these mice as well (Figure 2.11N-O). In order to
confirm that relevant species were in fact altered during the FT experiments, PCR
validation was performed on colonic flushes from these experimental FT groups. PCR
validation showed that mice (FT) TNBS+Resveratrol mice did have increased levels of
Akkermansia muciniphila (Figure 2.11P) and Ruminococcus gnavus (Figure 2.11Q) when
compared to (FT) TNBS+Vehicle mice. In addition, there was significantly lower levels
of Bacteroides acidifaciens in (FT) TNBS+Resveratrol groups compared to (FT)
TNBS+Vehicle (Figure 2.11R), confirming that prominent species from the sequencing
data were transferred successfully. Together, the fecal transfer experiments demonstrated
that microbiota from (FT) TNBS+Resveratrol groups provide significant protection from
colitis through enhancement of Tregs and suppression of Th17 and Th1 cells.
2.5 DISCUSSION
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Resversatrol is a potent anti-inflammatory agent. Studies from our lab and
elsewhere have shown the ability resveratrol to reduce the symptoms associated with
colitis, in different murine models (Martin et al., 2006; Singh et al., 2012; Wagnerova et
al., 2017; Yao et al., 2015; Youn et al., 2009), as well as in human patient populations
(Samsami-Kor et al., 2015). Resveratrol is known to act through multiple pathways. In
our previous reports, we were able to reveal some of the mechanisms that made this
natural compound such a successful treatment. For example, in the genetic IL-10-/model of colitis, we showed that resveratrol treatment was able to induce
immunosuppressive MDSCs that led to a reduction in clinical parameters in addition to
the reduction in CXCR3 expressing T cells (Singh et al., 2012). The ability of resveratrol
to induce these anti-inflammatory MDSCs has been shown in our lab in other disease
models (Altamemi et al., 2014; Guan et al., 2012; Rieder et al., 2012), and been
confirmed by others as well (Chen et al., 2015a; Hong et al., 2017). Other studies have
shown that the beneficial effects of resveratrol against colitis can be attributed to other
mechanisms, such as targeting sphingosine kinase 1 (SphK1) and apoptosis, restoring
nitric oxide levels, reducing neutrophil infiltration, inhibiting nuclear factor-kappaB
activation, acting as an anti-oxidant, as well as inhibiting adhesion molecules (Abdallah
and Ismael, 2011; Abdin, 2013; Yao et al., 2011). Resveratrol is also well-known to be a
ligand for the aryl hydrocarbon receptor (AhR), and our lab and others have shown this
natural compound’s ability to shift T cell differentiation from Th17 to Tregs, which is
dependent on this receptor-ligand interaction (Singh et al., 2007; Wang et al., 2013).
Classically, Th1 and Th2 cells were thought to characterize Crohn’s disease and
ulcerative colitis respectively, however, Th17 cells are now known to play an important

23

role in gut immunity and inflammation, particularly in regards to IBDs such as colitis
(Ueno et al., 2018). Genome-wide association (GWAS) studies in IBD patients found that
IL-17 regulating genes are greatly altered in the disease state, thus suggesting the
importance of this factor in IBD such as colitis (Ueno et al., 2018). In fact, both animal
models of colitis and human IBD patients are characterized by increased presence and
development of Th17 cells at sites of inflammation (Galvez, 2014; Jiang et al., 2014; Lee
et al., 2012). Th17 plasticity towards inflammatory (IFN-γ-producing Th1) or antiinflammatory (Treg) phenotypes make it a very unique cell population involved in
intestinal homeostasis (Galvez, 2014). Interestingly, recent research has shown that Th17
cells are greatly influenced by the microenvironment such as the microbiome and
microbial-derived byproducts (Ueno et al., 2018).
More recent studies have shown that resveratrol may protect against many clinical
disorders by modulating the gut microbiota (Bird et al., 2017; Chen et al., 2016; Sung et
al., 2017). However, such studies did not perform fecal transfer experiments to
demonstrate that the microbiota altered by resveratrol treatment could lead to suppression
of colitis-associated inflammation. In the present report, we therefore performed fecal
transfer experiments, which conclusively demonstrated that resveratrol-mediated
modulations in the gut microbiota is indeed responsible for attenuating colonic
inflammation. It is becoming apparent that the gut microbiome contributes significantly
to the development and progression of various diseases, particularly in the case of colitis
(Autenrieth and Baumgart, 2017; Conte et al., 2006; Kanauchi et al., 2003; Nishikawa et
al., 2009; Rapozo et al., 2017). With the gut microbiome playing such an important role
in this disease, recent research is even focused on fecal transfer experiments as a
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therapeutic option (Meighani et al., 2017; Paramsothy et al., 2017). In addition, potential
treatments against colitis are being examined more thoroughly to determine what, if any,
effects these possible therapeutics have on the gut microbiome (Jang et al., 2017; Yang et
al., 2017).
In the current study, we were able to show that bacteria, such as those belonging
to the Genus Ruminococcus, are increased during resveratrol treatment, which is
consistent with animal studies and human fecal transplant experiments in which bacteria
such as Ruminococcus and others were found to be anti-inflammatory, restoring and
maintaining normal gastrointestinal tract function and integrity (Satokari et al., 2014). In
fact, Ruminococcus gnavus and Akkermansia muciniphilia are mucolytic bacteria that are
found to be reduced in both ulcerative colitis and Crohn’s Disease patients when
compared to normal patient controls (Png et al., 2010). Therefore, restoration of these
bacteria, which we noted in our data after naïve mice or TNBS-induced colitis mice were
treated with resveratrol, could help in restoring or maintaining gut homeostasis,
particularly after the microbiome is altered during colitis due to microbial dysbiosis. On
the other hand, the current study shows that resveratrol can effectively reduce
Bacteroides acidifaciens, which was found to be significantly increased in TNBSinduced colitis, a finding also seen in a murine DSS model (Kang et al., 2013). B.
acidifaciens have several features which could lead to the progression and development
of colitis. This species is known to degrade mucin (Miyamoto and Itoh, 2000), the
protective layer in the colon producing the host epithelial surface from luminal-bound
bacteria. B. acidifaciens is also known to increase SCFA production of acetic and
succinic acids (Miyamoto and Itoh, 2000), both of which can contribute to colitis-
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associated inflammation. Acetic acid, given in high concentrations, can induce colitis in
murine models (Karakoyun et al., 2017). Succinic acid, which is produced by members of
Bacteroidaceae, like B. acidifaciens, was found to be increased in the colons of colitisinduced mice and when administered by enemas can produce ulcers in the colon (Ariake
et al., 2000). B. acidifaciens resembles closely another member of the same genus B.
fragilis, and these bacteria have been shown in the literature to trigger a strong
inflammatory cascade response, including activation of IL-17-dependent pathways
(Chung et al., 2018). By decreasing the presence of these bacteria during colitisinduction, resveratrol might be able to suppress the Th17 response which would normally
lead to resident tissue destruction and microbial dysbiosis.
From our present study, we were also able to show that not only does resveratrol
alter gut microbial composition during colitis disease induction, but these changes in the
gut microbiome lead to alterations in the production of SCFAs. In particular, we found
that i-butyric acid was significantly upregulated in resveratrol-treated mice during colitis
induction and slightly in naïve mice treated with resveratrol compared to those treated
only with Vehicle. From the literature, we know that butyrate/butyric acid has potent
anti-inflammatory properties (Dai et al., 2017; van der Beek et al., 2017; Wang et al.,
2017). There are studies that also show that butyrate plays an important role in regulating
the development of colitis, or acting as an agent to mitigate its deleterious effects (Cobo
et al., 2017; Zhang et al., 2016c). For example, oral administration of sodium butyrate
into DSS-induced colitis mice led to reduction of inflammation (Simeoli et al., 2017).
Butyrate deficiency was shown to increase susceptibility to the development of colitis
(Meisel et al., 2017). Therefore, the fact that resveratrol was able to increase production
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of this SCFA, particularly during colitis-induced conditions, provides a better
understanding of the mechanisms that promote its efficiency against colitis, as well as
other inflammatory disorders. Interestingly, we saw an increase in acetic acid in
resveratrol treatment only after colitis induction, and this SCFA is often used to induce
colitis (Sadraei et al., 2017). It is possible that the increase in butyric acid was able to
either negate the effects of increased acetic acid in our model. The uniqueness of our
findings lie in the fact that we were able to show through 16S rRNA gene sequencing and
fecal transfer experiments that the effectiveness of resveratrol against colitis could be
explained by the ability of this natural product to alter and reverse microbial dysbiosis
and SCFA production to promote an anti-inflammatory effect (induction of Treg/IL-10)
and suppress the inflammatory (Th1/Th17) T cell response, something that has not been
reported in the literature thus far. It is particularly interesting to note that the poor
bioavailability of resveratrol during oral consumption, which is attributed to the weak
aqueous solubility of the compound, has always been an issue in terms to suggesting this
natural product as a treatment of various disease (Peng et al., 2018). In fact, this
observation has led to a wealth of research focusing on how to increase the bioavailability
of this potent anti-inflammatory natural product so that it can be absorbed and circulated
to various affected organs, such as by way of encapsulation in nanoparticles or some
other vehicle (Borges et al., 2018; Zu et al., 2018). However, our findings suggest that
resveratrol alters the microbiome directly and this leads to the anti-inflammatory effects
during colitis, even before it becomes bioavailable to various organs after oral
consumption.
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In summary, the current study demonstrates the efficacy of resveratrol to
attenuate colitis may result from its ability to alter gut microbiota that promotes antiinflammatory T cell induction while suppressing pro-inflammatory T cells as summarized
in Figure 2.12.
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Figure 2.1 Gating strategy for flow cytometry. MLN lymph nodes from control
(Vehicle) mice were stained and examined by flow cytometry using the following gating
strategy: (A) Unstained negative controls were used to eliminate any non-specific false
positive signal. (B) Single color controls were stained with either CD3 (FITC), CD4 (PE),
or CD8 (PE-Cy7) to determine appropriate gating for histogram (top) and color dot plots
(bottom). (C) Intracellular staining of CD4+ cells was gated as shown and represented in
Figure 2.5.
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Figure 2.2 Treatment with resveratrol reduces clinical symptoms associated with
TNBS-induced colitis murine model. Balb/c mice were administered intrarectally with
1mg of TNBS to induce colitis. Four groups of mice were used: Vehicle, Resveratrol,
TNBS+Vehicle and TNBS+Resveratrol. The percent weight loss (A) was determined
over the course of the study. (B) Survival curve of mice up to day 6 with colitis and those
treated with RES. Colon lengths (C-D) were measured upon sacrifice (Day 5). Serum
levels of SAA (E), MPO (F) and Lcn2 (G) were evaluated by ELISA. Endoscopy (H) was
performed on mice on days 0, 3, and 5. Colonoscopy scores are provided (I). Significance
(p-value: *<0.05, **<0.01, ***<0.005, ****<0.001) was determined by using one-way
ANOVA and post-hoc Tukey’s test. In all data presented in the figure, 5 mice were used
in each group. Data presented is representative of at least 3 independent experiments.
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Figure 2.3 Treatment with resveratrol reduces clinical symptoms associated with
DSS-induced colitis murine model. C57BL/6 mice were given 7 days of 3% DSS ad
libitum followed by regular drinking water for 7 more days. Four groups of mice (n=5 per
group) were used: Vehicle, Resveratrol, DSS+Vehicle and DSS+Resveratrol. The
percent weight loss (A) was determined over the course of the study. Colon lengths (B-C)
were measured upon sacrifice (Day 10). Significance of the bar graphs (p-value: *<0.05,
**<0.01, ***<0.005, ****<0.001) were determined by using one-way ANOVA followed
by Tukey’s post-hoc multiple comparisons test.
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Figure 2.4 Treatment with resveratrol prevents cellular infiltration and mucin
degradation and maintains colon gut structural architecture in TNBS model. The
study was designed as described in Figure 2.2 legend. Colons (n=5) were excised from
experimental mice at the endpoint of experiment, fixed in 10% formaldehyde, and
embedded in paraffin blocks. Cross-section slides containing colons from experimental
groups were stained using H&E (A) or PAS (B) for histological evaluation. Images of
stained tissue were taken using both 4x and 20x objectives, and histological scores were
provided (C). Scale bars (white) depicted are at 100 µM. Data is representative of at least
3 independent experiments.
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Figure 2.5 Resveratrol alters T cell subsets during TNBS colitis. The study was
designed as described in Figure 2.2 legend. Flow cytometry histograms/dot plots are
shown for the following T cell subsets: CD3+ (A), CD4+ or CD8+ cells (B),
CD4+FOXP3+ (C), CD4+IL10+ (D) and CD4+IFNγ+ (E), and CD4+IL-17+ (F)
expressing cells. For Figures C-F, cells were gated on the CD4+ population. The gating
strategy for the CD4+ populations is detailed in Figure 2.1. Quantitative bar graphs
depicting absolute cell numbers of the T cell subsets is provided (G) Each experimental
group had at least 5 mice included, and significance (p-value: *<0.05, **<0.01,
***<0.005, ****<0.001) was determined for absolute cell numbers by using one-way
ANOVA followed by Tukey’s post-hoc multiple comparisons test. Data is representative
of at least 3 independent experiments.
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Figure 2.6 16S rRNA gene sequencing analysis. The study was designed as described
in Figure 2.2 legend. Gut microbiome samples were collected from experimental groups
by performing cecal flushes. Genomic DNA was isolated and V3-V4 regions of 16S
rRNA gene subunit were sequenced. Three randomly selected mice from each group
(n=3) were used for these experiments. All sequencing samples were analyzed using
Nephele software 16S metagenomics provided at Nephele website
(nephele.niaid.nih.gov). Alpha diversity (A), and Beta diversity (B) are depicted. LeFSe
analysis of the Nephele OTU output files generated the cladogram (C) and LDA score bar
graph (D) depicting microbial biomarkers among TNBS+Vehicle vs. TNBS+RES groups.
OTU percent abundances are shown for the species Bacteroides acidifaciens (E)
Ruminococcus gnavus (F) and Akkermansia muciphila (G). Validation of these
significantly-altered bacterial species were performed using PCR and the fold changes
are calculated using the delta-delta CT method with comparison to Vehicle controls (HJ). For 16S rRNA gene sequencing, 3 representative cecal flushes from each experimental
group were processed and sequenced. For PCR validation, 10 mice were used in each
group and fold changes were calculated using the delta-delta CT method compared to
Vehicle control. Significance (p-value: *<0.05, **<0.01, ***<0.005, ****<0.001) was
determined by using one-way ANOVA followed by Tukey’s post-hoc multiple
comparisons test. Experiments are representative of 3 independent experiments.
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Figure 2.7 16S rRNA sequencing analysis at the phylum to order level. Gut
microbiome samples (n=3 per group) were collected from experimental groups (Vehicle,
Resveratrol, TNBS+Resveratrol, TNBS+Vehicle) by performing cecal flushes. Genomic
DNA was isolated and V3-V4 regions of 16S rRNA subunit were sequenced. Three
randomly selected mice from each group were used for these experiments. All
sequencing samples were analyzed using Nephele software 16S metagenomics provided
at Nephele website (nephele.niaid.nih.gov). Stacked bar charts depicting OTU relative
expression with corresponding color-coded legend for the following levels: phylum (A),
class (B), and order (C).
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Figure 2.8 16S rRNA sequencing analysis at the family level. Gut microbiome
samples were collected from experimental groups (Vehicle, Resveratrol,
TNBS+Resveratrol, TNBS+Vehicle) by performing cecal flushes. Genomic DNA was
isolated and V3-V4 regions of 16S rRNA subunit were sequenced. Three randomly
selected mice from each group were used for these experiments. All sequencing samples
were analyzed using Nephele software 16S metagenomics provided at Nephele website
(nephele.niaid.nih.gov). (A) Stacked bar charts depicting OTU relative expression with
corresponding color-coded legend. (B) Bar graphs representing percent OTU abundance.
Significance of the bar graphs (p-value: *<0.05, **<0.01, ***<0.005, ****<0.001) were
determined by using one-way ANOVA followed by Tukey’s post-hoc multiple
comparisons test.
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Figure 2.9 16S rRNA sequencing analysis at the genus level. Gut microbiome samples
were collected from experimental groups (Vehicle, Resveratrol, TNBS+Resveratrol,
TNBS+Vehicle) by performing cecal flushes. Genomic DNA was isolated and V3-V4
regions of 16S rRNA subunit were sequenced. Three randomly selected mice from each
group were used for these experiments. All sequencing samples were analyzed using
Nephele software 16S metagenomics provided at Nephele website
(nephele.niaid.nih.gov). (A) Stacked bar charts depicting OTU relative expression with
corresponding color-coded legend. (B) Bar graphs representing percent OTU abundance.
Significance of the bar graphs (p-value: *<0.05, **<0.01, ***<0.005, ****<0.001) were
determined by using one-way ANOVA followed by Tukey’s post-hoc multiple
comparisons test.
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Figure 2.10 Resveratrol treatment alters SCFA production in TNBS colitis. The
study was designed as described in Figure 2.2 legend. SCFA were isolated from cecal
contents of experimental groups through acidification using metaphosphoric acid. GCFID analysis was performed to determine the concentrations of acetic (A), propionic (B),
i-butyric (C), n-buytric (D), i-valeric (E), and n-valeric (F) acids. SCFAs were identified
using standard compounds purchased from Sigma-Aldrich. Representative data from two
independent experiments with 5 mice in each group is depicted. Significance (p-value:
*<0.05, **<0.01, ***<0.005, ****<0.001) was determined using one-way ANOVA
followed by Tukey’s post-hoc multiple comparisons test.
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Figure 2.11 Transfer of resveratrol-treated fecal contents leads to amelioration of
colitis. Female Balb/c mice were treated for 4 weeks with streptomycin and ampicillin
(1g/L) prior to being injected intrarectally with 1mg of TNBS to induce colitis.
Antibiotic-treated mice were weighed (A) and PCR performed on colonic flush samples
to determine abundance of bacteria in the gut compared to naïve mice (B-C). These mice
received fecal transfer (FT) from either colitis disease groups, (FT) TNBS+Vehicle, or
from TNBS+Resveratrol-treatment groups, (FT) TNBS+RES. The percent weight loss
(D) was determined over the course of the study. Colon lengths were measured upon
sacrifice (E-F). Serum biomarkers for SAA (G), MPO (H), LCN2 (I) were detected using
ELISA kits. Endoscopic images (J, top panel) and H&E stains of colons (J, bottom panel)
are depicted (n=5 per group). Colonoscopy scores (K, top) and histological scores (K,
bottom) are provided. Cells were isolated from mesenteric lymph nodes of experimental
groups and absolute cell numbers from fecal transfer experiments were determined for
CD4+FOXP3+ (L), CD4+IL10+ (M), CD4+IL17+ (N) and CD4+IFNγ+ (O). PCR
validation from colonic flushes was performed after fecal transfer to confirm alterations
in Akkermansia muciphila (P) Ruminococcus gnavus (Q) and Bacteroides acidifaciens
(R), using delta-delta CT method with comparison to Vehicle controls. Each group had
10 recipient mice in this experiment and significance (p-value: *<0.05, **<0.01,
***<0.005, ****<0.001) was determined using one-way ANOVA followed by Tukey’s
post-hoc multiple comparisons test.
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Figure 2.12 Graphical Abstract. TNBS-induced colitis results in microbial dysbiosis,
with increased abundance of Bacteroides acidifaciens. However, treatment with
resveratrol prevents this colitis-associated gut microbial shift, leading to increased
abundance of bacteria such as Akkermansia muciphila and Ruminococcus gnavus, and
production of SCFA butyrate. Increased presence of Akkermansia muciphila,
Ruminococcus gnavus, and butyrate shifts the CD4+ T helper response from Th17 to
anti-inflammatory Tregs. Fecal transfer of resveratrol-treated mice confirms these
alterations in the immune response were the result of changes in the gut microbial profile
mediated by resveratrol.
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CHAPTER 3
RESVERATROL ATTENUATES MURINE AOM-DSS INDUCED COLORECTAL
CANCER BY PROMOTING BUTYRATE PRODUCTION AND INDUCING ANTIINFLAMMATORY T CELLS VIA ALTERATIONS IN THE GUT MICROBIOME AND
SUPPRESSION OF HDACS
3.1 ABSTRACT
Inflammatory bowel disease (IBD) is known to significantly increase the risk for
development of colorectal cancer (CRC), thereby suggesting that inflammation and
cancer development are closely intertwined. Thus, it is likely that agents that suppress
inflammation in the colon may prevent the onset of cancer. In the current study, we
investigated the effect of resveratrol, a stilbenoid, in inflammation-induced murine model
of CRC using a combination of azoxymethane (AOM) and dextran sodium sulphate
(DSS) and tested the role of microbiota in preventing inflammation-driven CRC.
Resveratrol treatment caused an increase in the levels of anti-inflammatory
CD4+FOXP3+ and CD4+IL10+ cells while decreasing proinflammatory such as Th1 and
Th17 cells, as well as attenuated development of CRC in AOM/DSS mice. Examination
of colonic contents showed that resveratrol altered the gut microbiome and increased
levels of the short chain fatty acid (SCFA), butryate. Fecal transfer from resveratroltreated AOM/DSS mice resulted in attenuation of CRC and suppression of inflammation
as evidenced by alterations in T cell subsets. Moreover, supplementation of butyrate in
CRC resulted in similar alterations in microbial profile. In vivo and In vitro data also
revealed both RES and BUT were capable of inhibiting histone deacetylases (HDACs),
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which correlated with Treg induction. Interestingly, analysis of TCGA datasets of CRC
patients, also revealed that increased expression of Treg-specific transcription factor
FoxP3 or anti-inflammatory IL-10 resulted in an increase in 5-year survival of patients
with CRC. Together, these data suggest that resveratrol-mediated shift in T cells from
pro-inflammatory to anti-inflammatory phenotype, in AOM/DSS model, may result from
alterations in gut microbiome and increased butyrate production leading to attenuation of
inflammation-driven CRC.
3.2 INTRODUCTION
The current study was undertaken to investigate alterations in the gut microbiome
by resveratrol during CRC. We show that in the AOM/DSS CRC murine model,
resveratrol was able to alter the gut microbiome profile and increase microbialproduction of short-chain fatty acid (SCFA), butyrate, to promote an anti-inflammatory T
cell response (Treg and CD4+IL-10) which decreased disease severity and tumor
development in the colon. Additionally, fecal transfer of resveratrol-treated fecal material
and butyrate supplementation experiments showed that modulation of gut microbiota and
suppression of histone deacetylases (HDACs) were key mechanisms through which
resveratrol, through butyrate-dependent mechanisms, was able to regulate the immune
response and prevent CRC development. Lastly, we show that in the human CRC
population, increased expression of Treg-associated genes (FoxP3 and IL-10) correlates
with increased survival rates, thereby providing additional proof of the role of antiinflammatory environment in CRC suppression.

3.3 MATERIALS AND METHODS
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Animals. Female C57BL/6 mice (aged 6-8 weeks) were purchased from Jackson
Laboratories (Bar Harbor, ME) and all mice were housed at the AAALAC-accredited
animal facility at the University of South Carolina, School of Medicine (Columbia, SC).
All procedures were performed according to NIH guidelines under protocols approved by
the Institutional Animal Care and Use Committee (IACUC).
Induction of AOM/DSS CRC in mice and treatment(s). To test the efficacy of
treatment in AOM/DSS-induced CRC model, AOM was purchased from Sigma-Aldrich
(St. Louis, MO), and administered one time via intraperitoneal (i.p.) injection into
C57BL/6 mice at a dose of 10 mg/kg at day zero, followed by three cycles of 2% DSS
(Chem-Impex International, Wood Dale, IL) as previously described (Cui et al., 2010).
For treatment groups, resveratrol (Sigma-Aldrich) was administered by oral gavage at
100 mg/kg suspended in 100 µl of water, as previously reported by us (Singh et al.,
2010). The regimen for resveratrol consisted of administering this compound 24 hours
prior to the injection of AOM, followed by daily treatment throughout the duration of the
experiment (10 weeks). Control groups consisted of naïve mice receiving either normal
water or 100 mg/kg resveratrol. For butyrate supplementation experiments, sodium
butyrate (BUT) from Sigma-Aldrich was given to mice at 200 mg/kg dissolved in water
using the same regimen (days and controls) as resveratrol for 10 weeks.
Procedures for evaluating CRC disease severity. During AOM/DSS induced
CRC, mice were weighed daily after AOM injection. Animals were euthanized at the
experimental endpoint (10 weeks after AOM injection) for further evaluation of clinical
signs to include counting the number and size of tumors in the colon highlighted by 1%
Alcian blue dye and measured by a ruler or digital caliper. Colonoscopies were
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performed weekly to experimental groups using a Karl Storz (Tuttlingen, Germany) Tele
Pack Vet X LED endoscope and scored the following way: 0 = normal colon, 1 =
presence of blood and tissue sloughing, 2 = presence of 1-2 colonic polyps, 3 = 3-5
colonic polyps present, 4 = 5-10 colonic polyps present, 5 = <10 polyps present in the
colon. Colon, mesenteric lymph node (MLN), spleen, and blood were collected from
euthanized mice for further evaluation. Colons were cleaned by saline wash and
sectioned for histological analysis. Colon sections (tumor and normal adjacent tissue)
were fixed with 4% paraformaldehyde and embedded in paraffin, cut into 5µm sections,
deparaffinized in xylene, serially diluted in decreasing concentrations of ethanol, and
stained with hematoxylin-eosin (H&E) and Periodic Acid Schiff (PAS) staining kits
(Sigma-Aldrich). Images of stained sections were taken using a Biotek (Winooski, VT)
Cytation 5 with digital wide field microscopy capabilities.
Cellular phenotyping by flow cytometry. Cells from MLN, spleen, and blood
were isolated from experimental groups and lysed with RBC lysis buffer (Sigma-Aldrich)
before being filtered and stained with appropriate antibodies for cellular phenotyping
using flow cytometry. All cells were pre-blocked with Fc receptor, washed with FACS
staining buffer (PBS with 2% fetal bovine serum), and stained with commerciallyavailable antibodies (Biolegend, San Diego, CA) as follows: FITC- anti-CD3, PE-antiCD8, and PE-CY7-anti-CD4 to identify T cells; FITC-anti-Gr1 and PE-anti-CD11b to
identify myeloid-derived suppressor cells (MDSCs). For phenotyping of T cell subsets,
intracellular (Intracellular Staining Permeabilization Wash Buffer) and intranuclear
(True-Nuclear Transcription Factor Buffer Set) staining kits (Biolegend) were used by
way of manufactures instructions. Permeabilized cells were stained with PE-Cy7-anti-
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CD4, PE-anti-Foxp3, FITC-anti-IL10, PE-anti-IFNγ, and/or FITC-anti-IL17 (Biolegend).
Flow cytometry data were analyzed using a CXP FC500 flow cytometry (Beckman
Coulter, Brea, CA).
In vitro treatment of activated splenocytes with resveratrol or BUT. For in
vitro experiments treated with resveratrol or BUT, whole splenocytes were excised from
8-10 week old C57BL/6 mice and single cell suspensions were cultured in anti-CD3coated (.5µg/ml) 96-well plates at 1 x106 cells/mL density in complete RPMI media for
24 hours at 37°C, 5% CO2. Cultured cells were then activated with soluble anti-CD28
(2µg/ml) in the presence or absence of resveratrol (5, 10, or 25 µM) or BUT (1mM,
5mM, or 10mM) for 24 hours (37°C, 5% CO2). In vitro doses of resveratrol were based
on previous reports from our lab (Singh et al., 2007). The range of doses for BUT was
determined using information gathered from other publications (Kespohl et al., 2017;
Salimi et al., 2017).
16S rRNA gut microbiota profiling, Phylogenetic Investigation of
Communities by Reconstruction of Unobserved States (PiCRUSt), and SCFA
analysis. 16S rRNA gut microbial profiling and SCFA quantification were done as
previously described in our lab (Chitrala et al., 2017). Briefly, colonic contents were
collected immediately after euthanasia and gathered in 2 ml eppendorf tubes while under
anaerobic conditions and stored at −80 °C for downstream analysis purposes. For 16S
rRNA sequencing, genomic DNA was extracted from 100 mg of colonic flush contents
by using the QIAamp DNA Stool Mini Kit (Qiagen, Valencia, CA) according to
instructions from the manufacturer. DNA libraries were prepped by amplification of the
16S rRNA V3-V4 hypervariable region with added Illumina adapter overhang nucleotide
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sequences and sequencing with Illumina (San Diego, CA) MiSeq platform. Sequenced
reads were than analyzed using Nephele (https://nephele.niaid.nih.gov), an open-source
analysis tool provided by the National Institute of Allergy and Infectious Diseases
(NIAID) Office of Cyber Infrastructure and Computational Biology (OCICB) in
Bethesda, MD (Weber et al., 2018). For microbial profiling, QIIME FASTQ paired end
with chimera removal, open reference, and SILVA rRNA database project (Silva_99)
options were used. For PiCRUSt data, a closed reference against the Greengenes database
(Greengene_99) option was used. Operational taxonomic unit (OTU) tables generated
from Nephele were further subjected to Linear Discrimination Analysis Effect Size
(LEfSe) provided by the Huttenhower group
(https://huttenhower.sph.harvard.edu/galaxy/) (Segata et al., 2011). For quantification of
SCFAs present in colonic flushes, HP 5890 gas chromatograph configured with flameionization detectors (GC-FID) was performed as previously described (Chitrala et al.,
2017; Zhao et al., 2006). SCFA detection by GC-FID was quantified using Varian MS
Workstation (version 6.9.2.) software and concentrations were calculated by using
standards for the detectable SCFAs.
Fecal transfer (FT) experiments. For FT experiments, colonic contents were
collected immediately after euthanasia, gathered in 2 ml eppendorf tubes while under
anaerobic conditions, and placed in 30% glycerol solution prior to inoculation into
recipient mice. Before FT inoculation, recipient mice were treated with 1g/L of
streptomycin and penicillin dissolved in water and orally gavaged at 100 µl total volume
daily for four weeks to deplete endogenous gut microbiota. Depletion of microbiota was
validated by PCR analysis using the universal 16S rRNA Eubacteria primer. AOM/DSS
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CRC induction was performed as previously described in recipient mice. 48 hours after
the last treatment with the antibiotic cocktail, recipient mice were given fecal material
collected from the following groups: Naïve, Resveratrol-treated only, AOM, and
AOM+Resveratrol. FT treatments were given via oral gavage every even days for a total
of 35 days. Body weight and other clinical parameters described previously were also
performed for the FT experiments to include weekly colonoscopies, 1% Alcian blue
staining for quantification of colonic tumors, colon histology (H&E and PAS stains), and
flow cytometry for analysis of T cell subsets.
Quantitative Real-Time PCR (qRT-PCR) for bacterial species validation and
HDAC expression. For validation of bacteria identified by 16S rRNA analysis, qRTPCR was used with primers designed to identify the 16s rRNA subunit of significantly
altered bacterial species. DNA was extracted from colonic samples using the QIAamp
DNA Stool Mini Kit (Qiagen) as previously described. For HDAC expression data, RNA
was extracted from single cell suspensions of MLN (in vivo) or cultured splenocytes (in
vitro) using RNeasy Mini kits (Qiagen) followed by conversion to cDNA using iScript
synthesis kit (Bio-Rad). PCR amplification was performed using QuantiFast (bacteria) or
QuantiTech (HDAC) SYBR Green PCR kits from Qiagen, and reactions were performed
on a CFX96 qPCR system from Bio-Rad (Hercules, CA). Primers were designed by
Intergrated DNA Technologies (Coralville, IA). Sequences for all primers are included in
Table 3.1.
Correlation of gene expression with survival in CRC patient data sets. The
correlation of gene expression pattern with survival of human patients with CRC was
performed using the TCGA datasets for colorectal cancer from The Cancer genome Atlas
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maintained at TCGA (https://cancergenome.nih.gov/). TCGA examines the genome-wide
expression, copy number variations, methylation status and mutations in an immense
number of samples with a primary advantage such as i) each patient sample is
accompanied with a comprehensive clinico-pathological data ii) a huge portion of the
samples with integrated molecular profiles iii) number of matched normals for tumor
samples iv) generation of data using latest and widely measured standard molecular
profiling technologies (Bacolod et al., 2015). Survival analysis for the TCGA datasets
were performed using the Kaplan-Meier survival curves which is defined as the
probability of survival in a given length of time while considering time in many small
intervals (Goel et al., 2010). It mainly involves the calculation of the probability of
occurrence of an event at a certain point of time.
Statistical analysis and data availability. GraphPad Prism software (San Diego,
CA) was used for all statistical analysis unless otherwise stated. Experiments were
repeated at least three times to confirm reproducibility. For statistical differences, oneway ANOVA and Tukey’s post-hoc comparison test was used unless otherwise noted in
the text. Significance was determined to have a p value of ≤ 0.05 (*), 0.01 (**), 0.005
(***), or 0.001 (****). Raw sequencing data (FASTq files) were uploaded to the NCBI
Sequence Read Archive (SRA).
3.4 RESULTS
Resveratrol attenuates AOM-induced CRC by preventing early onset of
inflammation and decreasing tumor burden
To study the effects of resveratrol on CRC in the context of studying host immune
response and microbiome, we used the well-characterized AOM/DSS CRC murine
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model. For these studies, experimental groups consisted of naïve mice (Naïve), naïve
mice treated with only resveratrol (Resveratrol), AOM/DSS disease mice with no
treatment (AOM), and AOM/DSS disease mice treated with resveratrol
(AOM+Reservatrol). Inducing CRC by AOM resulted in a significant decrease in body
weight (~20%) compared to controls (naïve or resveratrol-treated only), but treatment of
CRC mice with resveratrol reduced this disease-associated weight loss and resulted in
~8% weight gain by the end of the study (Figure 3.1A). In addition, the administration of
AOM resulted in decreased survival of mice (~75%) by the end of the study, whereas
CRC mice treated with resveratrol resulted in 100% survival (Figure 3.1B). Resveratrol
treatment also was able to reduce tumor burden in AOM-induced CRC mice as assessed
during the experimental endpoint (10 weeks), as AOM-treated mice developed at least 10
or more tumor polyps along the colon, whereas AOM+Reservatrol mice had little to no
tumors polyps present (Figure 3.1C-D). In order to monitor the first signs of
inflammation and tumor development during disease and treatment, colonoscopies were
performed weekly among experimental groups. In AOM mice, inflammation
development, which was characterized by the presence of bloody lesions and tissue
sloughing along the colon, developed around week 3 of the disease model, but
AOM+Resveratrol mice maintained more normal appearing colons (Figure 3.2). The
presence of tumors was seen in AOM mice by week 5 and continued developing to week
9, but CRC mice treated with resveratrol showed a marked decrease in colonic tumor
development (Figure 3.1E-F; Figure 3.2). Colon histology reinforced these observations
as AOM colons showed loss of normal mucosal architecture and abnormal tissue growth
with standard H&E staining which was not apparent in AOM+Resveratrol colon sections
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which more closely resembled controls (Figure 3.1G). PAS staining on fixed colon
sections was also performed as a way to access mucin production and goblet cell
formation (Agawa et al., 1988). Mice challenged with AOM showed a high reduction in
the number of goblet cells and presence of mucus compared to controls, but these
observations were greatly reversed in colon sections excised from AOM+Resveratrol
groups (Figure 3.1H). Collectively, these data demonstrated that resveratrol treatment
attenuated tumor development in the AOM CRC model, perhaps by way of preventing
early signs of inflammation caused by multiple cycles of DSS, as shown in week 3 of the
colonoscopy images.
Resveratrol treatment reduces inflammatory T cell subsets while increasing
anti-inflammatory T cells in AOM-induced CRC
In order to examine immune cell alterations during disease and treatment, cells
were isolated from the MLN, spleen, and blood of all experimental groups and
phenotyped using flow cytometry (Figures 3.3-3.6). In the MLN, expression of T cell
marker (CD3+), along with T helper (CD3+CD4+) and cytotoxic T cell (CD3+CD8+),
were significantly decreased in AOM mice compared to controls, and restoration of these
T cell phenotypes occurred in the AOM+Resveratrol groups (Figure 3.1I). These data
suggested that activated T cells in AOM group were leaving MLN and going to the colon
while resveratrol reversed this. Similar observations were seen in both the spleen (Figure
3.4) and the blood (Figure 3.5). Going further in phenotyping the CD4+ subsets,
intracellular/intranuclear staining was performed to identify the effect of resveratrol
inflammatory (IFNγ- and IL17-producing) cells) and to anti-inflammatory (FOXP3+
Tregs and IL10-producing) CD4+ T cell populations. The data collected from the MLN
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showed that there was a significant increase in both anti-inflammatory CD4+FOXP3+
(Fig. 1J) and CD4+IL10+ (Figure 3.1K) cells population in AOM mice treated with
resveratrol when compared with AOM disease mice. However, proinflammatory T cell
subsets, such as Th17 (Figure 3.1L) and Th1 (CD4+IFNγ+) (Figure 3.1M) were
significantly higher in AOM mice compared to the controls, but treatment with
resveratrol was able to effectively reduce these inflammatory T cell phenotypes. This
shift in the proinflammatory to anti-inflammatory T cell subsets after resveratrol
treatment was also observed in the spleen (Figure 3.5). Lastly, as MDSCs are known to
increase in the CRC human population and are thought to be a potential immunotherapy
target (Sun et al., 2012), data collected from the spleen and blood revealed that MDSCs
were significantly increased in the AOM disease state, but were effectively reduced by
treatment with resveratrol (Figure 3.6). Together, these data suggested that resveratrol
promoted an anti-inflammatory T cell response in the AOM CRC model.
Alterations in gut microbiota and SCFA composition in AOM-DSS colorectal
induced mice treated with resveratrol
In order to determine if resveratrol-mediated alterations in inflammation is
associated with changes in gut microbiome, we first analyzed the gut microbiota from all
experimental groups by using 16S rRNA V3-V4 sequencing technique for microbial
profiling. From colonic fecal matter, we isolated genomic DNA and performed
pyrosequencing with Illumina MiSeq platform. Nephele analysis output showed that the
alpha diversity, represented as chao1, was slightly enriched in the AOM and
AOM+Resveratrol groups compared to controls (Figure 3.7A). In terms of beta diversity,
depicted as a principle component analysis (PCA) plot, samples clustered within their
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own respective groups, with resveratrol-treated groups showing more similar diversity
compared to naïve controls, and the AOM disease group clustering further away from all
other experimental groups (Figure 3.7B). 16s rRNA sequencing analysis from Nephele
allowed sample reads to be classified into OTUs from the phylum to the species level
(Figures. 3.8-3.12), and divergent microbial composition among the experimental groups
was apparent starting even at the phylum level. At this taxa level, Verrucomicrobia,
Tenericutes, and TM7 were found to be significantly reduced in abundance within AOM
groups compared to the controls, whereas levels of these phyla were restored or increased
in AOM+Resveratrol mice (Figure 3.8). AOM mice also had a slight increase in
Firmicutes compared to the other groups, and an even more significant increase in
Proteobacteria, which were reduced to normal levels in the AOM+Resveratrol the
treatment group (Figure 3.8). At class level, Verrumcomicrobiae, Mollicutes, TM7-3, and
Alphaproteobacteria were decreased in AOM mice, but found to be restored in most
cases after treating mice with resveratrol (Figure 3.9). Deltaproteobacteria and Bacilli
were increased in AOM, and while Deltaproteobacteria levels were reduced to control
levels the in AOM+Resveratrol groups; in Bacilli, AOM+Resveratrol had the most of this
class (Figure 3.9). Within the order level, Verrucomicrobiales, Anaeroplasmales, and
CW040 showed significant reduction in abundance in the disease state when compared to
the treatment group, while Clostridiales, Turicibacterales, and Desulfovibrionales
showed significant increases in abundance in AOM mice compared to controls, and in
AOM+Resveratrol group, these were reduced except for Turicibaterales (Figure 3.10).
In a continuing trend, some bacteria at the family level, including Verrucomicrobiaceae,
Dehalobacteriaceae, Anaeroplasmataceae, F16, Lachnospiraceae, Mogibacteriaceae
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and Closteridiaceae showed a decrease in AOM groups but an increase in the
AOM+Resveratrol group, whereas Desulfovibrionaceae increased during the untreated
disease state, but reduced to control levels in AOM+resveratrol group (Figure 3.11).
Lastly, at genus level Ruminococcus, Akkermansia, Dehalobacterium, Anerostipes,
Anaeroplasma, Blautia, and Clostridium were reduced in AOM mice compared to
controls but were restored or increased significantly after treatment with resveratrol
(Figure 3.12), whereas, Oscillospira and Desulfovibrio increased in AOM, but were
significantly reduced in AOM+Resveratrol groups (Figure 3.12). As several bacteria were
altered in the disease and treated states, LEfSe analysis, which is a useful tool to
determine potential bacterial biomarkers among experimental groups (Segata et al.,
2011), was used to highlight the more relevant significant differences in the microbial
community. From this analysis, it was found that among the species detected by 16S
rRNA sequencing, Ruminococcus gnavus, Akkermansia muciniphillia, and Mucispirillum
schaedleri were among the potential biomarkers in the AOM+Resveratrol treatment
group (Figure 3.7C-D). As shown in Figure 3.7E, all of these species were significantly
reduced in AOM mice, but were increased after treatment with resveratrol, and we
validated these finding using PCR (Figure 3.7F).
In addition to microbial profiling, we investigated the resulting changes in the
microbial community altered bacterial-related metabolism, as PiCRUSt allows evaluation
of bacterial function to be performed with 16S rRNA data (Langille et al., 2013). Using
combined PiCRUSt (via Nephele) and LEfSe analyses, it was shown that there were
marked changes in microbial functions amongst the experimental groups particularly
after treatment with resveratrol, which included those that were connected to CRC (e.g.
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P53 signaling) (Slattery et al., 2018), and those involved in generation of Tregs (e.g.
TGF-β signaling) (Becker et al., 2018) (Figure 3.13). Lastly, we determined if changes in
SCFA production, metabolite produced by gut flora in the host organism (Marchix et al.,
2018), could be seen in response to these changes in the gut microbiome composition
triggered by treatment of CRC with resveratrol. Examination of colonic contents showed
that n-buytric and i-butyric acid concentrations were significantly reduced in the AOM
groups compared to controls. However, AOM group treated with resveratrol restored or
increased the levels of these SCFAs (Figure 3.7G). Among the other detectable SCFAs,
propionic acid, i-valeric acid, and n-valeric acid showed no significant changes among
the experimental groups (Figure 3.7G). Together, these studies demonstrated that
treatment of CRC-induced mice with resveratrol leads to significant changes in both the
gut microbial profile and function.
Fecal transfer from resveratrol-treated groups attenuates AOM/DSSinduced CRC and alters the T cell-specific immune response:
In order to determine whether or not resveratrol-induced alterations in the gut
microbiome were contributing to the altered immune response in CRC, we performed
fecal transfer (FT) experiments. After receiving antibiotics to deplete the existing gut
microbiome, AOM-induced CRC recipient mice were inoculated with feces from either
Naïve, Resveratrol, AOM, or AOM+Resveratrol groups. Mice inoculated with fecal
material from disease controls, referred to as AOM(FT), showed gradual decrease in
body weight throughout the study compared to controls, whereas AOM+Resveratrol(FT)
mice recovered and gained weight by the end of 10 weeks (Figure 3.14A).
AOM+Resveratrol(FT) mice also showed increased survival when compared to
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AOM(FT) mice (Figure 3.14B), along with decreased incidence of tumor development in
the colon (Figure 3.14C-D). In addition, weekly colonoscopy examination (Figure 3.15)
showed increased ulceration and sloughing in portions of the colon in mice fed diseasederived feces, however, mice that were given FT from resveratrol-treated groups showed
a reduced presence of polyps and abnormal colonic tissue growths at the end of the study
(Figure 3.14E-F). Histological examination by H&E stains revealed AOM(FT) colon
tissues had abnormal growth and damage to the mucosal layer, whereas
AOM+Resveratrol tissues resembled that of control colons (Figure 3.14G). PAS stains
also showed that AOM(FT) recipients had decreased mucus production and goblet cells,
and just as with treatment with resveratrol in the AOM disease state,
AOM+Resveratrol(FT) colon tissues had restored intestinal architecture with normal
mucus present and distribution of goblet cells (Figure 3.14H). Together, these FT
experiments demonstrated that the clinical benefits provided by resveratrol against AOMinduced CRC can be attributed, at least in part, to changes in gut microbiota. Next, we
tested if the changes in the gut microbiota induced by resveratrol also resulted in changes
in inflammation.
As in the previous experiment, flow cytometry analysis was performed in the FT
experiments and collected data showed in the MLNs (Figure 3.16) of AOM(FT) mice, a
marked decrease in both T helper (Figure 3.14I) and cytotoxic T cells (Figure 3.14J),
whereas AOM+Resveratrol(FT) mice had increased numbers of these cells present in the
tissue. Going further in phenotyping the CD4+ T helper phenotypes, AOM mice showed
significant decreases in anti-inflammatory Tregs (Figure 3.14K) and CD4+IL10producing cells (Figure 3.14L), which were significantly increased in all resveratrol-
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treated groups. On the other hand, proinflammatory Th17 (Figure 3.14M) and IL17producing CD4+ T cells (Figure 3.14N) were found to be significantly higher in
AOM(FT) recipients compared to the other FT groups, and while AOM+Resveratrol(FT)
recipients had decreased Th17 phenotype, this group was not able to decrease Th1
(CD4+IFNγ+) cells. In order to confirm the transfer of feces resembled our previous
sequencing data, PCR validation was performed showing a similar microbial profile for
significantly altered species Ruminococcus gnavus and Akkermansia muciniphilia, which
were decreased in AOM(FT) and increased in the AOM+Resveratrol(FT) group (Figure
3.14O). Collectively, these data demonstrated that the alterations of microbiome by
resveratrol were directly modulating the T cell immune response in AOM-induced CRC,
particularly in increasing anti-inflammatory subsets (Tregs and CD4+IL-10-producers),
while decreasing proinflammatory types (Th17 and Th1).
Butyrate supplementation attenuates AOM/DSS-induced CRC and promotes
an anti-inflammatory T cell response similar to resveratrol:
In the current study, one of the distinct outcomes gathered regarding resveratrolmediated alterations in the gut microbiome was the increase in SCFA butyrate, which is
known to have anti-inflammatory properties (Sitkin and Pokrotnieks, 2018; van der Beek
et al., 2017). To test its role further, supplementation with sodium butyrate (BUT) was
given in lieu of resveratrol to determine the potential effects of increased levels of this
SCFA produced in the AOM-induced CRC model. To address this, experimental groups
were designed to mimic the previous experiments with the exception of substituting
resveratrol with BUT, and these groups included: Naive alone, BUT alone, AOM, and
AOM+BUT. As expected, AOM mice had significant decrease in body weight (~20%)
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compared to controls, but like AOM+Resveratrol groups from the previous experiments,
AOM+BUT mice had significant reduction in weight loss over time (Figure 3.17A).
Additionally, while the AOM group had a decrease in overall percent survival,
AOM+BUT mice showed 100% survival after 10 weeks (Figure 3.17B). Similar to
AOM+Resveratrol mice, AOM+BUT mice had decreased or nonexistent colonic tumors
(Figure 3.17C-D). Colonoscopic examination at 5 different time points (weeks 0,3,5,7
and 9) during the experiment gave a clear picture of the development of CRC-associated
lesions and tissue sloughing after AOM injection, but AOM+BUT groups showed
marked decrease in tissue disruption (Figure 3.17E-F, Figure 3.18). Histological
examination of formalin-fixed colon tissues stained with H&E was also performed on
experimental groups, which clearly showed in AOM colons there was a loss of mucosal,
submucosal, and serosa architecture, which was not seen in AOM+BUT (Figure 3.17G).
PAS staining showed that AOM+BUT colons were also able to maintain significant
amount of mucus presence and number of goblet cells which were lost in AOM tissue
sections (Figure 3.17H). Supplementation with butyrate was thus able to attenuate the
clinical parameters of AOM-induced CRC much like resveratrol, so it was reasonable to
examine whether or not increased butyrate was able to alter the T cell repertoire.
Just as with resveratrol treatment, flow cytometric analysis of the MLN (Figure
3.19) showed expression of T cells in general, CD4+ T helper, and CD8+ cytotoxic T
cells increased in AOM+BUT groups after being depleted in number in AOM-induced
CRC (Figure 3.17I). AOM+BUT groups also had increased numbers in antiinflammatory Tregs (Fig. 4K) and CD4+IL-10 cells (Figure 3.17L) when compared to
AOM mice which had much lower number of these cells than the control groups.
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Alternatively, inflammatory Th17 (Figure 3.17M) and Th1 cells (Figure 3.17N), were
much lower in AOM+BUT mice when compared to the AOM disease controls, in
addition to anti-inflammatory CD4+FOXP3+ and CD4+IL10+ populations in both
mesenteric lymph node and blood. A similar shift from proinflammatory Th17/Th1 to
anti-inflammatory Tregs/IL-10 was seen after treatment with BUT in the spleen (Figure
3.20). Collectively, these data showed that butyrate supplementation reduces the
inflammatory T cell response much in the same manner as resveratrol, suggesting that
increased production of this SCFA by resveratrol is another mechanism through which
this natural compound may be effective against AOM-induced CRC.
Supplementation of butyrate alters the microbial profile in AOM-induced
CRC with similarities to resveratrol treatment:
As resveratrol-mediated increases in colonic butyrate could also lead to alterations
in the microbiome in addition to promoting anti-inflammatory T cell phenotypes, 16S
rRNA microbial sequencing was performed on experimental groups in the butyrate
supplementation experiments. Alpha diversity indicated that compared to the naïve
group, all other experimental groups (BUT, AOM, AOM+BUT) had lower overall
diversity within the samples (Figure 3.21A). Beta diversity or PCA clustering in the
butyrate supplementation experiments mimicked closely what was seen in the resveratrol
treatment experiments, with all experimental samples clustering within their own groups
tightly, but the AOM group being the most divergent (Figure 3.21B). OTU abundances
were calculated from the phylum to the genus level (Figure 3.22-3.25) as previously
done. Several significant differences were seen at taxa levels with butyrate
supplementation, however, for the current report and in context in explaining resveratrol-

58

mediated mechanisms, only those with changes similar to the resveratrol treatment
experiments are highlighted. For example, BUT-treated groups were able to restore or
increase bacteria at the phyla Verrucomicrobia and Tenericutes, which were significantly
reduced in the AOM group, while butyrate supplementation decreased Proteobacteria
which rose in AOM-induced CRC (Figure 3.22). At the class level, AOM+BUT mice had
increased Verrucomicrobiae, Mollicutes, and TM7-3 which were significantly reduced in
AOM disease mice, and the AOM-increased Deltaproteobacteria were reduced after
butyrate supplementation (Figure 3.23). At the order level, butyrate supplementation
increased Verrucomicrobiales, Anaeroplasmales, and CW040 much like resveratrol did
after being decreased in AOM groups, whereas Desulfovibrionales increased during
AOM disease, but was reduced in the AOM+BUT samples (Figure 3.24). At the family
level, Verrucomicrobiaceae, Anaeroplasmataceae, Closteridiaceae, Mogibacteriaceae,
and F16 were all reduced in AOM mice compared to controls as previously shown,
however, AOM+BUT increased levels of these gut microbials, whereas the increase seen
in families in AOM samples (Desulfovibrionaceae) were reduced after supplementation
with butyrate (Figure 3.25). At the genus level and closely mimicking resveratrol
treatment experiments, Ruminococcus, Akkermansia, Anerostipes, Anaeroplasma, and
Clostridium were reduced in AOM mice compared to controls but were restored or
increased significantly after butyrate supplementation, whereas Desulfovibrio increased
in AOM, but was significantly reduced in AOM+BUT groups (Figure 3.26). LeFSe
analysis was then performed to determine which bacterial species had the highest LDA
score among the experimental groups (Figure 3.21C-D), and combined with OTU
abundance data, Ruminicoccus gnavus and Akkermansia muciniphilia (Fig 3.21E) were
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found to be restored by butyrate after depletion in AOM-induced CRC, which was
validated with PCR (Figure 3.21F). Take altogether, these data suggested that resveratrolmediated alterations in the gut microbiome and shifting to anti-inflammatory T cell
phenotype in AOM-induced CRC can be explained, at least in part, by the ability of
resveratrol to increase levels of butyrate in the gut microenvironment.
Resveratrol and BUT inhibit HDACs in vivo and in vitro
The increase in colonic butyrate production in resveratrol-treated CRC mice was
interesting given the fact that previous reports show butyrate not only increases Treg
production (Arpaia et al., 2013; Vieira et al., 2019), but the HDAC inhibiting activities of
this SCFA have been implicated as a key mechanism in which it exerts anti-inflammatory
and anti-cancer properties (Martin-Gallausiaux et al., 2018; Sethi et al., 2018; Silva et al.,
2018), including in colorectal cancer models (Zhang et al., 2016b). With is in mind,
studies were performed to examine the ability of resveratrol and BUT to suppress
HDACs in vitro and in the CRC in vivo model and how this correlated with increased
Treg production. For in vitro studies, resveratrol increased Tregs in activated splenocytes
in a dose-dependent manner (Figure 3.27, Figure 3.28A). BUT significantly increased
Tregs at the higher doses (5 and 10mM) when treating activated cells in the same manner
(Figure 3.27, Figure 3.28B). Following these observations, the expression of class I
(HDAC I; HDACs 1, 2, 3, and 8) and class II HDACs (HDAC II; HDACs 4, 5, 6, 7, 9,
and 10) were examined in cultures with the most significantly increased Treg expression
(25µM for resveratrol and 5mM for BUT). Resveratrol in the in vitro cultured system was
able to significantly reduce expression of all HDAC I (Figure 3.28C), but interestingly
decreased only selective HDAC II, specifically not being able to reduce HDAC 6, 9, and
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10 (Figure 3.28D). BUT, being a well-known HDAC inhibitor, was able to reduce
expression of all HDACs, regardless of specific classes (Figure 3.28E-F). Lastly, the
expression of HDAC I and II was evaluated in in vivo CRC experiments given treatment
with either resveratrol or BUT. Interestingly, similar results were seen. For HDAC I,
resveratrol treatment compared to either naïve controls or CRC disease mice resulted in
decreased expression (Figure 3.28G). While HDAC II were all decreased upon treatment
with resveratrol compared to naïve controls, once again, select HDACs (HDAC 6, 9, and
10) were not inhibited by resveratrol compared to AOM disease controls (Figure 3.28H).
However, supplementation experiments with BUT resulted in overall decreased HDAC
expression for HDAC I and HDAC II (Figure 3.28I-J). Altogether, this data suggests that
while increased butyrate can lead to inhibition of HDACs, which correlates to increased
Treg expansion, resveratrol is able to at least in part reduce select HDAC expression
itself, independent of butyrate.
Increased expression of anti-inflammatory T cell markers results in increased
survival in human CRC patients:
Lastly, as the current study was able to show that resveratrol modulated the gut
microbiome to increase anti-inflammatory T cell subsets (Treg and IL-10-producers)
while decreasing proinflammatory Th17/Th1 types, we examined whether there was any
correlation between gene expression of T cell-specific makers in CRC patients with
survival. Looking at the TCGA datasets of CRC patients, it was shown that increased
expression of Treg-specific transcription factor FoxP3 (Figure 3.29A) or antiinflammatory IL-10 (Figure 3.29B) resulted in an increase in CRC 5-year patient
survival. High expression of TGF-β, known to influence the development of Tregs, also
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correlated with increased overall survival in the patient population (Figure 3.29C).
However, high expression of Th-17 associated IL-17 cytokine was just the opposite, as it
resulted in decreased patient survival, while patients with lower expression of IL-17 had
increased survival over time (Figure 3.29D). While expression of Th-17 transcription
factor RORγt was shown to have no difference in CRC patient survival over a 5-year
period (Figure 3.29E), expansion past 5 years showed that high expression of this
transcription factor was capable of bringing down overall CRC patient survival (Figure
3.29F). Just as in the AOM-induced mouse model in the current study, IFNγ expression,
associated with Th1 cells, didn’t seem to have much effect on CRC patient survival
(Figure 3.29G), but in the context of Th1-specific transcription factor (Tbx21), high
expression of this gene did appear to decrease the expected overall CRC patient survival.
The results in the current study are promising given that T cell differentiation altered by
resveratrol towards anti-inflammatory phenotype, via modulation of the gut microbiome,
appears to have significant impact in overall human CRC patient survival.
3.5 DISCUSSION
Published reports with resveratrol date back to the late 1970s, and since then
research has shown that this natural plant polyphenol has therapeutic properties ranging
from anti-inflammatory (Koushki et al., 2018), anti-oxidant (Samsamikor et al., 2016;
Singh et al., 2011a), anti-depressant (de Oliveira et al., 2018; Finnell et al., 2017), antiatherogenic (Riccioni et al., 2015), anti-aging (Li et al., 2017), as well as anti-cancer
(Guan et al., 2012; Ko et al., 2017; Singh et al., 2011b). Our lab has published
extensively on the anti-inflammatory properties of resveratrol in various disease models,
showing often how the effects of this compound are AhR-dependent (Alghetaa et al.,
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2018; Chen et al., 2015b; Rieder et al., 2012; Singh et al., 2007; Singh et al., 2010).
Activation of AhR by known ligands, such as resveratrol, has been shown by us as well
as others to have significant impact on T cell development and phenotype (Busbee et al.,
2013; Ehrlich et al., 2018). For example, we have shown that activation of AhR by
dietary indoles in a delayed-type hypersensitivity (DTH) model is essential for shifting
the T cell response from a proinflammatory Th17 to an anti-inflammatory Treg
phenotype (Singh et al., 2016). This is important in regards to CRC as studies have
shown that high expression of Tregs in CRC patients indicate a more favorable prognosis
(Hu et al., 2017; Xu et al., 2017), whereas increased Th17 has been linked to CRC
pathogenicity and tumor development (Bedoui et al., 2018; Lee et al., 2017; Yan et al.,
2018). The current report reinforces this notion, as gene expression data of CRC patients
seemed to indicate that high expression of anti-inflammatory T cell factors (FoxP3, IL10) improved patient survival, whereas proinflammatory makers linked to Th17 and Th1
phenotypes decreased overall survival in the patient population. It is important to note
that in the context of cancer, the exact role of Tregs/Th17 is not so clear, as other reports
indicate that Tregs promote cancer development, whereas inflammatory Th17 cells
prevent tumor invasion and metastasis (Amicarella et al., 2017; Timperi et al., 2016;
Zhuo et al., 2015). Reports seem to indicate that the role these T cell phenotypes in
cancer largely depends on the type of cancer along with the stage of disease severity, as
well as whether the cancer is driven by chronic inflammation, which could explain the
conflicted reports. For CRC, which is linked to chronic inflammation in the colon, an
anti-inflammatory response may be more favorable, at least in terms of the early stages of
the disease. This could explain why our lab as well as others have shown resveratrol as an
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effective preventative treatment in CRC animal models (Altamemi et al., 2014; Cui et al.,
2010; Huderson et al., 2018; Lee et al., 2018), which is in part due to the ability of this
compound to shift from a proinflammatory T cell response to anti-inflammatory one.
While the ability of resveratrol to illicit this type of immune response has been wellcharacterized, the significance of this report is in the fact that resveratrol-mediated
modulation of the gut microbiome seems to be an important mechanism in promoting this
T cell shift.
A recent report by Wong et al. showed that inoculation with feces from CRC
patients in germ-free or conventional mice resulted in an increase in colonic tumor
development, proinflammatory markers, and Th17 phenotype (Wong et al., 2017). These
findings are interesting because in addition to promoting the idea of Th17 as CRCinducing in nature as discussed already, this report showed that microbiota plays an
important role in CRC development and progression. Prior to and since this report, it has
been well-established that the complex interaction between microbiota and the host
immunity play major roles in CRC pathogenicity (Chen, 2018; Yang et al., 2018b). For
example, several bacteria, such as Helicobacter pylori, Streptococcus bovis, Bacteroides
fragilis, and Clostridium septicum have been known to be major contributors to CRC
development (de Almeida et al., 2018). Even shifts in certain phylum, such as increases
in Proteobacteria, have been associated with CRC malignancy (Mori et al., 2018). Thus,
it would stand to reason that therapeutics directed at combating CRC disease would also
be able to modulate the gut microbiome to promote more beneficial effects.
Previous reports have shown that resveratrol was capable of altering the gut
microbiome in other disease models (Etxeberria et al., 2015; Qiao et al., 2014). In line
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with the current study, researchers found that resveratrol was able to increase bacteria
such as Verrucomicrobia and Akkermansia muciniphila, while decreasing Bacteroides,
Dysgonomonas, and Turicibacter in a hypertension model with high-fructose diet (Tain et
al., 2018). Additionally, in an obesity model it was found that resveratrol treatment
increased Akkermansia and Ruminococcaceae, which were shown to alleviate the clinical
effects associated with a high-fat diet (Zhao et al., 2017). Interestingly enough, studies
found that Ruminococcus gnavus was in fact reduced in CRC patients when compared to
controls (Chen et al., 2012), and that Akkermansia muciniphilia was associated with
increased response to chemotherapy in CRC patients (Cani, 2018). The current study
showed that these species were decreased in AOM-induced CRC, which correlates well
with human CRC patients, but more importantly, resveratrol was able to restore or
increase these bacteria. This could further explain why resveratrol is such an effective
therapeutic in CRC models, as it seems to increase the presence of bacteria lost or
decreased during CRC development and progression. These particular bacteria appear to
possess properties essential for controlling and preventing tumor development in the
gastrointestinal system.
Alterations in the microbial profile were not the only interesting aspect obtained
from the current studies, but rather it was significant to find that resveratrol-mediated
alterations in the gut microbiome promoted SCFA, butyrate, production as well. Butyrate
has been shown to act in an anti-inflammatory manner in various disease models. For
example, supplementation with sodium butyrate was capable of attenuating diabetesassociated inflammation (Xu et al., 2018), as well as inflammation linked to high-fat-dietinduced non-alcoholic fatty liver disease (Sun et al., 2018). Oral administration of
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butyrate was also shown to reduce microbial-associated gastrointestinal inflammation and
liver disease in Gulf War illness by mechanisms such as decreasing inflammatorymediated toll-like receptor (TLR) activation (Seth et al., 2018). In the context of CRC
specifically, decreases in butyrate production are linked to CRC development (Chen and
Vitetta, 2018), and it was shown that butyrate inhibited aberrant epigenetic modifications
in CRC cells by upregulating α-ketoglutarate, which is important in mediating DNA
methylation (Sun and Zhu, 2018). A more recent report closely linked to the current one
showed that a mix of SCFA (butyrate, acetate, and propionate) was protective against
AOM-induced CRC and was able to suppress key inflammatory cytokines such as IL-6
and inducing apoptosis in tumor-associated epithelial cells (Tian et al., 2018). However,
in our studies, we focused solely on butyrate supplementation and showed that this SCFA
could alter T cells in CRC specifically by shifting from inflammatory Th1/Th2 to antiinflammatory Treg/IL-10-producers. One of the key mechanisms butyrate has been
shown to promote an anti-inflammatory response is through inhibition of HDACs(Patnala
et al., 2017; Zhang et al., 2016a), even in the case of promoting Treg production
specifically in CRC (Zhang et al., 2016b). Interestingly though, the results in the current
report seemed to suggest that resveratrol alone was promoting HDAC inhibition,
independent of butyrate, and this correlated with induction of Tregs. However, it is
important to note that resveratrol treatment in CRC resulted in increased colonic butyrate
levels, and the T cell subsets were examined in the gut-specific draining lymph node
(MLN). Therefore, the relationship between resveratrol modulation of the gut
microbiome, increased butyrate, HDAC expression, and Treg expansion needs to be
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further analyzed at the local site, in this case the colon, to further understand the interplay
related to these mechanisms.
Combined with the findings discussed above, the current study is able to provide
new and exciting insights into how resveratrol has the potential to be a strong preventive
agent against CRC. As the gut microbiota is now known to be important in disease
progression and development, the fact that resveratrol can modulate this
microenvironment in such a way as to induce a beneficial T cell immune response proven
to help CRC patients is important, and through FT experiments, this resveratrol-mediated
mechanism linked to microbiome-modulation appears more conclusive now. In addition,
to our knowledge, this is the first report to confirm this and also provide evidence that
resveratrol modulates the microbiome to increase butyrate production. Our studies also
suggest that resveratrol and other dietary AhR ligands may constitute preventive
modalities in the fight against CRC and potentially other types of inflammatory diseases
linked to microbial dysbiosis.
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Table 3.1. Primer Sequences
Primer
Forward
Ruminococcu AGAGGGATGTCAAGACCAGGT
s gnavus
A
Akkermansia
GTATCTAATCCCTTTCGCTCCC
muciniphila
Mucispirillum CACATGCAAGTCAGGGAGAAA
schaedleri
HDAC 1
CCGCATGACTCACAATTTGCT
HDAC 2
TACAACAGATCGCGTGATGAC
HDAC 3
GAAATGTTGCCCGGTGTTGGA
HDAC 4
AACTTCTTCCCAGGAAGTGGA
HDAC 5
TGGACTGGGATATTCACCATG
HDAC 6
ATTGCTGCTTTCCTGCACATC
HDAC 7
GCTGAAGAATGGCTTTGCTGT
HDAC 8
AGTGCCTGATTGACGGGAAGT
HDAC 9
AGGATGATGATGCCTGTGGTG
HDAC 10
AGCAGAAATATGGGCTGAAGA
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Reverse
TACTAGGTGTCGGGTGGAAAAG
GACTAGAGTAATGGAGGGGGA
A
CAGGTCTCCCCAACTTTTCCTA
TCTGGGCGAATAGAACGCAGG
TCCCTTTCCAGCACCAATATC
TGAGTTCTGATTCTCGATGCG
TGCGATAGGCATAACCACCGT
AGAGCCTGGAAAGAAGTTCCC
AATCAACTTGCCTCCTGCCAA
AATGAGGATCTTGCTGGCTTT
CGGTCAAATTTCCGTCGCAAT
GCCTGGTCAAATTCTGGTGCT
AGAAGCTTCCATGCTCATAGC

Figure 3.1 Treatment with resveratrol reduces clinical symptoms and alters T cell
phenotype in AOM-induced CRC model. C57BL/6 mice were injected intraperitoneal
with 10 mg of AOM followed by 3 cycles of 2% DSS, to induce CRC. Experimental
groups consisted of: Naïve (n=6), Resveratrol (n=6), AOM (n=6), and AOM+Resveratrol
(n=6). Clinical parameters consisted of percent weight loss (A) and survival (B), (C)
Representative colons stained with 1% Alcian blue, (D) Bar graph depicting number of
tumors counted in each experimental group, (E) Representative colonoscopic images
from experimental groups, (F) Bar graph depicting scores after examination of tumor
polyps detected during colonoscopies, (G) Representative colon sections stained with
H&E; scale bar = 100 µM at 40x objective, (H) Representative colon sections with PAS
staining; scale bar = 100 µM at 40x objective, (I) Bar graphs depicting absolute cell
numbers in MLN for all T cells (CD3+), T helper (CD3+CD4+), and cytotoxic
(CD3+CD8+) T cells. (J-M) Bar graphs depicting absolute cell numbers in MLN for
Tregs (J), Th cells producing IL-10 (K), Th17 (L), and Th1 (M) cells. Significance (pvalue: *<0.05, **<0.01, ***<0.005, ****<0.001) was determined by using one-way
ANOVA and post-hoc Tukey’s test for bar/dot graphs, Mann-Whitney test for weight
data, and log rank test for survival curve. Data are representative of at least 3 independent
experiments.
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Figure 3.2 Weekly colonoscopy images in AOM-induced CRC treated with
resveratrol. Induction of AOM CRC and treatment with resveratrol were performed as
described in Figure 3.1 legend. (A) Representative colonoscopies are shown from
experimental groups which included Naïve (n=6), Resveratrol (n=6), AOM (n=6),
AOM+Resveratrol (n=6) at weeks 1, 3, 5, and 7. Bar graphs depict colonoscopy scores
(described in Materials and Methods) for experimental groups at week 1(B), week 3 (C),
week 5 (D), and week 7 (E). Significance (p-value: *<0.05, **<0.01, ***<0.005,
****<0.001) was determined by using one-way ANOVA followed by Tukey’s post-hoc
multiple comparisons test for depicted bar graphs.
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Figure 3.3 T cell phenotyping in MLN of AOM-induced CRC mice treated with
resveratrol. Induction of AOM CRC and treatment with resveratrol was performed as
described in Figure 3.1 legend. Representative flow cytometry histograms and dot plots
are depicted for the following T cell subsets: CD3+ (A), CD3+CD4+CD8+ (B),
CD4+FOXP3+ (C), CD4+IL10+ (D) and CD4+IFNγ+ (E), and CD4+IL-17+ (F). For
Figures C-F, cells were gated on CD4+ population. Data are representative of at least 3
independent experiments.
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Figure 3.4 T cell phenotyping in spleen of AOM-induced CRC mice treated with
resveratrol. Induction of AOM CRC and treatment with resveratrol was performed as
described in Figure 3.1 legend. Flow cytometry dot plots and quantitative bar graphs
depicting absolute cell numbers are shown respectively for the following T cell subsets:
CD3+ (A-B), CD4+ or CD8+ cells (C-E), CD4+FOXP3+ (F-G), CD4+IL10+ (H-I) and
CD4+IFNγ+ (J-K), and CD4+IL-17+ (L-M) expressing cells. For Figures F-M, cells were
gated on CD4+ population. Each experimental group had at least 5 mice included, and
significance (p-value: *<0.05, **<0.01, ***<0.005, ****<0.001) was determined for
absolute cell numbers by using one-way ANOVA followed by Tukey’s post-hoc multiple
comparisons test. Data are representative of at least 3 independent experiments.
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Figure 3.5 T cell phenotyping in blood of AOM-induced CRC mice treated with
resveratrol. Induction of AOM CRC and treatment with resveratrol was performed as
described in Figure 3.1 legend. (A) Representative flow cytometry plots are depicted
showing CD3+ histogram (top) and CD4+/CD8+ dot plots (bottom) from experimental
groups. (B) Bar graphs showing absolute cell numbers for the following T cell subsets
respectively: CD3+, CD3+CD4+ (T helper), and CD3+CD8+ (cytotoxic T cells).
Significance (p-value: *<0.05, **<0.01, ***<0.005, ****<0.001) was determined by
using one-way ANOVA followed by Tukey’s post-hoc multiple comparisons test in bar
graphs. Experiments are representative of at least 3 independent experiments.
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Figure 3.6 MDSCs in the spleen and blood of AOM-induced CRC mice treated with
resveratrol. Induction of AOM CRC and treatment with resveratrol was performed as
described in Figure 3.1 legend. (A) Representative flow cytometry dot plots are depicted
showing MDSCs (CD11b+GR1+) in the spleen (top) and blood (bottom) from
experimental groups. (B) Bar graphs showing absolute cell numbers for MDSCs in the
spleen. (C) Bar graphs showing absolute cell numbers for MDSCs in the blood.
Significance (p-value: *<0.05, **<0.01, ***<0.005, ****<0.001) was determined by
using one-way ANOVA followed by Tukey’s post-hoc multiple comparisons test in bar
graphs. Experiments are representative of at least 3 independent experiments.
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Figure 3.7 16S rRNA sequencing analysis during AOM-induced CRC treated with
resveratrol. The study was designed as described in Figure 3.1 legend. Gut microbiome
samples were collected from experimental groups by performing colonic flushes in
experimental groups, which were: Naïve (n=7), Resveratrol (n=9), AOM (n=10), and
AOM+Resveratrol (n=9). Nephele analysis (nephele.niaid.nih.gov) was used to generate
charts for chao1 alpha diversity (A) and PCA beta diversity (B). LeFSe analysis of the
Nephele OTU output files generated the cladogram (C) and LDA score bar graph (D). (E)
OTU percent abundances are shown in bar graphs for the species Ruminococcus gnavus,
Akkermansia muciniphila, and Mucispirillums schaedleri. (F) PCR validation of
Ruminococcus gnavus, Akkermansia muciniphila, and Mucispirillums schaedleri. (G) Bar
graphs representing concentration of SCFAs acetic acid, propionic acid, i-butyric acid, nbutyric acid, i-valeric acid, and n-valeric acid. Significance (p-value: *<0.05, **<0.01,
***<0.005, ****<0.001) was determined by using one-way ANOVA followed by
Tukey’s post-hoc multiple comparisons test for depicted bar graphs. Experiments are
representative of 3 independent experiments.
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Figure 3.8 Significantly altered bacteria in AOM-induced CRC sample treated with
resveratrol at the phylum level. Induction of AOM CRC and treatment with resveratrol
was performed as described in Figure 3.1 legend, and 16S rRNA sequencing was
performed as described in Figure 3.7 legend. Significance (p-value: *<0.05, **<0.01,
***<0.005, ****<0.001) was determined by using one-way ANOVA followed by
Tukey’s post-hoc multiple comparisons test in bar graphs. Experiments are representative
of at least 3 independent experiments.
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Figure 3.9 Significantly altered bacteria in AOM-induced CRC sample treated with
resveratrol at the class level. Induction of AOM CRC and treatment with resveratrol
was performed as described in Figure 3.1 legend, and 16S rRNA sequencing was
performed as described in Figure 3.7 legend. Significance (p-value: *<0.05, **<0.01,
***<0.005, ****<0.001) was determined by using one-way ANOVA followed by
Tukey’s post-hoc multiple comparisons test in bar graphs. Experiments are representative
of at least 3 independent experiments.
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Figure 3.10 Significantly altered bacteria in AOM-induced CRC sample treated
with resveratrol at the order level. Induction of AOM CRC and treatment with
resveratrol was performed as described in Figure 3.1 legend, and 16S rRNA sequencing
was performed as described in Figure 3.7 legend. Significance (p-value: *<0.05, **<0.01,
***<0.005, ****<0.001) was determined by using one-way ANOVA followed by
Tukey’s post-hoc multiple comparisons test in bar graphs. Experiments are representative
of at least 3 independent experiments.
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Figure 3.11 Significantly altered bacteria in AOM-induced CRC sample treated
with resveratrol at the family level. Induction of AOM CRC and treatment with
resveratrol was performed as described in Figure 3.1 legend, and 16S rRNA sequencing
was performed as described in Figure 3.7 legend. Significance (p-value: *<0.05, **<0.01,
***<0.005, ****<0.001) was determined by using one-way ANOVA followed by
Tukey’s post-hoc multiple comparisons test in bar graphs. Experiments are representative
of at least 3 independent experiments.
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Figure 3.12 Significantly altered bacteria in AOM-induced CRC sample treated
with resveratrol at the genus level. Induction of AOM CRC and treatment with
resveratrol was performed as described in Figure 3.1 legend, and 16S rRNA sequencing
was performed as described in Figure 3.7 legend. Significance (p-value: *<0.05, **<0.01,
***<0.005, ****<0.001) was determined by using one-way ANOVA followed by
Tukey’s post-hoc multiple comparisons test in bar graphs. Experiments are representative
of at least 3 independent experiments.
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Figure 3.13 LefSe analysis of Nephele-generated PiCRUSt data investigating
bacterial function based on 16S rRNA sequencing. To study functional changes within
the microbial samples collected, Nephele-based was performed using the PiCRUSt
option, which requires a closed reference against the Greengenes database
(Greengene_99) at taxa levels 2 and 3 for KEGG annotations of the uploaded dataset.
LefSe was performed using the OTU table generated from the Nephele output analysis
software as described in Materials and Methods.
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Figure 3.14 Results from FT experiments in AOM-induced CRC model. Antibiotictreated C57BL/6 mice were injected i.p. with 10 mg of AOM to induce colorectal cancer
followed by 3 cycles of 2% DSS. Fecal material was inoculated into recipient mice from
the following donors: Naïve (n=4), Resveratrol (n=4), AOM (n=4), and
AOM+Resveratrol (n=4). Clinical parameters consisted of percent weight loss (A) and
survival (B), both which were found to have significant differences in AOM(FT) vs.
AOM+Resveratrol(FT) groups. (C) Representative colons stained with 1% Alcian blue.
(D) Bar graph depicting number of tumors counted in each experimental group. (E)
Representative colonoscope images from experimental groups. (F) Bar graph depicting
scores after examination of tumor polyps detected during colonoscopies. (G)
Representative colon sections stained with H&E; scale bar = 100 µM at 40x objective.
(H) Representative colon sections which underwent PAS staining; scale bar = 100 µM at
40x objective. (I-J) Bar graphs depicting absolute cell numbers in MLN for general T
cells T helper (I), and cytotoxic (J) T cells. (K-N) Bar graphs depicting absolute cell
numbers in MLN for Tregs (K), Th cells producing IL-10 (L), Th17 (M), and Th1 (N)
cells. (O) PCR validation for the bacterial species Ruminococcus gnavus and
Akkermansia muciniphila. Significance (p-value: *<0.05, **<0.01, ***<0.005,
****<0.001) was determined by using one-way ANOVA and post-hoc Tukey’s test for
bar/dot graphs, Mann-Whitney test for weight data, and log rank test for survival curve.
Data are representative of at least 3 independent experiments.
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Figure 3.15 Weekly colonoscopy images in FT experiments. Induction of AOM CRC
and FT were performed as described in Figure 3.14 legend. (A) Representative
colonoscopies are shown from experimental groups which included Naïve(FT) (n=4),
Resveratrol(FT) (n=4), AOM(FT) (n=4), AOM+Resveratrol(FT) (n=4) at weeks 1, 3, 5,
and 7. Bar graphs depict colonoscopy scores (described in Materials and Methods) for
experimental groups at week 1(B), week 3 (C), week 5 (D), and week 7 (E). Significance
(p-value: *<0.05, **<0.01, ***<0.005, ****<0.001) was determined by using one-way
ANOVA followed by Tukey’s post-hoc multiple comparisons test for depicted bar
graphs.
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Figure 3.16 T cell phenotyping in MLN of FT experiments. Induction of AOM CRC
and FT were performed as described in Figure 3.14 legend. Representative flow
cytometry dot plots are depicted for the following T cell subsets: CD3+CD4+CD8+ (A),
CD4+FOXP3+ (B), CD4+IL10+ (C) and CD4+IFNγ+ (D), and CD4+IL-17+ (E). For
Figures B-E, cells were gated on CD4+ population. Data are representative of at least 3
independent experiments.
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Figure 3.17 Treatment with sodium butyrate (BUT) reduces clinical symptoms and
alters T cell phenotype in AOM-induced CRC model. Female C57BL/6 mice were
injected intraperitoneal with 10 mg of AOM to induce colorectal cancer followed by 3
cycles of 2% DSS. Experimental groups consisted of: Naïve (n=4), BUT (n=4), AOM
(n=4), and AOM+BUT (n=4). Clinical parameters consisted of percent weight loss (A)
and survival (B), both of which were found to have significant differences in AOM vs.
AOM+Resveratrol groups. (C) Representative colons stained with 1% Alcian blue. (D)
Bar graph depicting number of tumors counted in each experimental group. (E)
Representative colonoscopic images from experimental groups. (F) Bar graph depicting
scores after examination of tumor polyps detected during colonoscopies. (G)
Representative colon sections stained with H&E; scale bar = 100 µM at 40x objective.
(H) Representative colon sections which underwent PAS staining; scale bar = 100 µM at
40x objective. (I) Bar graphs depicting absolute cell numbers in MLN for general T cells
(CD3+), T helper (CD3+CD4+), and cytotoxic (CD3+CD8+) T cells. (J-M) Bar graphs
depicting absolute cell numbers in MLN for Tregs (J), Th cells producing IL-10 (K),
Th17 (L), and Th1 (M) cells. Significance (p-value: *<0.05, **<0.01, ***<0.005,
****<0.001) was determined by using one-way ANOVA and post-hoc Tukey’s test for
bar/dot graphs, Mann-Whitney test for weight data, and log rank test for survival curve.
Data are representative of at least 3 independent experiments.
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Figure 3.18 Weekly colonoscopy images in AOM-induced CRC treated with BUT.
Induction of AOM CRC and treatment with resveratrol was performed as described in
Figure 3.17 legend. (A) Representative colonoscopies are shown from experimental
groups which included Naïve (n=4), BUT (n=4), AOM (n=4), AOM+BUT (n=4) at
weeks 1, 3, 5, and 7. Bar graphs depict colonoscopy scores (described in Materials and
Methods) for experimental groups at week 1(B), week 3 (C), week 5 (D), and week 7 (E).
Significance (p-value: *<0.05, **<0.01, ***<0.005, ****<0.001) was determined by
using one-way ANOVA followed by Tukey’s post-hoc multiple comparisons test for
depicted bar graphs.

86

Figure 3.19 T cell phenotyping in MLN of AOM-induced CRC mice treated with
BUT. Induction of AOM CRC and treatment with resveratrol was performed as described
in Figure 3.17legend. Representative flow cytometry histograms and dot plots are
depicted for the following T cell subsets: CD3+ (A), CD3+CD4+CD8+ (B),
CD4+FOXP3+ (C), CD4+IL10+ (D) and CD4+IFNγ+ (E), and CD4+IL-17+ (F). For
Figures C-F, cells were gated on CD4+ population. Data are representative of at least 3
independent experiments.
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Figure 3.20 T cell phenotyping in spleen of AOM-induced CRC mice treated with
BUT. Induction of AOM CRC and treatment with resveratrol was performed as described
in Figure 3.17 legend. Flow cytometry dot plots and quantitative bar graphs depicting
absolute cell numbers are shown respectively for the following T cell subsets: CD3+ (AB), CD4+ or CD8+ cells (C-E), CD4+FOXP3+ (F-G), CD4+IL10+ (H-I) and
CD4+IFNγ+ (J-K), and CD4+IL-17+ (L-M) expressing cells. For Figures F-M, cells were
gated on CD4+ population. Each experimental group had at least 5 mice included, and
significance (p-value: *<0.05, **<0.01, ***<0.005, ****<0.001) was determined for
absolute cell numbers by using one-way ANOVA followed by Tukey’s post-hoc multiple
comparisons test. Data are representative of at least 3 independent experiments.
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Figure 3.21 16S rRNA sequencing analysis during AOM-induced CRC treated with
BUT. AOM induction and treatment with BUT were performed as described in Figure
3.17 legend. Gut microbiota samples were collected from experimental groups by
performing colonic flushes in experimental groups, which were: Naïve (n=5), BUT
(n=5), AOM (n=5), and AOM+BUT (n=5). Nephele analysis (nephele.niaid.nih.gov)
was used to generate charts for chao1 alpha diversity (A) and PCA beta diversity (B).
LeFSe analysis of the Nephele OTU output files generated the cladogram (C) and LDA
score bar graph (D). (E) OTU percent abundances are shown in bar graphs for the species
Ruminococcus gnavus and Akkermansia muciniphila. (F) PCR validation of
Ruminococcus gnavus and Akkermansia muciniphila. Significance (p-value: *<0.05,
**<0.01, ***<0.005, ****<0.001) was determined by using one-way ANOVA followed
by Tukey’s post-hoc multiple comparisons test for depicted bar graphs. Experiments are
representative of 3 independent experiments.
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Figure 3.22 Significantly altered bacteria in AOM-induced CRC sample treated
with BUT at the phylum level. Induction of AOM CRC and treatment with resveratrol
was performed as described in Figure 3.17 legend, and 16S rRNA sequencing was
performed as described in Figure 3.21 legend. Significance (p-value: *<0.05, **<0.01,
***<0.005, ****<0.001) was determined by using one-way ANOVA followed by
Tukey’s post-hoc multiple comparisons test in bar graphs. Experiments are representative
of at least 3 independent experiments.
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Figure 3.23 Significantly altered bacteria in AOM-induced CRC sample treated
with BUT at the class level. Induction of AOM CRC and treatment with resveratrol was
performed as described in Figure 3.17legend, and 16S rRNA sequencing was performed
as described in Figure 3.21 legend. Significance (p-value: *<0.05, **<0.01, ***<0.005,
****<0.001) was determined by using one-way ANOVA followed by Tukey’s post-hoc
multiple comparisons test in bar graphs. Experiments are representative of at least 3
independent experiments.
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Figure 3.24 Significantly altered bacteria in AOM-induced CRC sample treated
with BUT at the order level. Induction of AOM CRC and treatment with resveratrol
was performed as described in Figure 3.17 legend, and 16S rRNA sequencing was
performed as described in Figure 3.21 legend. Significance (p-value: *<0.05, **<0.01,
***<0.005, ****<0.001) was determined by using one-way ANOVA followed by
Tukey’s post-hoc multiple comparisons test in bar graphs. Experiments are representative
of at least 3 independent experiments.
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Figure 3.25 Significantly altered bacteria in AOM-induced CRC sample treated
with BUT at the family level. Induction of AOM CRC and treatment with resveratrol
was performed as described in Figure 3.17 legend, and 16S rRNA sequencing was
performed as described in Figure 3.21 legend. Significance (p-value: *<0.05, **<0.01,
***<0.005, ****<0.001) was determined by using one-way ANOVA followed by
Tukey’s post-hoc multiple comparisons test in bar graphs. Experiments are representative
of at least 3 independent experiments.
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Figure 3.26 Significantly altered bacteria in AOM-induced CRC sample treated
with BUT at the genus level. Induction of AOM CRC and treatment with resveratrol
was performed as described in Figure 3.17 legend, and 16S rRNA sequencing was
performed as described in Figure 3.21 legend. Significance (p-value: *<0.05, **<0.01,
***<0.005, ****<0.001) was determined by using one-way ANOVA followed by
Tukey’s post-hoc multiple comparisons test in bar graphs. Experiments are representative
of at least 3 independent experiments.
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Figure 3.27 Resveratrol and BUT dose-dependently increase Tregs in vitro. Whole
splenocytes (seeded at 1 x 106 cells/ml) from 8-10 week old C57BL/6 mice were
activated using CD3 (.5µg/ml) and CD28 (2µg/ml) in the absence or presence of
appropriate vehicle control, resveratrol (5, 10, or 25µM), or BUT (1, 5, or 10mM). After
24 hours, cells were fixed and stained with antibodies to identify percentages of Tregs
(CD4+FoxP3+). Plots are representative flow dot plots for vehicle control and the various
doses of RES and BUT gated on the CD4 population. A total of 3 independent wells
(n=3) were used for each group and the data is representative of 2 independent
experiments.
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Figure 3.28 Treatment with Resveratrol and BUT leads to HDAC suppression.
Whole splenocytes (seeded at 1 x 106 cells/ml) from 8-10 week old C57BL/6 mice were
activated using CD3 (.5µg/ml) and CD28 (2µg/ml) in the absence or presence of
appropriate vehicle control, resveratrol (5, 10, or 25µM), or BUT (1, 5, or 10mM). Tregs
were identified by flow cytometry as represented in Figure 3.27. (A) Treg percentages
after treatment with various doses of resveratrol. (B) Treg percentages after treatment
with varying doses of BUT. Fold change expression as assessed by PCR for HDAC I (C)
and HDAC II (D) after treatment with resveratrol (25µM). Fold change expression as
assessed by PCR for HDAC I (E) and HDAC II (F) after treatment with BUT (5mM).
Expression of HDAC I (G) and HDAC II (H) was evaluated from MLNs isolated from
experimental groups (Naive, Resveratrol, AOM, and AOM+Resveratrol). Expression of
HDAC I (I) and HDAC II (J) was evaluated from MLNs isolated from experimental
groups (Naive, BUT, AOM, and AOM+BUT). For in vitro experiments, each group
consisted of 3 wells (n=3), and the data are representative of 2 independent experiments.
For in vivo experiments, each group consisted of 5 mice (n=5), and the data is
representative of at least 3 independent experiments.Significance (p-value: *<0.05,
**<0.01, ***<0.005, ****<0.001) was determined by using one-way ANOVA followed
by Tukey’s post-hoc multiple comparisons test for depicted bar graphs.
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Figure 3.29 Human CRC patient survival correlated with gene expression. TCGA
datasets for colorectal cancer from The Cancer genome Atlas maintained at (TCGA,
https://cancergenome.nih.gov/) were used to correlate gene expression with patient
survival over a 5-year period or more. Correlations to patient survival were performed
based on the following gene expressions: (A) FoxP3, (B) IL-10, (C) TGF-β, (D) IL-17A,
(E) ROR-γt, (F) ROR-γt (past five year interval), (G) IFN-γ, and (H) Tbx21. KaplanMeier survival curves, defined as the probability of survival in a given length of time
while considering time in many small intervals, were used to generate survival curves
plots.
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CHAPTER 4
RESVERATROL DOWNREGULATES MIR-31 TO PROMOTE CD4+FOXP3+ T
REGULATORY CELLS DURING PREVENTION OF TNBS-INDUCED COLITIS
4.1 ABSTRACT
Colitis, an inflammatory bowel disease, is associated with aberrant regulation of
the colonic mucosal immune system. Resveratrol, a natural plant product, has been found
to exert anti-inflammatory properties and attenuate the development of murine colitis. In
the current study, we examined the role of microRNA (miR) in the ability of resveratrol
to suppress colonic inflammation. Resveratrol treatment of mice bearing TNBS-induced
colitis improved the overall clinical scores by reversing weight loss and colitis-associated
pathogenesis. Flow cytometric analysis of the mesenteric lymph nodes (MLNs)
demonstrated that resveratrol reduced colitis-associated induction of inflammatory T cells
(Th17 and Th1) while increasing CD4+Foxp3+ regulatory T cells (Tregs) and IL-10producing CD4+ T cells. miR microarray analysis and PCR validation from CD4+ cells
isolated from MLN showed that treatment with resveratrol decreased the expression of
several miRs (miR-31, Let7a, miR-132) that targeted cytokines and transcription factors
involved in anti-inflammatory T cell responses (Foxp3 and TGF-β). Transfection studies
with FoxP3-targeting miR-31 mimic or inhibitors confirmed that this miR directly
regulated the expression of Foxp3. Analysis of data from human patients with ulcerative
colitis (UC) revealed that miR-31 expression was significantly increased when compared
to controls and additionally, this miR was highly induced in UC colon biopsies that
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exhibited colon cancer-associated neoplastic lesions. Together, the current study
demonstrates resveratrol-mediated attenuation of colitis may be regulated by miR-31
through induction of Foxp3+ Tregs and that miR-31 may serve as a therapeutic target for
human colitis.
4.2 INTRODUCTION
Previously, we have shown that treatment with resveratrol, a natural product
found in a variety of plant products (Busbee et al., 2013), is able to lessen disease burden
in chemical (dextran sodium sulfate, DSS) and genetic (IL-10 knockout) models of colitis
(Singh et al., 2010; Singh et al., 2012), as well as colitis-associated colon cancers
(Altamemi et al., 2014; Cui et al., 2010). A current review by Nunes et al. highlights
findings from our lab as well as others showing the effectiveness of resveratrol in
ameliorating or preventing animal models of colitis (Nunes et al., 2018). One of the key
findings from our previous report in the colitis-associated tumorigenesis model was that
resveratrol was able to regulate several microRNAs (miRs) that modulated inflammatory
genes and factors (Altamemi et al., 2014). This was a significant finding because miRs,
small non-coding RNA molecules that target and regulate gene transcripts (Guo et al.,
2018), were found to be important in both the development and progression of colitis,
particularly in terms of regulating inflammation, serving as disease biomarkers, and
responding to therapies (Feng et al., 2018; Lopetuso et al., 2018; Minacapelli et al., 2019;
Morilla et al., 2018; Schonauen et al., 2018; Singh et al., 2014a). The importance of miRs
in regulating colitis was highlighted in our previous report showing that deficiency in
only one miR (miR-155) was able to protect mice from developing severe colitis
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symptoms by a reduction in the inflammatory T helper (Th) type responses (Singh et al.,
2014a).
In the current report, we investigated the effectiveness of resveratrol treatment in
another mouse model of chemically-induced colitis, using 2,4,6-Trinitrobenzenesulfonic
acid solution (TNBS), which is known to activate inflammatory T cells. We found that
resveratrol treatment attenuated severe disease development, resulting in a shift from a
pro-inflammatory Th17 phenotype to a more anti-inflammatory T cell response
characterized by increased regulatory T cells (Tregs) and those producing IL-10.
Microarray analysis of miR profiles in T cells revealed several miRs (e.g. miR-31, Let7a, and miR-132) that target anti-inflammatory T cell factors were downregulated by
resveratrol. In this study we further analyzed the role of miR-31, which was found to
target Treg transcription factor FoxP3. These findings were even more interesting after
analysis of human UC colitis patients revealed this patient population had significantly
higher expression of miR-31 in disease-associated tissues. Altogether, the study
highlights that miR-31 is a potential target for prevention of colitis and possibly CRC.
4.3 MATERIALS AND METHODS
Animals. Female mice (BALB/c) aged 8-10 weeks were obtained from Jackson
Laboratories (Bar Harbor, ME) and housed at the University of South Carolina, School of
Medicine (Columbia, SC) AAALAC-accredited animal facility. All mice were housed in
specific pathogen (SPF) free conditions in rooms with controlled temperature, ventilation,
and normal light/dark cycles. All procedures performed on mice followed National
Institutes of Health (NIH) guidelines under protocols approved by the Institutional
Animal Care and Use Committee (IACUC).
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Induction of colitis and treatment with resveratrol. Colitis was induced in
experimental mice as previously described (Elson et al., 1996). Briefly, TNBS purchased
from Sigma-Aldrich (MO, USA) was administered by intrarectal injection using a 38 mm
catheter into lightly anesthetized (5% isoflurane) at a concentration of 1 mg TNBS
dissolved in 0.1 ml of ethanol (50%). Mice were keep upright for 30 seconds following
injection to ensure proper dispersion of the chemical into the colon area. Vehicle control
mice were given an injection of 0.1 ml of ethanol (50%) without TNBS to negate any
inflammatory or adverse effects caused by the alcohol. Resveratrol, purchased from
Sigma-Aldrich, was given 24 hours prior to TNBS injection and given daily until
completion of the experiment (5 days) by using a 30 mm oral gavage needle at a dose of
100 mg/kg in 0.1ml of vehicle (1% carboxymethyl cellulose, CMC). In the current study,
the following experimental groups were used: Control mice (Vehicle) were given 50%
ethanol intrarectal administration and daily oral gavage of vehicle (1% CMC); Naïve
mice given treatment (Resveratrol) were given intrarectal administration of 50% ethanol
and daily oral gavage of 100 mg/kg of the resveratrol. Disease controls (TNBS+Veh)
were given 1mg intrarectal administration of TNBS and daily oral gavage of vehicle (1%
CMC). Treatment groups (TNBS+Res) were given 1mg intrarectal administration of
TNBS and daily oral gavage of resveratrol (100 mg/kg).
Assessment of disease parameters. To assess disease, experimental mice were
weighed daily through the entirety of the experiment (5-6 days). Colonoscopies were
performed to evaluate extent of damage (ulcerations and bleeding) to the colons prior to
the end of the experiment (day 3). At the study endpoint, mice were euthanized by
overdose of isoflurane. Excised colons were measured for length and proximal colons
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sections (1cm) were collected for histology. 10% formalin fixed tissues were stained with
hematoxylin and eosin (H&E) to assess colonic damage caused by TNBS administration.
To assess T cell response to disease and treatment, flow cytometry was performed on
single cell suspensions isolated from MLNs and stained using antibodies for the
following T cell and T cell subsets: overall T cells (CD3+), T helper cells (CD4+),
cytotoxic T cells (CD8+), Tregs (CD4+FoxP3+), IL-10 producing cells (CD4+IL-10+),
Th17 cells (CD4+IL-17+), and Th1 cells (CD4+IFNγ+). All antibodies used in these
studies were purchased from BioLegend (CA, USA). For transcription factor staining,
True-Nuclear Transcription Factor Buffer set from BioLegend was used as per
instructions from the manufacturer.
Analysis of miRNA. MicroRNA arrays were performed on RNA isolated from
cells collected from the MLN of experimental mice as previously described (Miranda et
al., 2018). Each sample consisted of a pool of 5 biological replicates. For each miRNA
microarray, FlashTag Biotin HSR RNA Labeling kit from Affymetrix (Thermo Fisher
Scientific, MA, USA) was used and tagged samples were later hybridized to the
Affymetrix miRNA 4.0 chip. Chips were scanned with an Affymetrix GCS 3000 system.
For transcriptome microarrays, 100ng total RNA was used as starting material. RNA was
prepared for hybridization by using the Affymetrix GeneChip WT PLUS Reagent Kit
according to protocol from the manufacturer. Affymetrix Expression Console Version
software was used to evaluate quality control of the samples, as well as initial analysis of
the microarray data to include principal component analysis, heatmaps depicting raw
signal expression, log2 fold change (FC) calculations, and direct comparisons among the
experimental groups. Ingenuity Pathway Analysis (IPA, http://www.ingenuity.com/) was
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used to generate miRNA-gene target pathways based on differentially regulated miRNA
profiles, which was determined to be a greater than ±2 log2 fold change between two
different experimental groups. miR validation studies were performed by first preparing
complimentary DNA (cDNA) from isolated RNA samples using the miScript II RT kit
(Qiagen, MD, USA) followed by quantitative real time PCR (qRT-PCR) using a CFX
Connect Real Time System (Bio-Rad, PA, USA). PCR reactions were performed using
mouse-specific miR primers purchased from Qiagen. Primers included mmu-miR-31-5p
(MI0000579), mmu-Let-7a (MIMAT0004620), and mmu-miR-132-3p
(MIMAT0000144). Expression levels were normalized to Snord96a (MS00033733)
levels. Fold changes were calculated using the 2−ΔΔCT method.
Transfection experiments with miR-31-5p mimic or inhibitor and target gene
quantification. Transfection experiments were carried out as previously described
(Alghetaa et al., 2018; Busbee et al., 2015). Excised MLNs from naïve BALB/c were
prepared in a single cell suspension before culturing in complete RPMI 1640 media
supplemented with heat inactivated 10% fetal bovine serum, 10mM L-glutamine, 10mM
HEPES, 50µM β-mercaptoethanol, and 100µg/ml penicillin/streptomycin. MLN cells
were seeded (2 x 105 cells per well) in a 24-well plate and activated with 1 µg/ml of
bacterial toxin staphylococcal enterotoxin B (SEB) purchased from Toxin Technologies
Inc. (FL, USA). Cells were then transfected with either 20nM of synthetic mmu-miR-31–
5p mimic (AGGCAAGAUGCUGGCAUAGCUG) or anti-mmu-miR-31–5p
(AGGCAAGAUGCUGGCAUAGCUG) using HiPerfect Transfection Reagent from
Qiagen for 24 hours. Expression levels for miR-31 and transcriptional factor FoxP3
(forward: CCCATCCCCAGGAGTCTTG; reverse: ACCATGACTAGGGGCACTGTA)
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were determined using qRT-PCR. For FoxP3, expression levels were normalized to β
actin (forward: GGCTGTATTCCCCTCCG; reverse:
CCAGTTGGTAACAATGCCATGT).
Dataset for human colitis patient population. Data on human miR-31
expression levels was obtained from the National Center for Biotechnology Information
(NCBI) Gene Expression Omnibus (GEO) repository. The human dataset used was GEO
accession GSE68306 provided by Huang et al. and published elsewhere (Pekow et al.,
2017). The data set consisted of colon tissue biopsies from normal healthy controls
(n=16) and ulcerative colitis (UC) patients (n=29). For UC patients, samples consisted of
three distinct tissue biopsy types: UC associated with neoplastic tissues (n=11), UC
patients without neoplasia (n=9), and non-dysplastic UC mucosa adjacent to a neoplastic
lesion (n=9). For the current report, analysis was performed using two different
comparisons. First, expression of miR-31 in healthy tissue samples (n=16) was compared
to UC patients (n=29). Second, miR-31 expression from healthy controls (n=16) was
compared to colonic tissues from UC patients associated with neoplasia (n=11). Raw
expression values were obtained from the provided online dataset and based on
NanoString nCounter v1.7.0 platform performed on RNA isolated from formalin-fixed
paraffin embedded tissue samples.
Statistical Analysis. GraphPad Prism software (CA, USA) was used for most of
the statistical analysis depicted in the current report unless otherwise noted. For in vivo
colitis experiments, at least 5 mice were used per experimental group. For in vitro assays,
all experiments were performed in triplicate. For statistical differences, significance (p
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value of ≤ 0.05) was determined using one-way ANOVA followed by Tukey’s post-hoc
multiple comparisons test unless otherwise stated.
4.4 RESULTS
Treatment with resveratrol reduces severity of TNBS-induced colitis
In the current study, we investigated the efficiency of resveratrol to prevent a
chemically-induced murine colitis model using TNBS. To investigate prevention of
disease by this natural compound, treatment groups were given resveratrol 24 hours prior
to induction of disease by TNBS, followed by daily oral administrations of the treatment.
As shown, colitis mice (TNBS+Veh) had significant weight loss (~15%) during the
course of the study compared to control groups (Vehicle or Resveratrol), but colitis mice
pre-treated with resveratrol (TNBS+Res) had significantly decreased incidence of weight
loss (Fig. 1A-B). Another hallmark of many colitis models is the shortening of the colon
after disease induction. The colons from TNBS mice were significantly shorter while
TNBS+Res mice had similar colon lengths when compared to controls (Fig. 1C-D).
Colonoscopies performed during the peak of disease (day 3) revealed that while TNBS
mice had typical disease-associated features such as ulcerations and bleeding compared
to normal colons, colons of TNBS+Res mice had reduced presence of these classical
clinical parameters (Fig. 1E). Histological evaluation corroborated with these
observations from colonoscopies as there were significant signs of tissue damage (e.g.
cellular infiltration, loss of normal colonic tissue architecture) in TNBS mouse colons
compared to controls, and this damage was not present or reduced in colons from
TNBS+Res mice (Fig. 1F). These observations together demonstrated that resveratrol
treatment effectively prevented TNBS-induced colitis.
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Treatment of TNBS-induced colitis mice with resveratrol results in a shift
from a pro-inflammatory to anti-inflammatory T helper response in MLN
To investigate if this effect of resveratrol was due to reduction in proinflammatory T helper responses (IL-17) while inducing anti-inflammatory types (Tregs
and IL-10 production), MLNs from the TNBS experimental groups were evaluated to
determine T cell distribution during disease and treatment. The T cell subsets evaluated
included all T cells (Fig. 2A), T helper and cytotoxic T cells (Fig. 2B), Tregs (Fig. 2C),
IL-10 T helper cells (Fig. 2D), and Th17 cells (Fig. 2E). Based on percentages obtained
from flow cytometry phenotyping (Figs. 2A-E), absolute cell numbers were assessed in
MLNs from all experimental groups. Overall T cells (Fig. 3A), including CD4+ T helper
(Fig. 3B) and CD8+ cytotoxic (Fig. 3C), were significantly increased in TNBS+Veh mice
compared to the other experimental groups, and TNBS+Res mice reduced these subsets
to the levels seen in normal controls. Despite an overall increase in CD4+ T cells, there
was a decrease in the anti-inflammatory Treg (Fig. 3D) and IL-10-producing (Fig. 2E)
cells during TNBS induction, while colitis mice treated with resveratrol had significantly
higher numbers of these anti-inflammatory subsets compared to controls. A significant
proportion of the CD4+ T cell subsets in TNBS+Veh mice appeared to be proinflammatory Th17 cells (Fig. 3F), and treatment with resveratrol during the disease state
showed ablation of the increase in this T cell subset, comparable to control levels. Taken
altogether, treatment with resveratrol appeared to prevent colitis-associated increases in
pro-inflammatory Th17 cells, likely through the induction of anti-inflammatory subsets
such as Tregs and CD4+ IL-10-producing cells.
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Resveratrol treatment downregulates miRs that target Treg transcription
factor FoxP3 and other anti-inflammatory T cell-associated factors
Next, we investigated if miRs regulated the anti-inflammatory properties of
resveratrol. To that end, we investigated the miR profile of cells from the MLN.
Principal component analysis (PCA) from pooled samples from all experimental groups
showed that the miR profiles of controls (Vehicle and Resveratrol) were most similar
with opposite deviations occurring when compared to TNBS+Veh and TNBS+Res
groups (Fig. 4A). Direct comparisons among two groups at a time, with the significance
criteria set to a ±2-fold change, revealed the greatest difference was among the
TNBS+Veh vs. TNBS+Res groups (Fig. 4B). Comparison of these two groups showed
260 total miRs (out of 3195 probed) were significantly altered, with TNBS+Res
downregulating 198 and upregulating 62 compared to TNBS+Veh (Fig. 4C). A heatmap
showing raw expression of these 260 significantly altered miRs for all experimental
groups is depicted in Fig. 3D. IPA analysis of these 260 significantly altered miRs
revealed several were downregulated in the TNBS+Res group that targeted key antiinflammatory T cell components such as FoxP3 (miR-31-5p, miR-182-5p, miR-210-3p),
IL-10 (miR-146-a-5p and miR-27a-5p), TGFβ2/3 (miR132-3p, miR-1999a-5p, miR193a3p, miR-148a-3p, let-7a-3p, miR-29b-3p), and several SMAD proteins (miR-330-5p,
miR-139-3p, miR-30c-1-3p*, miR-16-5p*, miR-27a-3p) (Fig. 5). Among these miRs
targeting key anti-inflammatory T cell factors, miR-31, predicted to target FoxP3, was
the most significantly downregulated (-6.790 fold change) when comparing TNBS+Res
vs TNBS+Veh groups (Fig. 5). Thus, the microarray data suggested that treatment with
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resveratrol was able to downregulate miRs that normally targeted anti-inflammatory gene
expression and components.
Resveratrol downregulates FoxP3-targeting miR-31 which is highly
upregulated in human colitis patients
As miR-31 was the most significantly downregulated miR indicated in targeting
anti-inflammatory T cell response and factors, PCR was performed to validate the
microarray results. Results showed that miR-31 was significantly increased in the MLN
of TNBS+Veh mice compared to the control groups, whereas TNBS mice treated with
resveratrol had decreased expression of this miRNA (Fig. 6A). Validation was also
performed on other miRs highlighted in Fig. 5 to include let-7a (Fig. 6B) and miR-132
(Fig. 6C). As with miR-31, results showed these miRs were increased in the disease state
(TNBS+Veh), but treatment with resveratrol (TNBS+Res) prevented their diseaseassociated upregulation. Next, alignment analysis was performed to determine the
potential of FoxP3 being a target. miR-31 was found to have three potential binding sites
on the 3’-untranslated region (UTR) of the FoxP3 transcript, two of which had highlyprobable miR-target mRNA interactions as predicted by mirSVR and PhastCons scores
(Fig. 6D). Transfection experiments were performed to determine if alterations in this
miR affected FoxP3 expression by giving SEB-activated T cells from the MLN either
mock (just transfection reagent), miR-31-mimic, or miR-31-inhibitor. PCR validation of
miR-31 expression showed the transfection was successful (Fig. 6E), and the results
indicated that when miR-31 was upregulated (miR-mimic), expression of FoxP3
transcript was downregulated (Fig. 6F). On the contrary, if miR-31 was inhibited, as in
the case of treatment with resveratrol, then FoxP3 expression was increased. Collectively,
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these data showed that FoxP3 expression was altered by miR-31, a diseased-associated
miR that resveratrol treatment prevented from becoming upregulated. Lastly, as the
TNBS-induced model indicated FoxP3-targeting miR-31 was a potential target in this
murine model of colitis, human studies looking at miR expression in colon biopsies of
UC patients was investigated to determine any applicable correlation between this animal
model and the human patient population. As shown, miR-31 was found to be
significantly increased in patients with UC when compared to controls (Fig. 6G).
Interestingly enough, this upregulation of miR-31 was found to be even more significant
in UC colon biopsies that developed colon cancer-associated neoplastic lesions when
compared to healthy controls (Fig. 6H). These data provided a link with observed miR-31
upregulation in the mouse model of colitis and human UC patient population, which
resveratrol was able to prevent, effectively inhibiting miR-31 from targeting antiinflammatory FoxP3-mediated response.
4.5 DISCUSSION
Previous studies have shown resveratrol is capable of preventing or at least
reducing symptoms associated with animal models of colitis by a variety of different
mechanisms. For example, in our earliest reports in the DSS-induced model of colitis, we
showed resveratrol upregulated silent mating type information regulation-1 (SIRT-1) and
downregulating nuclear transcription factor-kappaB (NF-κB) in immune cells (Singh et
al., 2010). In a more recent report by Zhang et al., researchers confirmed our results that
resveratrol treatment in the DSS model upregulated SIRT-1 in addition to mechanistic
target of rapamycin (mTOR), while also downregulating other pro-inflammatory factors
(e.g. autophagy‑related 12, Beclin‑1, and microtubule‑associated protein light chain 3 II)
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(Zhang et al., 2019). As in this report, Yao et al. showed resveratrol effectively regulated
Treg/Th17 signaling during DSS-induced colitis via modulating hypoxia inducible factor
(HIF)-1α/mammalian target of rapamycin (mTOR) signaling pathways (Yao et al., 2015).
In another chemically-induced colitis model in rats using oxazolone, resveratrol treatment
was shown to exert anti-inflammatory and pro-apoptotic properties by inhibiting
myeloperoxidase (MPO) and sphingosine kinase 1 (SphK1) (Abdin, 2013). In fact, the
success of resveratrol treatment in animal models of colitis translates even into the human
patient population. A double-blinded, placebo-controlled pilot study in UC patients has
shown that supplementation of 500mg/kg of resveratrol for 6 weeks appears to improve
quality of life and partially reduce disease severity in this patient population, thought to
be due to the ability of this natural product to reduce oxidative stress (Samsami-Kor et
al., 2015; Samsamikor et al., 2016). In addition to the growing number of studies
identifying resveratrol as a potential preventative and therapeutic against colitis and even
CRC, there are a number of reports linking dysregulation in miRs possible mechanisms
which drive disease development and progression.
As early as a decade ago, reports highlighted the differential expression of certain
miRs in patients with colitis (UC and CD) and CRC (Ahmed et al., 2009; Takagi et al.,
2010; Wu et al., 2008). In one of the earliest animal model reports, Chen et al. identified
miR-155 was altered in activated CD4+ cells from TNBS-induced colitis mice (Chen et
al., 2010), which supported our previous report showing miR-155 deficient mice had
protection against colitis induction (Singh et al., 2014a). Since these early reports, the
role of miR dysregulation in colitis is becoming more established from both a potential
diagnostic tool to areas of therapeutic intervention. For example, a recent published
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report suggest that serum levels of miR-146-5p are a better diagnostic tool to evaluate UC
and CD severity than the standard C-reactive protein levels (Chen et al., 2019). miR-449a
was suggested to be a possible predictor of colitis-associated CRC progression (Feng et
al., 2018). Going beyond just diagnostic and biomarkers of disease, miRs are being
looked as potential promoters and inhibitors of colitis as well. miR-590-5p, via inhibition
of Yes-associated protein 1 (YAP), was shown to reduce intestinal inflammation in both
colon cancer cells and mouse models of colitis with significant correlations in intestinal
tissues from CD patients (Yu et al., 2018). An antagomir for miR-148a was reported to be
a potentially effective drug treatment in amelioration of colitis because of its ability to
selectively deplete the pro-inflammatory Th1 response without interrupting other
protective immunological function during chronic colitis (Maschmeyer et al., 2018). The
current report advances previous studies on miRs by demonstrating that miR-31 is a
potential therapeutic target in colitis and CRC prevention.
The current study identifies the miR-31/FoxP3 axis as a means to prevent colitis
development, showing this miR was significantly upregulated in the TNBS-induced
murine model of colitis as well as documented in a dataset of UC colitis patients. In 2011,
researchers reported that miR-31 was found to be highly dysregulated in epithelial cells
from chronically inflamed mouse colons and APC(Min/+) tumors (Necela et al., 2011),
and in that same year a report described how miR-31 increase correlated with chronic
inflammation in IBD developing into neoplasia (Olaru et al., 2011). However, while
many reports identify miR-31 as being abnormally high in colitis patients and animal
models of colitis, the exact role of this miR in disease progression and development is
somewhat controversial.
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Liu et al. found that colon epithelial-specific deletion of miR-31 resulted in a more severe
form of colitis-associated colorectal cancer than wild-type counterparts (Liu et al., 2017),
and another report suggested that overexpression of miR-31 in UC targeted and regulated
the pro-inflammatory IL-13 signaling (Gwiggner et al., 2018). These reports align with
other studies suggesting miR-31 is important in protecting against colitis by way of
engaging mucosal healing processes during inflammatory events within the colon (Tian
et al., 2019; Whiteoak et al., 2018). It is important to note that such findings do not
necessarily contradict our data suggesting resveratrol-mediated targeting of miR-31
assists in prevention of colitis. Such reports indicated miR-31 seemed to be protective in
epithelial cells, whereas our report shows that in CD4+ immune cells, downregulating
miR-31 helps initiate a potential anti-inflammatory Treg response. Thus, while
upregulation of miR-31 in colonic epithelial cells might serve a protective role, in
immune cells it has the potential to promote inflammation by reducing Treg
development. This highlights the need to better understand through additional research
how regulating miRs in different cell types might have varying consequences.
Nevertheless, the current study provides evidence for additional pathways through which
resveratrol offers a highly valuable preventative and therapeutic properties against colitis
and possibly colitis-associated CRC.
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Figure 4.1 Treatment with resveratrol reduces clinical parameters in TNBS-induced
colitis. BALB/c mice were injected intrarectally with 1mg of TNBS to induce colitis.
Mice treated with resveratrol were given 100mg/kg in vehicle (1% CMC) by oral gavage
24 hours prior to the TNBS injection as well as daily up until the experimental end point
(day 4). Experimental groups consisted of: Vehicle (n=5), Resveratrol (n=5), TNBS+Veh
(n=5), and TNBS+Res (n=5). Initial clinical parameters consisted of evaluating weight
(A), percent weight loss (B) and colon length (C-D). (E) Representative colonoscopies
are shown from experimental groups during peak of disease (day 3). (F) Representative
colon sections from fixed and paraffin-embedded tissue sections stained with H&E at 20x
objective. Significance (p-value: *<0.05, **<0.01, ***<0.005, ****<0.001) was
determined by using one-way ANOVA and post-hoc Tukey’s test for bar graphs and
Mann-Whitney test for weight data. Data are representative of at least 3 independent
experiments.
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Figure 4.2 Treatment with resveratrol alters T cell subsets in the MLN of TNBSinduced mice. TNBS disease and treatment with resveratrol were performed as described
in Figure 4.1 legend. MLNs were excised from experimental groups (n=5 per
experimental group), stained with T cell-specific antibodies, and analyzed by flow
cytometry. Representative T cell subset staining by flow cytometry was as follows: (A)
CD3+ positive histogram plot; (B) CD4+ and CD8+ dot plot; (C) CD4+-gated FoxP3+
dot plot; (D) CD4+-gated IL-10 dot plot; (E) CD4+-gated IL-17 dot plot.
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Figure 4.3 Treatment with resveratrol increases absolute cell numbers of antiinflammatory T cell subsets in the MLN of TNBS-induced mice. TNBS disease and
treatment with resveratrol were performed as described in Figure 4.1 legend. MLNs were
excised from experimental groups (n=5 per experimental group), stained with T cellspecific antibodies, and analyzed by flow cytometry (as represented in Figure 4.2). Bar
graphs depict absolute cell numbers in MLN for all T cells (F), T helper cells (G),
cytotoxic T cells ( H), Tregs (I), T helper producing IL-10 cells (J), and Th17 cells (K).
Significance (p-value: *<0.05, **<0.01, ***<0.005, ****<0.001) was determined by
using one-way ANOVA and post-hoc Tukey’s test for bar dot graphs. Data are
representative of at least 3 independent experiments.
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Figure 4.4 Treatment with resveratrol alters the miR profile in TNBS-induced
colitis MLN. TNBS disease and treatment with resveratrol were performed as described
in Figure 4.1 legend. RNA from MLN of experimental groups was isolated for miR
microarray analysis using the murine-specific Affymetrix miRNA 4.0 chip. Experimental
groups (Vehicle, Resveratrol, TNBS+Veh, and TNBS+Res) consisted of pools of 5 mice
per group. Affymetrix Expression Console Version software was used to generate the
following comparisons: (A) 3D PCA plot comparing all experimental groups; (B)
multiple bar graph comparisons depicting significantly altered upregulated and
downregulated (± 2 fold change) miRs between two experimental groups; (C) scatter plot
depicting 260 significantly upregulated (red dots) and downregulated (green dots) miRs
out of 3195 total between TNBS+Res and TNBS+Veh; and (D) heat map depicting raw
expression values of the 260 aforementioned miRs among the 4 different experimental
groups.
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Figure 4.5 Treatment with resveratrol results in downregulation of several miRs
that target anti-inflammatory T cell-associated factors. TNBS disease and treatment
with resveratrol were performed as described in Figure 4.1 legend. 260 significantly
altered miRs between TNBS+Res vs. TNBS+Veh noted in Figure 4.3 legend were
subjected to Ingenuity Pathway Analysis (IPA). Depicted is an IPA-generated interaction
chart showing significantly altered miRs targeting factors associated with antiinflammatory T cell responses. Green colors represent downregulated miRs and Red
colors represent upregulated miRs. The calculated fold changes between TNBS+Res and
TNBS+Veh groups are depicted below each included miR. Purple arrows indicate
predicted, highly predicted, and experimentally-proven interactions of the miR with
target mRNA shown.
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Figure 4.6 Resveratrol prevents FoxP3-targeting miR-31 upregulation in TNBSinduced colitis which correlates with miR-31 upregulation in human UC patients.
TNBS disease and treatment with resveratrol were performed as described in Figure 4.1
legend. RNA was isolated from MLN of Vehicle (n=5), Resveratrol (n=5), TNBS+Veh
(n=5), and TNBS+Res (n=5) to validate expression levels of miR-31 (A), Let-7a (B), and
miR-132 (C). (D) Predicted miR-31 and FoxP3 alignment sites (with mirSVR and
Phastcon scores) were obtained from microrna.org. For transfection experiments, singlecell suspensions from normal mouse MLN were seeded (1x105 cells per well) and
activated with SEB (1µg/ml) for 24 hours before collecting total RNA from groups.
Experimental groups consisted of transfection reagent only mock (n=5), miR-31 mimic
(n=5), and miR-31 inhibitor (n=5). Depicted are PCR-generated expression fold changes
for miR-31 (E) and FoxP3 (F). For human samples depicted, raw expression values of
miR-31 from colonic biopsies were obtained from GEO data GSE68306. Two
comparisons are depicted: (G) Normal Healthy controls (n=16) vs. all UC patients
(n=29); and (H) Normal Healthy controls (n=16) vs. UC patients associated with
neoplasia (n=11). Significance (p-value: *<0.05, **<0.01, ***<0.005, ****<0.001) was
determined by using one-way ANOVA and post-hoc Tukey’s test for bar dot graphs
when comparing three or more groups. Data are representative of at least 3 independent
experiments. For human datasets, significance was determined using an unpaired, twotailed t test.
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CHAPTER 5
SUMMARY AND CONCLUSION
Resveratrol, a natural polyphenol found in various food and beverage products
such as grapes, peanuts, and wine, is a potent anti-inflammatory agent capable of
preventing or reducing symptoms associated with colitis and colitis-induced CRC by a
variety of mechanisms. Using well-established murine models of both colitis (TNBS) and
CRC (AOM/DSS), results showed that resveratrol was able to prevent or greatly reduce
the symptoms associated with these animal models, which is supported by previously
published reports. Highlighted in this disseration is the ability of resveratrol to regulate
the gut microbiome and induce epigenetic modifications (e.g. miRs and HDACs) to
promote induction of anti-inflammatory T cell subset, Tregs (CD4+FoxP3+).
In the microbiome, resveratrol promotes a microenvironment with increased
production of SCFA butyrate, a suppressor of HDACS capable of inducing Tregs. In both
the colitis model and CRC model, resveratrol was shown to alter the gut microbiome to
favor butyrate production. In particular, in both disease models resveratrol decreased
Bacteriodes acidifaciens and enriched Akkermansia muciniphilia and Ruminococcus
gnavus species. Fecal transfer experiments provided evidence that the resveratrol-altered
microbiome was directly responsible for the anti-inflammatory immune response and
subsequent protection against colitis and CRC, a new and exiting finding not previously
known. Interestingly, in addition to suppression of HDACs by increased butyrate
production, resveratrol was shown to be able to suppress a majority of HDACs
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independently of butyrate, and this directly correlated with increased Treg induction. In
addition to alterations in the microbiome leading to Treg-promoting HDAC suppression,
resveratrol is capable of downregulating several miRs (miR-31, let-7a, and miR-132) that
target Treg-related factors (FoxP3, SMAD proteins, STATs, and TGF-β). Transfection
experiments confirmed that miR-31 downregulation by resveratrol increased Treg-related
transcription factor FoxP3, which was a signficant finding considering that UC patients
were shown to have increased expression of this particular miR.
These new findings and mechanisms by which resveratrol regulates inflammation,
which has the potential to promote cancer, provide additional evidence to suggest this
natural compound can be a beneficial therapeutic or preventative measure against colitis
and colitis associated CRC by way of induction of Tregs. The ability of resveratrol to
induce Tregs is important not only because this T cell subset has anti-inflammatory
properties, but also data presented here shows that increased Tregs correlate with
increased survival of CRC patients. Inasmuch, the data and results presented here
promote a strong case for this natural compound to be used as a safe alternative to treat
and prevent colitis and CRC.

120

REFERENCES
Abdallah, D.M., and Ismael, N.R. (2011). Resveratrol abrogates adhesion molecules and
protects against TNBS-induced ulcerative colitis in rats. Canadian journal of physiology
and pharmacology 89, 811-818.
Abdin, A.A. (2013). Targeting sphingosine kinase 1 (SphK1) and apoptosis by colonspecific delivery formula of resveratrol in treatment of experimental ulcerative colitis in
rats. European journal of pharmacology 718, 145-153.
Agawa, S., Muto, T., and Morioka, Y. (1988). Mucin abnormality of colonic mucosa in
ulcerative colitis associated with carcinoma and/or dysplasia. Diseases of the colon and
rectum 31, 387-389.
Ahmed, F.E., Jeffries, C.D., Vos, P.W., Flake, G., Nuovo, G.J., Sinar, D.R., Naziri, W.,
and Marcuard, S.P. (2009). Diagnostic microRNA markers for screening sporadic human
colon cancer and active ulcerative colitis in stool and tissue. Cancer Genomics
Proteomics 6, 281-295.
Akgun, E., Caliskan, C., Celik, H.A., Ozutemiz, A.O., Tuncyurek, M., and Aydin, H.H.
(2005). Effects of N-acetylcysteine treatment on oxidative stress in acetic acid-induced
experimental colitis in rats. J Int Med Res 33, 196-206.
Al Bakir, I., Curtius, K., and Graham, T.A. (2018). From Colitis to Cancer: An
Evolutionary Trajectory That Merges Maths and Biology. Frontiers in immunology 9,
2368.
Alghetaa, H., Mohammed, A., Sultan, M., Busbee, P., Murphy, A., Chatterjee, S.,
Nagarkatti, M., and Nagarkatti, P. (2018). Resveratrol protects mice against SEB-induced
acute lung injury and mortality by miR-193a modulation that targets TGF-beta signalling.
Journal of cellular and molecular medicine 22, 2644-2655.
Altamemi, I., Murphy, E.A., Catroppo, J.F., Zumbrun, E.E., Zhang, J., McClellan, J.L.,
Singh, U.P., Nagarkatti, P.S., and Nagarkatti, M. (2014). Role of microRNAs in
resveratrol-mediated mitigation of colitis-associated tumorigenesis in Apc(Min/+) mice.
The Journal of pharmacology and experimental therapeutics 350, 99-109.
Amicarella, F., Muraro, M.G., Hirt, C., Cremonesi, E., Padovan, E., Mele, V., Governa,
V., Han, J., Huber, X., Droeser, R.A., et al. (2017). Dual role of tumour-infiltrating T
helper 17 cells in human colorectal cancer. Gut 66, 692-704.

121

Antonelli, E., Villanacci, V., and Bassotti, G. (2018). Novel oral-targeted therapies for
mucosal healing in ulcerative colitis. World journal of gastroenterology 24, 5322-5330.
Ariake, K., Ohkusa, T., Sakurazawa, T., Kumagai, J., Eishi, Y., Hoshi, S., and Yajima, T.
(2000). Roles of mucosal bacteria and succinic acid in colitis caused by dextran sulfate
sodium in mice. Journal of medical and dental sciences 47, 233-241.
Arpaia, N., Campbell, C., Fan, X., Dikiy, S., van der Veeken, J., deRoos, P., Liu, H.,
Cross, J.R., Pfeffer, K., Coffer, P.J., et al. (2013). Metabolites produced by commensal
bacteria promote peripheral regulatory T-cell generation. Nature 504, 451-455.
Autenrieth, D.M., and Baumgart, D.C. (2017). [Microbiome and Gut Inflammation].
Deutsche medizinische Wochenschrift 142, 261-266.
Bacolod, M.D., Das, S.K., Sokhi, U.K., Bradley, S., Fenstermacher, D.A., Pellecchia, M.,
Emdad, L., Sarkar, D., and Fisher, P.B. (2015). Examination of Epigenetic and other
Molecular Factors Associated with mda-9/Syntenin Dysregulation in Cancer Through
Integrated Analyses of Public Genomic Datasets. Adv Cancer Res 127, 49-121.
Becker, W., Nagarkatti, M., and Nagarkatti, P.S. (2018). miR-466a Targeting of TGFbeta2 Contributes to FoxP3(+) Regulatory T Cell Differentiation in a Murine Model of
Allogeneic Transplantation. Frontiers in immunology 9, 688.
Bedoui, S.A., Barbirou, M., Stayoussef, M., Dallel, M., Mokrani, A., Makni, L., Mezlini,
A., Bouhaouala, B., Yacoubi-Loueslati, B., and Almawi, W.Y. (2018). Association of
interleukin-17A polymorphisms with the risk of colorectal cancer: A case-control study.
Cytokine 110, 18-23.
Bird, J.K., Raederstorff, D., Weber, P., and Steinert, R.E. (2017). Cardiovascular and
Antiobesity Effects of Resveratrol Mediated through the Gut Microbiota. Advances in
nutrition 8, 839-849.
Borges, S.C., Ferreira, P.E.B., da Silva, L.M., de Paula Werner, M.F., Irache, J.M.,
Cavalcanti, O.A., and Buttow, N.C. (2018). Evaluation of the treatment with resveratrolloaded nanoparticles in intestinal injury model caused by ischemia and reperfusion.
Toxicology 396-397, 13-22.
Bose, D., Zimmerman, L.J., Pierobon, M., Petricoin, E., Tozzi, F., Parikh, A., Fan, F.,
Dallas, N., Xia, L., Gaur, P., et al. (2011). Chemoresistant colorectal cancer cells and
cancer stem cells mediate growth and survival of bystander cells. British journal of
cancer 105, 1759-1767.
Buhrmann, C., Shayan, P., Goel, A., and Shakibaei, M. (2017). Resveratrol Regulates
Colorectal Cancer Cell Invasion by Modulation of Focal Adhesion Molecules. Nutrients
9.
Busbee, P.B., Nagarkatti, M., and Nagarkatti, P.S. (2015). Natural indoles, indole-3carbinol (I3C) and 3,3'-diindolylmethane (DIM), attenuate staphylococcal enterotoxin B-

122

mediated liver injury by downregulating miR-31 expression and promoting caspase-2mediated apoptosis. PloS one 10, e0118506.
Busbee, P.B., Rouse, M., Nagarkatti, M., and Nagarkatti, P.S. (2013). Use of natural AhR
ligands as potential therapeutic modalities against inflammatory disorders. Nutrition
reviews 71, 353-369.
Cani, P.D. (2018). Human gut microbiome: hopes, threats and promises. Gut.
Catalanotto, C., Cogoni, C., and Zardo, G. (2016). MicroRNA in Control of Gene
Expression: An Overview of Nuclear Functions. Int J Mol Sci 17.
Chen, D.F., Gong, B.D., Xie, Q., Ben, Q.W., Liu, J., and Yuan, Y.Z. (2010).
MicroRNA155 is induced in activated CD4(+) T cells of TNBS-induced colitis in mice.
World journal of gastroenterology 16, 854-861.
Chen, G.Y. (2018). The Role of the Gut Microbiome in Colorectal Cancer. Clin Colon
Rectal Surg 31, 192-198.
Chen, J., Pitmon, E., and Wang, K. (2017). Microbiome, inflammation and colorectal
cancer. Semin Immunol 32, 43-53.
Chen, J., and Vitetta, L. (2018). Inflammation-Modulating Effect of Butyrate in the
Prevention of Colon Cancer by Dietary Fiber. Clin Colorectal Cancer.
Chen, L., Yang, S., Liao, W., and Xiong, Y. (2015a). Modification of Antitumor
Immunity and Tumor Microenvironment by Resveratrol in Mouse Renal Tumor Model.
Cell biochemistry and biophysics 72, 617-625.
Chen, L., Yang, S., Zumbrun, E.E., Guan, H., Nagarkatti, P.S., and Nagarkatti, M.
(2015b). Resveratrol attenuates lipopolysaccharide-induced acute kidney injury by
suppressing inflammation driven by macrophages. Molecular nutrition & food research
59, 853-864.
Chen, M.L., Yi, L., Zhang, Y., Zhou, X., Ran, L., Yang, J., Zhu, J.D., Zhang, Q.Y., and
Mi, M.T. (2016). Resveratrol Attenuates Trimethylamine-N-Oxide (TMAO)-Induced
Atherosclerosis by Regulating TMAO Synthesis and Bile Acid Metabolism via
Remodeling of the Gut Microbiota. mBio 7, e02210-02215.
Chen, P., Li, Y., Li, L., Yu, Q., Chao, K., Zhou, G., Qiu, Y., Feng, R., Huang, S., He, Y.,
et al. (2019). Circulating microRNA146b-5p is superior to C-reactive protein as a novel
biomarker for monitoring inflammatory bowel disease. Aliment Pharmacol Ther 49, 733743.
Chen, W., Liu, F., Ling, Z., Tong, X., and Xiang, C. (2012). Human intestinal lumen and
mucosa-associated microbiota in patients with colorectal cancer. PloS one 7, e39743.

123

Chitrala, K.N., Guan, H., Singh, N.P., Busbee, B., Gandy, A., Mehrpouya-Bahrami, P.,
Ganewatta, M.S., Tang, C., Chatterjee, S., Nagarkatti, P., et al. (2017). CD44 deletion
leading to attenuation of experimental autoimmune encephalomyelitis results from
alterations in gut microbiome in mice. European journal of immunology 47, 1188-1199.
Chung, L., Thiele Orberg, E., Geis, A.L., Chan, J.L., Fu, K., DeStefano Shields, C.E.,
Dejea, C.M., Fathi, P., Chen, J., Finard, B.B., et al. (2018). Bacteroides fragilis Toxin
Coordinates a Pro-carcinogenic Inflammatory Cascade via Targeting of Colonic
Epithelial Cells. Cell Host Microbe 23, 203-214 e205.
Cobo, E.R., Kissoon-Singh, V., Moreau, F., Holani, R., and Chadee, K. (2017). MUC2
Mucin and Butyrate Contribute to the Synthesis of the Antimicrobial Peptide Cathelicidin
in Response to Entamoeba histolytica- and Dextran Sodium Sulfate-Induced Colitis.
Infection and immunity 85.
Conte, M.P., Schippa, S., Zamboni, I., Penta, M., Chiarini, F., Seganti, L., Osborn, J.,
Falconieri, P., Borrelli, O., and Cucchiara, S. (2006). Gut-associated bacterial microbiota
in paediatric patients with inflammatory bowel disease. Gut 55, 1760-1767.
Cui, X., Jin, Y., Hofseth, A.B., Pena, E., Habiger, J., Chumanevich, A., Poudyal, D.,
Nagarkatti, M., Nagarkatti, P.S., Singh, U.P., et al. (2010). Resveratrol suppresses colitis
and colon cancer associated with colitis. Cancer prevention research 3, 549-559.
Dai, H., Liu, X., Yan, J., Aabdin, Z.U., Bilal, M.S., and Shen, X. (2017). Sodium
Butyrate Ameliorates High-Concentrate Diet-Induced Inflammation in the Rumen
Epithelium of Dairy Goats. Journal of agricultural and food chemistry 65, 596-604.
de Almeida, C.V., Taddei, A., and Amedei, A. (2018). The controversial role of
Enterococcus faecalis in colorectal cancer. Therap Adv Gastroenterol 11,
1756284818783606.
de la Lastra, C.A., and Villegas, I. (2005). Resveratrol as an anti-inflammatory and antiaging agent: mechanisms and clinical implications. Molecular nutrition & food research
49, 405-430.
de Oliveira, M.R., Chenet, A.L., Duarte, A.R., Scaini, G., and Quevedo, J. (2018).
Molecular Mechanisms Underlying the Anti-depressant Effects of Resveratrol: a Review.
Mol Neurobiol 55, 4543-4559.
Diaz-Gerevini, G.T., Repossi, G., Dain, A., Tarres, M.C., Das, U.N., and Eynard, A.R.
(2016). Beneficial action of resveratrol: How and why? Nutrition 32, 174-178.
Edwards, B.K., Noone, A.M., Mariotto, A.B., Simard, E.P., Boscoe, F.P., Henley, S.J.,
Jemal, A., Cho, H., Anderson, R.N., Kohler, B.A., et al. (2014). Annual Report to the
Nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and
impact on survival among persons with lung, colorectal, breast, or prostate cancer.
Cancer 120, 1290-1314.

124

Ehrlich, A.K., Pennington, J.M., Bisson, W.H., Kolluri, S.K., and Kerkvliet, N.I. (2018).
TCDD, FICZ, and Other High Affinity AhR Ligands Dose-Dependently Determine the
Fate of CD4+ T Cell Differentiation. Toxicol Sci 161, 310-320.
Elshaer, M., Chen, Y., Wang, X.J., and Tang, X. (2018). Resveratrol: An overview of its
anti-cancer mechanisms. Life sciences 207, 340-349.
Elson, C.O., Beagley, K.W., Sharmanov, A.T., Fujihashi, K., Kiyono, H., Tennyson,
G.S., Cong, Y., Black, C.A., Ridwan, B.W., and McGhee, J.R. (1996). Hapten-induced
model of murine inflammatory bowel disease: mucosa immune responses and protection
by tolerance. Journal of immunology 157, 2174-2185.
Etxeberria, U., Arias, N., Boque, N., Macarulla, M.T., Portillo, M.P., Martinez, J.A., and
Milagro, F.I. (2015). Reshaping faecal gut microbiota composition by the intake of transresveratrol and quercetin in high-fat sucrose diet-fed rats. The Journal of nutritional
biochemistry 26, 651-660.
Feng, Y., Dong, Y.W., Song, Y.N., Xiao, J.H., Guo, X.Y., Jiang, W.L., and Lu, L.G.
(2018). MicroRNA449a is a potential predictor of colitisassociated colorectal cancer
progression. Oncology reports 40, 1684-1694.
Finnell, J.E., Lombard, C.M., Melson, M.N., Singh, N.P., Nagarkatti, M., Nagarkatti, P.,
Fadel, J.R., Wood, C.S., and Wood, S.K. (2017). The protective effects of resveratrol on
social stress-induced cytokine release and depressive-like behavior. Brain, behavior, and
immunity 59, 147-157.
Foersch, S., Waldner, M.J., and Neurath, M.F. (2012). Colitis and colorectal cancer.
Digestive diseases 30, 469-476.
Galvez, J. (2014). Role of Th17 Cells in the Pathogenesis of Human IBD. ISRN
inflammation 2014, 928461.
Global Burden of Disease Cancer, C., Fitzmaurice, C., Dicker, D., Pain, A., Hamavid, H.,
Moradi-Lakeh, M., MacIntyre, M.F., Allen, C., Hansen, G., Woodbrook, R., et al. (2015).
The Global Burden of Cancer 2013. JAMA oncology 1, 505-527.
Goel, M.K., Khanna, P., and Kishore, J. (2010). Understanding survival analysis: KaplanMeier estimate. Int J Ayurveda Res 1, 274-278.
Gong, W.H., Zhao, N., Zhang, Z.M., Zhang, Y.X., Yan, L., and Li, J.B. (2017). The
inhibitory effect of resveratrol on COX-2 expression in human colorectal cancer: a
promising therapeutic strategy. Eur Rev Med Pharmacol Sci 21, 1136-1143.
Guan, H., Singh, N.P., Singh, U.P., Nagarkatti, P.S., and Nagarkatti, M. (2012).
Resveratrol prevents endothelial cells injury in high-dose interleukin-2 therapy against
melanoma. PloS one 7, e35650.

125

Guo, G., Zhou, J., Yang, X., Feng, J., Shao, Y., Jia, T., Huang, Q., Li, Y., Zhong, Y.,
Nagarkatti, P.S., et al. (2018). Role of MicroRNAs Induced by Chinese Herbal Medicines
Against Hepatocellular Carcinoma: A Brief Review. Integrative cancer therapies 17,
1059-1067.
Gwiggner, M., Martinez-Nunez, R.T., Whiteoak, S.R., Bondanese, V.P., Claridge, A.,
Collins, J.E., Cummings, J.R.F., and Sanchez-Elsner, T. (2018). MicroRNA-31 and
MicroRNA-155 Are Overexpressed in Ulcerative Colitis and Regulate IL-13 Signaling
by Targeting Interleukin 13 Receptor alpha-1. Genes (Basel) 9.
Hart, A. (2019). Diet in the etiology of inflammatory bowel disease. Revista espanola de
enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva
111, 3-4.
Hibberd, A.A., Lyra, A., Ouwehand, A.C., Rolny, P., Lindegren, H., Cedgard, L., and
Wettergren, Y. (2017). Intestinal microbiota is altered in patients with colon cancer and
modified by probiotic intervention. BMJ Open Gastroenterol 4, e000145.
Hofseth, L.J., Singh, U.P., Singh, N.P., Nagarkatti, M., and Nagarkatti, P.S. (2010).
Taming the beast within: resveratrol suppresses colitis and prevents colon cancer. Aging
(Albany NY) 2, 183-184.
Hong, E.H., Heo, E.Y., Song, J.H., Kwon, B.E., Lee, J.Y., Park, Y., Kim, J., Chang, S.Y.,
Chin, Y.W., Jeon, S.M., et al. (2017). Trans-scirpusin A showed antitumor effects via
autophagy activation and apoptosis induction of colorectal cancer cells. Oncotarget 8,
41401-41411.
Hu, G., Li, Z., and Wang, S. (2017). Tumor-infiltrating FoxP3(+) Tregs predict favorable
outcome in colorectal cancer patients: A meta-analysis. Oncotarget 8, 75361-75371.
Huderson, A.C., Rekha Devi, P.V., Niaz, M.S., Adunyah, S.E., and Ramesh, A. (2018).
Alteration of benzo(a)pyrene biotransformation by resveratrol in Apc (Min/+) mouse
model of colon carcinogenesis. Invest New Drugs.
Jang, S.H., Park, J., Kim, S.H., Choi, K.M., Ko, E.S., Cha, J.D., Lee, Y.R., Jang, H., and
Jang, Y.S. (2017). Oral administration of red ginseng powder fermented with probiotic
alleviates the severity of dextran-sulfate sodium-induced colitis in a mouse model.
Chinese journal of natural medicines 15, 192-201.
Jiang, W., Su, J., Zhang, X., Cheng, X., Zhou, J., Shi, R., and Zhang, H. (2014). Elevated
levels of Th17 cells and Th17-related cytokines are associated with disease activity in
patients with inflammatory bowel disease. Inflammation research : official journal of the
European Histamine Research Society [et al] 63, 943-950.
Jobin, C. (2017). Human Intestinal Microbiota and Colorectal Cancer: Moving Beyond
Associative Studies. Gastroenterology 153, 1475-1478.

126

Jung, M.J., Lee, J., Shin, N.R., Kim, M.S., Hyun, D.W., Yun, J.H., Kim, P.S., Whon,
T.W., and Bae, J.W. (2016). Chronic Repression of mTOR Complex 2 Induces Changes
in the Gut Microbiota of Diet-induced Obese Mice. Scientific reports 6, 30887.
Kanauchi, O., Mitsuyama, K., Araki, Y., and Andoh, A. (2003). Modification of
intestinal flora in the treatment of inflammatory bowel disease. Current pharmaceutical
design 9, 333-346.
Kang, C.S., Ban, M., Choi, E.J., Moon, H.G., Jeon, J.S., Kim, D.K., Park, S.K., Jeon,
S.G., Roh, T.Y., Myung, S.J., et al. (2013). Extracellular vesicles derived from gut
microbiota, especially Akkermansia muciniphila, protect the progression of dextran
sulfate sodium-induced colitis. PloS one 8, e76520.
Karakoyun, B., Ertas, B., Yuksel, M., Akakin, D., Cevik, O., and Sener, G. (2017).
Ameliorative effects of riboflavin on acetic acid-induced colonic injury in rats. Clinical
and experimental pharmacology & physiology.
Kespohl, M., Vachharajani, N., Luu, M., Harb, H., Pautz, S., Wolff, S., Sillner, N.,
Walker, A., Schmitt-Kopplin, P., Boettger, T., et al. (2017). The Microbial Metabolite
Butyrate Induces Expression of Th1-Associated Factors in CD4(+) T Cells. Frontiers in
immunology 8, 1036.
Khosravi, A., Yanez, A., Price, J.G., Chow, A., Merad, M., Goodridge, H.S., and
Mazmanian, S.K. (2014). Gut microbiota promote hematopoiesis to control bacterial
infection. Cell Host Microbe 15, 374-381.
Kim, H.S., and Berstad, A. (1992). Experimental colitis in animal models. Scandinavian
journal of gastroenterology 27, 529-537.
Kim, T.T., Parajuli, N., Sung, M.M., Bairwa, S.C., Levasseur, J., Soltys, C.M., Wishart,
D.S., Madsen, K., Schertzer, J.D., and Dyck, J.R.B. (2018). Fecal transplant from
resveratrol-fed donors improves glycaemia and cardiovascular features of the metabolic
syndrome in mice. Am J Physiol Endocrinol Metab.
Ko, J.H., Sethi, G., Um, J.Y., Shanmugam, M.K., Arfuso, F., Kumar, A.P., Bishayee, A.,
and Ahn, K.S. (2017). The Role of Resveratrol in Cancer Therapy. Int J Mol Sci 18.
Kodani, T., Rodriguez-Palacios, A., Corridoni, D., Lopetuso, L., Di Martino, L., Marks,
B., Pizarro, J., Pizarro, T., Chak, A., and Cominelli, F. (2013). Flexible colonoscopy in
mice to evaluate the severity of colitis and colorectal tumors using a validated endoscopic
scoring system. J Vis Exp, e50843.
Koushki, M., Dashatan, N.A., and Meshkani, R. (2018). Effect of Resveratrol
Supplementation on Inflammatory Markers: A Systematic Review and Meta-Analysis of
Randomized Controlled Trials. Clin Ther.
Langille, M.G., Zaneveld, J., Caporaso, J.G., McDonald, D., Knights, D., Reyes, J.A.,
Clemente, J.C., Burkepile, D.E., Vega Thurber, R.L., Knight, R., et al. (2013). Predictive

127

functional profiling of microbial communities using 16S rRNA marker gene sequences.
Nature biotechnology 31, 814-821.
Lee, J.Y., Seo, E.H., Oh, C.S., Paik, J.H., Hwang, D.Y., Lee, S.H., and Kim, S.H. (2017).
Impact Of Circulating T Helper 1 And 17 Cells in the Blood on Regional Lymph Node
Invasion in Colorectal Cancer. J Cancer 8, 1249-1254.
Lee, S.J., McLachlan, J.B., Kurtz, J.R., Fan, D., Winter, S.E., Baumler, A.J., Jenkins,
M.K., and McSorley, S.J. (2012). Temporal expression of bacterial proteins instructs host
CD4 T cell expansion and Th17 development. PLoS pathogens 8, e1002499.
Lee, S.R., Jin, H., Kim, W.T., Kim, W.J., Kim, S.Z., Leem, S.H., and Kim, S.M. (2018).
Tristetraprolin activation by resveratrol inhibits the proliferation and metastasis of
colorectal cancer cells. Int J Oncol 53, 1269-1278.
Li, J., Zhang, C.X., Liu, Y.M., Chen, K.L., and Chen, G. (2017). A comparative study of
anti-aging properties and mechanism: resveratrol and caloric restriction. Oncotarget 8,
65717-65729.
Liu, L., Tabung, F.K., Zhang, X., Nowak, J.A., Qian, Z.R., Hamada, T., Nevo, D.,
Bullman, S., Mima, K., Kosumi, K., et al. (2018). Diets That Promote Colon
Inflammation Associate With Risk of Colorectal Carcinomas That Contain
Fusobacterium nucleatum. Clin Gastroenterol Hepatol 16, 1622-1631 e1623.
Liu, Z., Bai, J., Zhang, L., Lou, F., Ke, F., Cai, W., and Wang, H. (2017). Conditional
knockout of microRNA-31 promotes the development of colitis associated cancer.
Biochem Biophys Res Commun 490, 62-68.
Lopetuso, L.R., De Salvo, C., Pastorelli, L., Rana, N., Senkfor, H.N., Petito, V., Di
Martino, L., Scaldaferri, F., Gasbarrini, A., Cominelli, F., et al. (2018). IL-33 promotes
recovery from acute colitis by inducing miR-320 to stimulate epithelial restitution and
repair. Proceedings of the National Academy of Sciences of the United States of America
115, E9362-E9370.
Lopez, A., Pouillon, L., Beaugerie, L., Danese, S., and Peyrin-Biroulet, L. (2018).
Colorectal cancer prevention in patients with ulcerative colitis. Best Pract Res Clin
Gastroenterol 32-33, 103-109.
Marchix, J., Goddard, G., and Helmrath, M.A. (2018). Host-Gut Microbiota Crosstalk in
Intestinal Adaptation. Cellular and molecular gastroenterology and hepatology 6, 149162.
Martin-Gallausiaux, C., Beguet-Crespel, F., Marinelli, L., Jamet, A., Ledue, F., Blottiere,
H.M., and Lapaque, N. (2018). Butyrate produced by gut commensal bacteria activates
TGF-beta1 expression through the transcription factor SP1 in human intestinal epithelial
cells. Scientific reports 8, 9742.

128

Martin, A.R., Villegas, I., Sanchez-Hidalgo, M., and de la Lastra, C.A. (2006). The
effects of resveratrol, a phytoalexin derived from red wines, on chronic inflammation
induced in an experimentally induced colitis model. British journal of pharmacology 147,
873-885.
Martinez-Moya, P., Ortega-Gonzalez, M., Gonzalez, R., Anzola, A., Ocon, B.,
Hernandez-Chirlaque, C., Lopez-Posadas, R., Suarez, M.D., Zarzuelo, A., MartinezAugustin, O., et al. (2012). Exogenous alkaline phosphatase treatment complements
endogenous enzyme protection in colonic inflammation and reduces bacterial
translocation in rats. Pharmacological research 66, 144-153.
Maschmeyer, P., Petkau, G., Siracusa, F., Zimmermann, J., Zugel, F., Kuhl, A.A.,
Lehmann, K., Schimmelpfennig, S., Weber, M., Haftmann, C., et al. (2018). Selective
targeting of pro-inflammatory Th1 cells by microRNA-148a-specific antagomirs in vivo.
J Autoimmun 89, 41-52.
Meighani, A., Hart, B.R., Bourgi, K., Miller, N., John, A., and Ramesh, M. (2017).
Outcomes of Fecal Microbiota Transplantation for Clostridium difficile Infection in
Patients with Inflammatory Bowel Disease. Digestive diseases and sciences.
Meisel, M., Mayassi, T., Fehlner-Peach, H., Koval, J.C., O'Brien, S.L., Hinterleitner, R.,
Lesko, K., Kim, S., Bouziat, R., Chen, L., et al. (2017). Interleukin-15 promotes
intestinal dysbiosis with butyrate deficiency associated with increased susceptibility to
colitis. The ISME journal 11, 15-30.
Mikhailov, T.A., and Furner, S.E. (2009). Breastfeeding and genetic factors in the
etiology of inflammatory bowel disease in children. World journal of gastroenterology
15, 270-279.
Minacapelli, C.D., Bajpai, M., Geng, X., Van Gurp, J., Poplin, E., Amenta, P.S., Brant,
S.R., and Das, K.M. (2019). miR-206 as a Biomarker for Response to Mesalamine
Treatment in Ulcerative Colitis. Inflammatory bowel diseases 25, 78-84.
Miranda, K., Yang, X., Bam, M., Murphy, E.A., Nagarkatti, P.S., and Nagarkatti, M.
(2018). MicroRNA-30 modulates metabolic inflammation by regulating Notch signaling
in adipose tissue macrophages. International journal of obesity 42, 1140-1150.
Miyamoto, Y., and Itoh, K. (2000). Bacteroides acidifaciens sp. nov., isolated from the
caecum of mice. International journal of systematic and evolutionary microbiology 50 Pt
1, 145-148.
Molodecky, N.A., Soon, I.S., Rabi, D.M., Ghali, W.A., Ferris, M., Chernoff, G.,
Benchimol, E.I., Panaccione, R., Ghosh, S., Barkema, H.W., et al. (2012). Increasing
incidence and prevalence of the inflammatory bowel diseases with time, based on
systematic review. Gastroenterology 142, 46-54 e42; quiz e30.

129

Mori, G., Rampelli, S., Orena, B.S., Rengucci, C., De Maio, G., Barbieri, G., Passardi,
A., Casadei Gardini, A., Frassineti, G.L., Gaiarsa, S., et al. (2018). Shifts of Faecal
Microbiota During Sporadic Colorectal Carcinogenesis. Scientific reports 8, 10329.
Morilla, I., Uzzan, M., Laharie, D., Cazals-Hatem, D., Denost, Q., Daniel, F., Belleannee,
G., Bouhnik, Y., Wainrib, G., Panis, Y., et al. (2018). Colonic MicroRNA Profiles,
Identified by a Deep Learning Algorithm, That Predict Responses to Therapy of Patients
With Acute Severe Ulcerative Colitis. Clinical gastroenterology and hepatology : the
official clinical practice journal of the American Gastroenterological Association.
Necela, B.M., Carr, J.M., Asmann, Y.W., and Thompson, E.A. (2011). Differential
expression of microRNAs in tumors from chronically inflamed or genetic (APC(Min/+))
models of colon cancer. PloS one 6, e18501.
Nishikawa, J., Kudo, T., Sakata, S., Benno, Y., and Sugiyama, T. (2009). Diversity of
mucosa-associated microbiota in active and inactive ulcerative colitis. Scandinavian
journal of gastroenterology 44, 180-186.
Nunes, S., Danesi, F., Del Rio, D., and Silva, P. (2018). Resveratrol and inflammatory
bowel disease: the evidence so far. Nutrition research reviews 31, 85-97.
Olaru, A.V., Selaru, F.M., Mori, Y., Vazquez, C., David, S., Paun, B., Cheng, Y., Jin, Z.,
Yang, J., Agarwal, R., et al. (2011). Dynamic changes in the expression of MicroRNA-31
during inflammatory bowel disease-associated neoplastic transformation. Inflammatory
bowel diseases 17, 221-231.
Ong, C., Aw, M.M., Liwanag, M.J., Quak, S.H., and Phua, K.B. (2018). Rapid rise in the
incidence and clinical characteristics of pediatric inflammatory bowel disease in a SouthEast Asian cohort in Singapore, 1994-2015. Journal of digestive diseases 19, 395-403.
Paramsothy, S., Paramsothy, R., Rubin, D.T., Kamm, M.A., Kaakoush, N.O., Mitchell,
H.M., and Castano-Rodriguez, N. (2017). Faecal Microbiota Transplantation for
Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Journal of
Crohn's & colitis.
Patnala, R., Arumugam, T.V., Gupta, N., and Dheen, S.T. (2017). HDAC Inhibitor
Sodium Butyrate-Mediated Epigenetic Regulation Enhances Neuroprotective Function of
Microglia During Ischemic Stroke. Mol Neurobiol 54, 6391-6411.
Pekow, J., Meckel, K., Dougherty, U., Huang, Y., Chen, X., Almoghrabi, A., Mustafi, R.,
Ayaloglu-Butun, F., Deng, Z., Haider, H.I., et al. (2017). miR-193a-3p is a Key Tumor
Suppressor in Ulcerative Colitis-Associated Colon Cancer and Promotes Carcinogenesis
through Upregulation of IL17RD. Clinical cancer research : an official journal of the
American Association for Cancer Research 23, 5281-5291.
Peng, R.M., Lin, G.R., Ting, Y., and Hu, J.Y. (2018). Oral delivery system enhanced the
bioavailability of stilbenes: Resveratrol and pterostilbene. BioFactors 44, 5-15.

130

Pittman, M.E. (2018). Fecal Microbiota and Screening for Colorectal Cancer. Clinical
chemistry.
Png, C.W., Linden, S.K., Gilshenan, K.S., Zoetendal, E.G., McSweeney, C.S., Sly, L.I.,
McGuckin, M.A., and Florin, T.H. (2010). Mucolytic bacteria with increased prevalence
in IBD mucosa augment in vitro utilization of mucin by other bacteria. The American
journal of gastroenterology 105, 2420-2428.
Qiao, Y., Sun, J., Xia, S., Tang, X., Shi, Y., and Le, G. (2014). Effects of resveratrol on
gut microbiota and fat storage in a mouse model with high-fat-induced obesity. Food
Funct 5, 1241-1249.
Rapozo, D.C., Bernardazzi, C., and de Souza, H.S. (2017). Diet and microbiota in
inflammatory bowel disease: The gut in disharmony. World journal of gastroenterology
23, 2124-2140.
Rezasoltani, S., Asadzadeh-Aghdaei, H., Nazemalhosseini-Mojarad, E., Dabiri, H.,
Ghanbari, R., and Zali, M.R. (2017). Gut microbiota, epigenetic modification and
colorectal cancer. Iran J Microbiol 9, 55-63.
Riccioni, G., Gammone, M.A., Tettamanti, G., Bergante, S., Pluchinotta, F.R., and
D'Orazio, N. (2015). Resveratrol and anti-atherogenic effects. Int J Food Sci Nutr 66,
603-610.
Rieder, S.A., Nagarkatti, P., and Nagarkatti, M. (2012). Multiple anti-inflammatory
pathways triggered by resveratrol lead to amelioration of staphylococcal enterotoxin Binduced lung injury. British journal of pharmacology 167, 1244-1258.
Sadraei, H., Asghari, G., Khanabadi, M., and Minaiyan, M. (2017). Anti-inflammatory
effect of apigenin and hydroalcoholic extract of Dracocephalum kotschyi on acetic acidinduced colitis in rats. Research in pharmaceutical sciences 12, 322-329.
Salimi, V., Shahsavari, Z., Safizadeh, B., Hosseini, A., Khademian, N., and TavakoliYaraki, M. (2017). Sodium butyrate promotes apoptosis in breast cancer cells through
reactive oxygen species (ROS) formation and mitochondrial impairment. Lipids in health
and disease 16, 208.
Samsami-Kor, M., Daryani, N.E., Asl, P.R., and Hekmatdoost, A. (2015). AntiInflammatory Effects of Resveratrol in Patients with Ulcerative Colitis: A Randomized,
Double-Blind, Placebo-controlled Pilot Study. Archives of medical research 46, 280-285.
Samsamikor, M., Daryani, N.E., Asl, P.R., and Hekmatdoost, A. (2016). Resveratrol
Supplementation and Oxidative/Anti-Oxidative Status in Patients with Ulcerative Colitis:
A Randomized, Double-Blind, Placebo-controlled Pilot Study. Archives of medical
research 47, 304-309.
San Hipolito-Luengo, A., Alcaide, A., Ramos-Gonzalez, M., Cercas, E., Vallejo, S.,
Romero, A., Talero, E., Sanchez-Ferrer, C.F., Motilva, V., and Peiro, C. (2017). Dual

131

Effects of Resveratrol on Cell Death and Proliferation of Colon Cancer Cells. Nutrition
and cancer 69, 1019-1027.
Satokari, R., Fuentes, S., Mattila, E., Jalanka, J., de Vos, W.M., and Arkkila, P. (2014).
Fecal transplantation treatment of antibiotic-induced, noninfectious colitis and long-term
microbiota follow-up. Case reports in medicine 2014, 913867.
Schonauen, K., Le, N., von Arnim, U., Schulz, C., Malfertheiner, P., and Link, A. (2018).
Circulating and Fecal microRNAs as Biomarkers for Inflammatory Bowel Diseases.
Inflammatory bowel diseases 24, 1547-1557.
Segata, N., Izard, J., Waldron, L., Gevers, D., Miropolsky, L., Garrett, W.S., and
Huttenhower, C. (2011). Metagenomic biomarker discovery and explanation. Genome
biology 12, R60.
Seth, R.K., Kimono, D., Alhasson, F., Sarkar, S., Albadrani, M., Lasley, S.K., Horner, R.,
Janulewicz, P., Nagarkatti, M., Nagarkatti, P., et al. (2018). Increased butyrate priming in
the gut stalls microbiome associated-gastrointestinal inflammation and hepatic metabolic
reprogramming in a mouse model of Gulf War Illness. Toxicol Appl Pharmacol 350, 6477.
Sethi, V., Kurtom, S., Tarique, M., Lavania, S., Malchiodi, Z., Hellmund, L., Zhang, L.,
Sharma, U., Giri, B., Garg, B., et al. (2018). Gut Microbiota Promotes Tumor Growth in
Mice by Modulating Immune Response. Gastroenterology 155, 33-37 e36.
Silva, L.G., Ferguson, B.S., Avila, A.S., and Faciola, A.P. (2018). Sodium propionate and
sodium butyrate effects on histone deacetylase (HDAC) activity, histone acetylation, and
inflammatory gene expression in bovine mammary epithelial cells. Journal of animal
science 96, 5244-5252.
Simeoli, R., Mattace Raso, G., Pirozzi, C., Lama, A., Santoro, A., Russo, R., MonteroMelendez, T., Berni Canani, R., Calignano, A., Perretti, M., et al. (2017). An orally
administered butyrate-releasing derivative reduces neutrophil recruitment and
inflammation in dextran sulphate sodium-induced murine colitis. British journal of
pharmacology 174, 1484-1496.
Singh, C.K., Kumar, A., Hitchcock, D.B., Fan, D., Goodwin, R., LaVoie, H.A.,
Nagarkatti, P., DiPette, D.J., and Singh, U.S. (2011a). Resveratrol prevents embryonic
oxidative stress and apoptosis associated with diabetic embryopathy and improves
glucose and lipid profile of diabetic dam. Molecular nutrition & food research 55, 11861196.
Singh, N.P., Hegde, V.L., Hofseth, L.J., Nagarkatti, M., and Nagarkatti, P. (2007).
Resveratrol (trans-3,5,4'-trihydroxystilbene) ameliorates experimental allergic
encephalomyelitis, primarily via induction of apoptosis in T cells involving activation of
aryl hydrocarbon receptor and estrogen receptor. Molecular pharmacology 72, 15081521.

132

Singh, N.P., Singh, U.P., Hegde, V.L., Guan, H., Hofseth, L., Nagarkatti, M., and
Nagarkatti, P.S. (2011b). Resveratrol (trans-3,5,4'-trihydroxystilbene) suppresses EL4
tumor growth by induction of apoptosis involving reciprocal regulation of SIRT1 and
NF-kappaB. Molecular nutrition & food research 55, 1207-1218.
Singh, N.P., Singh, U.P., Rouse, M., Zhang, J., Chatterjee, S., Nagarkatti, P.S., and
Nagarkatti, M. (2016). Dietary Indoles Suppress Delayed-Type Hypersensitivity by
Inducing a Switch from Proinflammatory Th17 Cells to Anti-Inflammatory Regulatory T
Cells through Regulation of MicroRNA. Journal of immunology 196, 1108-1122.
Singh, U.P., Murphy, A.E., Enos, R.T., Shamran, H.A., Singh, N.P., Guan, H., Hegde,
V.L., Fan, D., Price, R.L., Taub, D.D., et al. (2014a). miR-155 deficiency protects mice
from experimental colitis by reducing T helper type 1/type 17 responses. Immunology
143, 478-489.
Singh, U.P., Singh, N.P., Guan, H., Busbee, B., Price, R.L., Taub, D.D., Mishra, M.K.,
Fayad, R., Nagarkatti, M., and Nagarkatti, P.S. (2014b). The emerging role of leptin
antagonist as potential therapeutic option for inflammatory bowel disease. International
reviews of immunology 33, 23-33.
Singh, U.P., Singh, N.P., Singh, B., Hofseth, L.J., Price, R.L., Nagarkatti, M., and
Nagarkatti, P.S. (2010). Resveratrol (trans-3,5,4'-trihydroxystilbene) induces silent
mating type information regulation-1 and down-regulates nuclear transcription factorkappaB activation to abrogate dextran sulfate sodium-induced colitis. The Journal of
pharmacology and experimental therapeutics 332, 829-839.
Singh, U.P., Singh, N.P., Singh, B., Hofseth, L.J., Taub, D.D., Price, R.L., Nagarkatti,
M., and Nagarkatti, P.S. (2012). Role of resveratrol-induced CD11b(+) Gr-1(+) myeloid
derived suppressor cells (MDSCs) in the reduction of CXCR3(+) T cells and
amelioration of chronic colitis in IL-10(-/-) mice. Brain, behavior, and immunity 26, 7282.
Sitkin, S., and Pokrotnieks, J. (2018). Clinical Potential of Anti-inflammatory Effects of
Faecalibacterium prausnitzii and Butyrate in Inflammatory Bowel Disease. Inflammatory
bowel diseases.
Slattery, M.L., Mullany, L.E., Wolff, R.K., Sakoda, L.C., Samowitz, W.S., and Herrick,
J.S. (2018). The p53-signaling pathway and colorectal cancer: Interactions between
downstream p53 target genes and miRNAs. Genomics.
Song, M., Garrett, W.S., and Chan, A.T. (2015). Nutrients, foods, and colorectal cancer
prevention. Gastroenterology 148, 1244-1260 e1216.
Song, M., Sasazuki, S., Camargo, M.C., Shimazu, T., Charvat, H., Yamaji, T., Sawada,
N., Kemp, T.J., Pfeiffer, R.M., Hildesheim, A., et al. (2018). Circulating Inflammatory
Markers and Colorectal Cancer Risk: A Prospective Case-cohort Study in Japan. Int J
Cancer.

133

Sun, B., Jia, Y., Hong, J., Sun, Q., Gao, S., Hu, Y., Zhao, N., and Zhao, R. (2018).
Sodium Butyrate Ameliorates High-Fat-Diet-Induced Non-alcoholic Fatty Liver Disease
through Peroxisome Proliferator-Activated Receptor alpha-Mediated Activation of beta
Oxidation and Suppression of Inflammation. Journal of agricultural and food chemistry
66, 7633-7642.
Sun, H.L., Zhou, X., Xue, Y.F., Wang, K., Shen, Y.F., Mao, J.J., Guo, H.F., and Miao,
Z.N. (2012). Increased frequency and clinical significance of myeloid-derived suppressor
cells in human colorectal carcinoma. World journal of gastroenterology 18, 3303-3309.
Sun, X., and Zhu, M.J. (2018). Butyrate Inhibits Indices of Colorectal Carcinogenesis via
Enhancing alpha-Ketoglutarate-Dependent DNA Demethylation of Mismatch Repair
Genes. Molecular nutrition & food research 62, e1700932.
Sung, M.M., Kim, T.T., Denou, E., Soltys, C.M., Hamza, S.M., Byrne, N.J., Masson, G.,
Park, H., Wishart, D.S., Madsen, K.L., et al. (2017). Improved Glucose Homeostasis in
Obese Mice Treated With Resveratrol Is Associated With Alterations in the Gut
Microbiome. Diabetes 66, 418-425.
Sykora, J., Pomahacova, R., Kreslova, M., Cvalinova, D., Stych, P., and Schwarz, J.
(2018). Current global trends in the incidence of pediatric-onset inflammatory bowel
disease. World journal of gastroenterology 24, 2741-2763.
Tabung, F.K., Liu, L., Wang, W., Fung, T.T., Wu, K., Smith-Warner, S.A., Cao, Y., Hu,
F.B., Ogino, S., Fuchs, C.S., et al. (2018). Association of Dietary Inflammatory Potential
With Colorectal Cancer Risk in Men and Women. JAMA oncology 4, 366-373.
Tain, Y.L., Lee, W.C., Wu, K.L.H., Leu, S., and Chan, J.Y.H. (2018). Resveratrol
Prevents the Development of Hypertension Programmed by Maternal Plus Post-Weaning
High-Fructose Consumption through Modulation of Oxidative Stress, Nutrient-Sensing
Signals, and Gut Microbiota. Molecular nutrition & food research, e1800066.
Takagi, T., Naito, Y., Mizushima, K., Hirata, I., Yagi, N., Tomatsuri, N., Ando, T.,
Oyamada, Y., Isozaki, Y., Hongo, H., et al. (2010). Increased expression of microRNA in
the inflamed colonic mucosa of patients with active ulcerative colitis. J Gastroenterol
Hepatol 25 Suppl 1, S129-133.
Tian, Y., Xu, J., Li, Y., Zhao, R., Du, S., Lv, C., Wu, W., Liu, R., Sheng, X., Song, Y., et
al. (2019). MicroRNA-31 Reduces Inflammatory Signaling and Promotes Regeneration
in Colon Epithelium, and Delivery of Mimics in Microspheres Reduces Colitis in Mice.
Gastroenterology.
Tian, Y., Xu, Q., Sun, L., Ye, Y., and Ji, G. (2018). Short-chain fatty acids administration
is protective in colitis-associated colorectal cancer development. The Journal of
nutritional biochemistry 57, 103-109.
Timperi, E., Pacella, I., Schinzari, V., Focaccetti, C., Sacco, L., Farelli, F., Caronna, R.,
Del Bene, G., Longo, F., Ciardi, A., et al. (2016). Regulatory T cells with multiple
134

suppressive and potentially pro-tumor activities accumulate in human colorectal cancer.
Oncoimmunology 5, e1175800.
Tung, Y.C., Lin, Y.H., Chen, H.J., Chou, S.C., Cheng, A.C., Kalyanam, N., Ho, C.T., and
Pan, M.H. (2016). Piceatannol Exerts Anti-Obesity Effects in C57BL/6 Mice through
Modulating Adipogenic Proteins and Gut Microbiota. Molecules 21.
Ueno, A., Jeffery, L., Kobayashi, T., Hibi, T., Ghosh, S., and Jijon, H. (2018). Th17
plasticity and its relevance to inflammatory bowel disease. Journal of autoimmunity 87,
38-49.
van der Beek, C.M., Dejong, C.H.C., Troost, F.J., Masclee, A.A.M., and Lenaerts, K.
(2017). Role of short-chain fatty acids in colonic inflammation, carcinogenesis, and
mucosal protection and healing. Nutrition reviews 75, 286-305.
Vieira, R.S., Castoldi, A., Basso, P.J., Hiyane, M.I., Camara, N.O.S., and Almeida, R.R.
(2019). Butyrate Attenuates Lung Inflammation by Negatively Modulating Th9 Cells.
Frontiers in immunology 10, 67.
Wagnerova, A., Babickova, J., Liptak, R., Vlkova, B., Celec, P., and Gardlik, R. (2017).
Sex Differences in the Effect of Resveratrol on DSS-Induced Colitis in Mice.
Gastroenterology research and practice 2017, 8051870.
Wang, B., Sun, J., Li, X., Zhou, Q., Bai, J., Shi, Y., and Le, G. (2013). Resveratrol
prevents suppression of regulatory T-cell production, oxidative stress, and inflammation
of mice prone or resistant to high-fat diet-induced obesity. Nutrition research 33, 971981.
Wang, F., Liu, J., Weng, T., Shen, K., Chen, Z., Yu, Y., Huang, Q., Wang, G., Liu, Z.,
and Jin, S. (2017). The Inflammation Induced by Lipopolysaccharide can be Mitigated by
Short-chain Fatty Acid, Butyrate, through Upregulation of IL-10 in Septic Shock.
Scandinavian journal of immunology 85, 258-263.
Weber, N., Liou, D., Dommer, J., MacMenamin, P., Quinones, M., Misner, I., Oler, A.J.,
Wan, J., Kim, L., Coakley McCarthy, M., et al. (2018). Nephele: a cloud platform for
simplified, standardized and reproducible microbiome data analysis. Bioinformatics 34,
1411-1413.
Whiteoak, S.R., Claridge, A., Balendran, C.A., Harris, R.J., Gwiggner, M., Bondanese,
V.P., Erlandsson, F., Hansen, M.B., Cummings, J.R.F., and Sanchez-Elsner, T. (2018).
MicroRNA-31 Targets Thymic Stromal Lymphopoietin in Mucosal Infiltrated CD4+ T
Cells: A Role in Achieving Mucosal Healing in Ulcerative Colitis? Inflammatory bowel
diseases 24, 2377-2385.
Wong, S.H., Zhao, L., Zhang, X., Nakatsu, G., Han, J., Xu, W., Xiao, X., Kwong,
T.N.Y., Tsoi, H., Wu, W.K.K., et al. (2017). Gavage of Fecal Samples From Patients
With Colorectal Cancer Promotes Intestinal Carcinogenesis in Germ-Free and
Conventional Mice. Gastroenterology 153, 1621-1633 e1626.
135

Wu, F., Zikusoka, M., Trindade, A., Dassopoulos, T., Harris, M.L., Bayless, T.M., Brant,
S.R., Chakravarti, S., and Kwon, J.H. (2008). MicroRNAs are differentially expressed in
ulcerative colitis and alter expression of macrophage inflammatory peptide-2 alpha.
Gastroenterology 135, 1624-1635 e1624.
Wu, S.L., Yu, L., Meng, K.W., Ma, Z.H., and Pan, C.E. (2005). Resveratrol prolongs
allograft survival after liver transplantation in rats. World journal of gastroenterology 11,
4745-4749.
Xu, P., Fan, W., Zhang, Z., Wang, J., Wang, P., Li, Y., and Yu, M. (2017). The
Clinicopathological and Prognostic Implications of FoxP3(+) Regulatory T Cells in
Patients with Colorectal Cancer: A Meta-Analysis. Front Physiol 8, 950.
Xu, Y.H., Gao, C.L., Guo, H.L., Zhang, W.Q., Huang, W., Tang, S.S., Gan, W.J., Xu, Y.,
Zhou, H., and Zhu, Q. (2018). Sodium butyrate supplementation ameliorates diabetic
inflammation in db/db mice. J Endocrinol 238, 231-244.
Yan, G., Liu, T., Yin, L., Kang, Z., and Wang, L. (2018). Levels of peripheral Th17 cells
and serum Th17-related cytokines in patients with colorectal cancer: a meta-analysis. Cell
Mol Biol (Noisy-le-grand) 64, 94-102.
Yang, H., Wang, W., Romano, K.A., Gu, M., Sanidad, K.Z., Kim, D., Yang, J., Schmidt,
B., Panigrahy, D., Pei, R., et al. (2018a). A common antimicrobial additive increases
colonic inflammation and colitis-associated colon tumorigenesis in mice. Science
translational medicine 10.
Yang, S., Li, W., Sun, H., Wu, B., Ji, F., Sun, T., Chang, H., Shen, P., Wang, Y., and
Zhou, D. (2015). Resveratrol elicits anti-colorectal cancer effect by activating miR-34cKITLG in vitro and in vivo. BMC Cancer 15, 969.
Yang, Y., Chen, G., Yang, Q., Ye, J., Cai, X., Tsering, P., Cheng, X., Hu, C., Zhang, S.,
and Cao, P. (2017). Gut microbiota drives the attenuation of dextran sulphate sodiuminduced colitis by Huangqin decoction. Oncotarget 8, 48863-48874.
Yang, Y., Xu, C., Wu, D., Wang, Z., Wu, P., Li, L., Huang, J., and Qiu, F. (2018b).
gammadelta T Cells: Crosstalk Between Microbiota, Chronic Inflammation, and
Colorectal Cancer. Frontiers in immunology 9, 1483.
Yao, J., Wang, J.Y., Liu, L., Zeng, W.S., Li, Y.X., Xun, A.Y., Zhao, L., Jia, C.H., Feng,
J.L., Wei, X.X., et al. (2011). Polydatin ameliorates DSS-induced colitis in mice through
inhibition of nuclear factor-kappaB activation. Planta medica 77, 421-427.
Yao, J., Wei, C., Wang, J.Y., Zhang, R., Li, Y.X., and Wang, L.S. (2015). Effect of
resveratrol on Treg/Th17 signaling and ulcerative colitis treatment in mice. World journal
of gastroenterology 21, 6572-6581.

136

Youn, J., Lee, J.S., Na, H.K., Kundu, J.K., and Surh, Y.J. (2009). Resveratrol and
piceatannol inhibit iNOS expression and NF-kappaB activation in dextran sulfate
sodium-induced mouse colitis. Nutrition and cancer 61, 847-854.
Yu, M., Luo, Y., Cong, Z., Mu, Y., Qiu, Y., and Zhong, M. (2018). MicroRNA-590-5p
Inhibits Intestinal Inflammation by Targeting YAP. J Crohns Colitis 12, 993-1004.
Zeng, Y.H., Zhou, L.Y., Chen, Q.Z., Li, Y., Shao, Y., Ren, W.Y., Liao, Y.P., Wang, H.,
Zhu, J.H., Huang, M., et al. (2017). Resveratrol inactivates PI3K/Akt signaling through
upregulating BMP7 in human colon cancer cells. Oncol Rep 38, 456-464.
Zhang, H., Du, M., Yang, Q., and Zhu, M.J. (2016a). Butyrate suppresses murine mast
cell proliferation and cytokine production through inhibiting histone deacetylase. The
Journal of nutritional biochemistry 27, 299-306.
Zhang, L., Xue, H., Zhao, G., Qiao, C., Sun, X., Pang, C., and Zhang, D. (2019).
Curcumin and resveratrol suppress dextran sulfate sodiuminduced colitis in mice.
Molecular medicine reports.
Zhang, M., Zhou, Q., Dorfman, R.G., Huang, X., Fan, T., Zhang, H., Zhang, J., and Yu,
C. (2016b). Butyrate inhibits interleukin-17 and generates Tregs to ameliorate colorectal
colitis in rats. BMC gastroenterology 16, 84.
Zhang, T., Ding, C., Zhao, M., Dai, X., Yang, J., Li, Y., Gu, L., Wei, Y., Gong, J., Zhu,
W., et al. (2016c). Sodium Butyrate Reduces Colitogenic Immunoglobulin A-Coated
Bacteria and Modifies the Composition of Microbiota in IL-10 Deficient Mice. Nutrients
8.
Zhao, G., Nyman, M., and Jonsson, J.A. (2006). Rapid determination of short-chain fatty
acids in colonic contents and faeces of humans and rats by acidified water-extraction and
direct-injection gas chromatography. Biomedical chromatography : BMC 20, 674-682.
Zhao, L., Zhang, Q., Ma, W., Tian, F., Shen, H., and Zhou, M. (2017). A combination of
quercetin and resveratrol reduces obesity in high-fat diet-fed rats by modulation of gut
microbiota. Food Funct 8, 4644-4656.
Zhuo, C., Xu, Y., Ying, M., Li, Q., Huang, L., Li, D., Cai, S., and Li, B. (2015). FOXP3+
Tregs: heterogeneous phenotypes and conflicting impacts on survival outcomes in
patients with colorectal cancer. Immunol Res 61, 338-347.
Zou, S., Fang, L., and Lee, M.H. (2018). Dysbiosis of gut microbiota in promoting the
development of colorectal cancer. Gastroenterol Rep (Oxf) 6, 1-12.
Zu, Y., Overby, H., Ren, G., Fan, Z., Zhao, L., and Wang, S. (2018). Resveratrol
liposomes and lipid nanocarriers: Comparison of characteristics and inducing browning
of white adipocytes. Colloids and surfaces B, Biointerfaces 164, 414-423.

137

